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Type 2 diabetes (T2D) is an international health burden. Globally, it is the most common 
chronic disease and its incidence is increasing. Type 2 diabetes mellitus is a metabolic 
proinflammatory disorder characterised by chronic hyperglycaemia resulting in an altered 
immune response and delayed healing. Patients with T2D are common in general dental 
practice. Oral complications of T2D are well recognised, particularly associated with 
periodontal disease but the influence of hyperglycaemia on the dental pulp is unclear.  
Inflammation and immune responses of the dental pulp are similar to those in other 
connective tissue in the body and are mediated by several cellular and molecular factors to 
minimise harmful effects induced by the irritating factors. Hyperglycaemia affects body tissues 
through a non-enzymatic process known as glycation and the accumulation of irreversible 
advanced glycation end products (AGEs). AGEs accumulation is responsible for diabetic 
complications such as thickened connective tissue and increased tissue inflammation. AGEs 
exert noxious effects on tissues through an advanced glycation end-product receptor (RAGE).  
Normal tissue and a regulated inflammatory response contribute to healing. The histological, 
immunological and inflammatory changes in human clinically normal dental pulp in T2D 
patients are limited. Improved knowledge and understanding of these changes may assist 
clinicians in planning care to manage patients with T2D diagnosed with pulp disease.  
Hypothesis & Objectives 
The hypothesis of this thesis is that T2D affects the clinically normal dental pulp by altering 
histological, immunological, and inflammatory responses. To test this hypothesis, the current 
study has three main objectives. The first is to evaluate the histological, immunological and 
inflammatory changes in the clinically normal dental pulp of patients with T2D. The second 
objective is to evaluate the glycation process in the dental pulp by evaluating AGEs and their 
receptors RAGE, Galectin-3 (Gal-3), and the related inflammatory response. The third is to 
establish an in vitro diabetic model and evaluate the effect of high glucose concentration on 
human dental pulp cell (hDPCs) behaviour and gene expression.  
Methods 
Ethical approval for this study was gained from the University of Otago Human Ethics 
Committee (Health) (Project Reference H16/069 and Project Reference H18/077) and Māori 
consultation was entered with the Ngāi Tahu Research Committee. Clinically normal (healthy) 
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and extracted permanent teeth were collected from T2D (n=20) and non-diabetic (n=20) 
participants for the first and second objectives. 
To achieve the first and second objectives, histological staining, immunohistochemistry 
(IHC), immunofluorescence (IF), double immunofluorescence (DIF) and quantitative 
polymerase chain reaction (qPCR) were used. Following extraction, teeth from T2D (n=10) and 
non-diabetic (n=10) participants were cut transversely below the cementoenamel junction 
(CEJ), formalin fixed, decalcified in 10% ethylenediaminetetraacetic acid (EDTA), and 
paraffin embedded. Sections were stained with haematoxylin and eosin (H&E), Massons 
trichrome, Van Gieson (VG) and silver reticulin stains for histological evaluation. Other 
sections were used for IHC using anti-TLR2, anti-TLR4, anti- CD4, anti-CD68, anti-CD83, 
anti-FOXP3, anti-interleukin (IL)1!, anti-IL6, anti-tumour necrosis factor (TNF)-", anti-
AGEs, and anti-RAGE. Three sections were used for IF using anti-AGEs and other five sections 
were used for DIF using anti-RAGE with anti-CD4 and anti-vimentin.   
Remaining teeth from T2D (n=10) and non-diabetic (n=14) participants were used for gene 
expression analyses. Immediately after extraction teeth were sectioned transversely below the 
CEJ, and the coronal pulp was removed for ribonucleic acid (RNA) extraction. Messenger RNA 
(mRNA) levels for AGE, RAGE, S100A12 and NF-#B were determined using TaqMan assays.  
For the cell culture experiments, coronal pulp tissue was excavated from mature unerupted 
third molar teeth extracted from healthy adults (n=4) and cell lines generated using the explant 
method. An in vitro diabetic model by using different glucose concentrations mimicking blood 
glucose concentrations was used to evaluate the effect of normal and high glucose on viability 
and gene expression of hDPCs at 1, 3 and 5-day time-points.  
Data Analysis  
Histological slides and IHC samples were scanned by an Aperio Scanscope CS2 image 
capture device, analysed under light microscopy and digitised with ImageScope. Data analysis 
was performed qualitatively and semi-quantitatively (number of positive cells/image area) to 
assess the histological changes and the protein expression in the specimens.   
The DIF sections for RAGE, vimentin and CD4 were viewed and images were taken using 
an EVOS M5000 inverted fluorescent microscope. The slides were examined, and the 
individual and merged proteins in non-T2D and T2D dental pulp were qualitatively identified. 
The staining was examined, and proteins were qualitatively identified, and merged in non-T2D 
and T2D dental pulp.  
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The mRNA expression analysis was performed using comparative quantification cycle (Cq) 
values. The fold difference (FD) for each gene was calculated between the two groups. Data 
analyses were performed with GraphPad Prism®, using a Student’s t- tests at P-value <0.05.  
The viability data analysis in cell culture was performed using GraphPad Prism and Excel 
software for Mac OS Catalina (Version 10.15.4). The data are presented as mean and standard 
deviation (SD). A Student’s t-test was used and the differences between the groups were 
considered significant when P-value <0.05. 
The gene expression in cell culture was performed by using the comparative Cq method to 
calculate the difference in the mRNA expression between the 5.5mM and 25mM D-glucose 
concentrations at the different time-points.    
Results 
Histological changes were observed in normal dental pulp of participants with T2D 
compared to healthy controls. T2D resulted in a dental pulp that was less cellular, less vascular, 
evidence of thickened blood vessel walls, increased pulp calcification, increased collagen and 
decreased elastin deposition. The positive cell count/area showed increased expression of CD68 
(P<0.001), CD83 (P=0.04), and decreased expression of FOXP3 (P=0.01) in T2D dental pulp 
compared with non-T2D samples. The positive cell count/area analysis also showed that the 
cytokines were significantly increased in T2D (IL1! (P=0.01), IL6 (P<0.0001), IL17 
(P<0.0001) and TNF-"	 (P=0.01)). The glycation process was significantly increased in the 
dental pulp of T2D as evidenced by increased IHC expression of AGE (P<0.0001) and RAGE 
(P=0.02). The qPCR results showed that the expression of RAGE, S100A12, NF-#B and 
COL1A1 mRNA genes was significantly increased in the dental pulp of T2D compared with 
the non-T2D samples (P<0.0001), while no significant changes were detected for Gal-3 mRNA 
expression. The glycation process was also assessed by IF and DIF which showed increased 
accumulation of AGE in the extracellular matrix (ECM) and around blood vessel walls. DIF 
showed co-localisation of RAGE and vimentin and co-localisation of RAGE and CD4, 
indicating RAGE was expressed on fibroblasts and CD4+ve cells.  
The results of the study using an in vitro diabetic cell culture model showed that high glucose 
concentration was associated with a reduced viability rate of hDPCs with increasing time. 
Furthermore, the used highest glucose concentration resulted in increased expression of 
collagen type III (COL3A1) and increased mineralisation due to the increased expression of 
ALP over time. The cell culture mRNA showed that high glucose resulted in increased gene 
expression of RAGE and decreased expression of Gal-3.  
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Conclusions  
T2D leads to changes in dental pulp morphology, altered immunosurveillance and increased 
cytokine expression in the dental pulp. The glycation process was clearly evident in the pulp 
from T2D patients and may be responsible for the changes observed. These changes in clinically 
normal dental pulp in T2D patients may influence the healing response following pulpal injury 
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Diabetes mellitus (DM) is a chronic systemic disease characterised by metabolic 
abnormalities of fats, proteins and carbohydrates, and hyperglycaemia (World Health 
Organisation 2019, American Diabetes Association 2020). It occurs either from an absolute or 
a relative deficiency of insulin production, insulin action or both (McCowen & Smith 2013). 
Long-term, uncontrolled DM can result in serious complications affecting major organs and 
systems in the body. Nerves, blood vessels, heart, kidneys and eyes are particularly affected, 
and DM may result in retinopathy with blindness, nephropathy which can cause renal failure, 
and neuropathy with a risk of foot ulcers, amputation, joint stiffness, sexual dysfunction and 
poor wound healing. Diabetes patients have a high risk of developing other peripheral vascular, 
cerebrovascular and cardiovascular diseases (World Health Organisation 2019).  
Type 2 diabetes mellitus (T2D) is a metabolic proinflammatory disorder characterised by 
chronic hyperglycaemia and increased levels of certain inflammatory mediators (Zozulinska & 
Wierusz-Wysocka 2006, Al-Shukaili et al. 2013, Daniele et al. 2014). Diabetic patients with 
peripheral vascular changes have an altered immunological response and increased 
susceptibility to infection and delayed healing (Blakytny & Jude 2006, Zhou et al. 2018).  
Within the oral environment, T2D has a known association with the periodontal tissues, 
specifically an increased severity of gingivitis and periodontitis (Salvi et al. 2008). The dental 
pulp of T2D patients shows some morphological changes such as an increased amount of 
fibrous connective tissue and thickening of the vascular walls (Moraru et al. 2017). However, 
most reports describing the effects of T2D on the dental pulp have been from animal studies 
(Inagaki et al. 2010, Nakajima et al. 2013, Nakajima et al. 2015). Hyperglycaemia can affect 
dental pulp repair and healing (Garber et al. 2009) but there is limited understanding about what 
is occurring at a molecular level and cellular level in the human dental pulp of T2D patients.   
Hyperglycaemia affects body tissues through a non-enzymatic process known as glycation. 
The glycation process is associated with damage of the tissues by accumulation of irreversible 
advanced glycation end products (AGEs) (Goldin et al. 2006, Thomas 2011). Accumulated 
AGEs can cause tissue damage via its receptor RAGE, leading to inflammation and pathology 
(Brownlee 2005, Ott et al. 2014). Disruption of wound healing in hyperglycaemia can occur 
due to AGE/RAGE triggering the production of proinflammatory cytokines, adhesion 
molecules and chemokines which stimulate the release of inflammatory cells within the tissues 
and sustaining the inflammatory response (Bulut et al. 2001, Bierhaus et al. 2005). AGEs 
accumulation occurs in a variety of body tissues but most understanding of AGEs/RAGE in the 
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oral region comes from understanding of periodontal diseases (Akram et al. 2019). 
Histopathological studies have shown AGEs upregulation in periodontal and gingival 
fibroblasts, blood vessels, endothelial cells, epithelium and connective tissue (Lalla et al. 2001, 
Rajeev et al. 2011, Zizzi et al. 2013, Detzen et al. 2019). The amount of AGEs accumulation 
is associated with the duration of diabetes, glycated haemoglobin, age and body mass index 
(BMI) (Zizzi et al. 2013). AGEs accumulation in cartilage of patients with diabetes is associated 
with stiffness and aging in osteoarthritis and is due to increased crosslinking of collagen fibres 
by glycation (Verzijl et al. 2002).  
There is a lack of data concerning the level and role of many immune and inflammatory 
markers in the clinically normal (healthy) dental pulp of T2D patients. Furthermore, whether 
or not AGEs accumulate in dental pulp and the effect of their receptor RAGE is not known. 
This knowledge is needed to better understand the morphological and inflammatory differences 
between the dental pulp of patients with T2D and those without. This information may better 
inform clinical decision making and treatment outcomes. 
The purpose of this laboratory-based study was to investigate the morphological and 
inflammatory effects of T2D in the clinically normal dental pulp, comparing samples from 
patients with and without T2D using different techniques. The thesis is divided into five 
chapters:  
Chapter 1: This is a literature review and is divided into two parts. The first part is a review 
of what is currently known about dental pulp histology and cellular, immunological and 
inflammatory responses to irritants. The second part reviews T2D prevalence, its pathogenesis, 
glycation and the association between hyperglycaemia and the dental pulp, identifying current 
gaps in our knowledge.   
Chapter 2: Provides the demographic, medical, clinical and dental data collected from 
research participants. Furthermore, it presents the results of a questionnaire which gathered 
socio-economic data using the non-occupational index of socio-economic deprivation 
(NZiDep).  
Chapter 3: This chapter investigates the influence of T2D on the inflammatory response of 
clinically normal dental pulp as demonstrated with histology (routine and special stains) and 
immunohistochemistry (IHC).  
Chapter 4: This chapter investigates the glycation effect within dental pulp using IHC, 
immunofluorescence and real time quantitative polymerase chain reaction (RT-qPCR) to 
examine the protein and gene expression of AGE and RAGE. 
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Chapter 5: This chapter develops and uses an in vitro diabetic cell culture model to study 
the effect of high glucose levels on human dental pulp cells (hDPCs) using cell viability and 





Chapter 1  
Literature Review 
1.1 Dental Pulp   
Dental pulp is a unique specialised loose connective tissue located in the central part of the 
tooth coronally in the pulp chamber and in the root canal space (Nanci 2008). The dental pulp 
is derived from neural crest cells (ectomesenchyme) that proliferate and condense to form 
dental papilla which then develops into the mature pulp (Sinanan et al. 2004, Janebodin et al. 
2011).  
The dental pulp has several important roles during and after tooth development. These 
include an inductive role early in tooth formation, a role in the synthesis of dentine and roles in 
nutrition and sensation. Moreover, the pulp has a protective function by sensing noxious stimuli 
and reacting via the formation of reactionary or reparative (tertiary dentine) (Sloan 2015).  
1.1.1 Dental Pulp Histology 
The coronal dental pulp is surrounded by dentine and the two function together as a unit 
called the pulp-dentine complex (Goldberg & Smith 2004, Sloan 2015). Odontoblasts are 
located in the peripheral dental pulp and their processes extend to the inner part of the dentinal 
tubules. The predentine lies external to the peripheral part of the dental pulp. Classically, the 
dental pulp has two defined regions: the central and the peripheral (Pashley et al. 2002).  
There are four distinct zones from the peripheral to central dental pulp (Figure 1.1). 
a) Odontoblast Layer  
The odontoblast layer is located in the outermost part of dental pulp, immediately under the 
predentine. The odontoblasts have a palisaded appearance which varies in height, and their 
nuclei are not all at the same level which makes the layer appears to be 3-5 cells in thickness; 
however, there is only one layer of odontoblasts. The odontoblast cell bodies are connected by 
a tight gap junction which permits cell-to-cell passage of signal molecules. The odontoblasts of 
mature coronal pulp are columnar (Hargreaves et al. 2012). Where there is a pulpal reaction to 
irritation with the laying down of tertiary dentine, the odontoblasts may be flattened or lost 
(Simon et al. 2011).  
b) Cell-Free Zone of Weil or Subodontoblast Layer  
This layer is located immediately under the odontoblast layer. The cell free zone (CFZ) is a 
narrow zone approximately 40µm in width and contains plexuses of capillaries and small 
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unmyelinated nerve fibres, and the fine cytoplasmic processes of fibroblasts from the 
subodontoblastic layer. The functional status of the pulp affects the presence or absence of the 
CFZ. This layer may not be present when dentine forms rapidly in young pulps or when 
reparative dentine forms in older pulp (Ricucci & Siqueira 2013, Sloan 2015). 
1. Cell-Rich Zone  
The cell-rich zone (CRZ) contains fibroblasts, immune cells such as macrophages and 
dendritic cells, and undifferentiated mesenchymal cells which may contribute to reparative 
processes by proliferation and differentiation. The main body of the pulp occupies the area 
circumscribed by the CRZ. Blood capillaries found within CRZ form between the odontoblasts 
and exchange nutrients during dentinogenesis. These vessels migrate out from the odontoblast 
layer after dentinogenesis as dentine does not require a large amount of nutrients after formation 
(Shi & Gronthos 2003). 
2. Central Dental Pulp  
The central pulp is called also pulp proper and its forms the central mass of the pulp. The 
central pulp consists of loose connective tissue. It contains the large vessels and nerves and 
their branches supply the outer pulp layers. The main cells of the dental pulp are fibroblasts, 
and the main extracellular components are collagen and ground substance (Pashley et al. 2002). 
The pulp proper also contains perivascular cells which reside in the pulp centre and this gives 
the pulp tissue its vascular nature (Sloan 2015).  
 
Figure 1.1: Morphological zone of the dental pulp (Keijo et al. 2016) 
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1.1.2 Dental Pulp Vessels and Nerves 
The dental pulp is highly vascular and surrounded by a non-compliant shell of dentine. This 
means it has a limited ability to expand or shrink, for example in response to acute 
inflammation, since it is enclosed within a rigid wall of dentine. Blood vessels are fundamental 
components of the dental pulp, responsible mainly for regulation of the dynamic transportation 
of nutrients, hormones, and gases and removal of metabolic waste products. They are also 
involved with the immune defence system of the dental pulp (Hargreaves et al. 2012). 
Histologically, three types of blood vessels can be detected in the dental pulp; arterioles, 
venules and capillaries. The walls of the arterioles are thicker due to thicker tunica media than 
venules which reflects the variation in the pressure of blood flow. The arterioles have a more 
uniform shape and they are more circular than the venules. Generally, the venule walls are 
thinner than the arterioles and they appear floppy and irregular in shape (Nanci 2008). 
Compared with other systemic vessels, pulpal arterioles and venules have very thin walls 
(Pashley et al. 2002, Hargreaves et al. 2012). The dental pulp circulation is known as a 
microcirculation system due to lack of true arteries and veins and there is only one portal of 
entry via the apical foramen.  
The small arterioles (one or more) enter the dental pulp through the apical foramen and then 
rise through the radicular pulp of the root. When they reach the pulp chamber in the crown, 
they branch out peripherally to form a dense capillary network under the odontoblast layer. 
Arterioles and venules are arranged axially with capillary loops extending outward into the 
dentine (Orchardson & Cadden 2001). The more centrally located pulpal arteries range between 
50 and 150µm in diameter and possess endothelial cells which pass around the vessel wall in a 
radial fashion. Small venules drain the capillary and leave as veins via the apical foramen. 
Terminal branches of the smaller arterioles are the capillary network. 
Capillaries have the smallest vessel diameter with smaller, thin-walled vessels, 
approximately 10 to 15µm in diameter. The capillaries are made up of the single layer of 
flattened dark-staining endothelial cells only with no muscular or adventitial layers (Hargreaves 
et al. 2012). There is a basement membrane that houses pericytes which are neurovascular 
signalling cells that respond to blood pressure changes. Capillaries are also highly specialised 
vessels, and they convey blood between the arterioles and venules (Shinaoka et al. 2013). 
Human dental pulp blood vessels are controlled by nerve fibres (Rodd & Boissonade 2006). 
Blood vessels and nerve fibres not only play an important role in normal tooth function and 
self-repair, but also exert great significance on the dental pulp tissue regeneration process. The 
association of nerve bundles and blood vessels in the dental pulp is described as a neurovascular 
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bundle. The nerve fibres in the dental pulp are surrounded by a connective tissue sheath which 
is composed of collagen fibres. The majority of the nerve bundles reach the coronal dentine 
where they fan out to form the nerve plexus of Raschkow. There, they anastomose and terminate 
as free nerve endings that synapse onto and into the odontoblast cell layer (Nanci 2008, Keijo 
et al. 2016).  
Healing following pulpal injury requires angiogenesis and a blood supply. Pulpal irritation 
can result in circulatory disturbances, transient reduction in pulpal blood flow and vasodilation 
of blood vessels (Ahmed et al. 2017). The persistence of irritation can lead to atherosclerosis 
and thickening of blood vessels walls (Moraru et al. 2017), which may impair pulp healing and 
repair. Angiogenesis, with the formation of new blood vessels from the existing vasculature, is 
essential for pulp repair and wound healing and is tightly regulated. Angiogenic signals, such 
as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)-β are released 
from injured dental pulp cells, endothelial cells, the extracellular matrix (ECM) and dentine 
matrix and can stimulate the migration of stem and progenitor cells to contribute to healing 
(Mathieu et al. 2005, Tran-Hung et al. 2006, Rombouts et al. 2017).  
1.1.3 Dental Pulp Cells 
Dental pulp contains different types of cells: fibroblasts, odontoblasts, immunocompetent 
cells (macrophages, dendritic cells (DC), and lymphocytes), stem cells, vascular cells, 
pericytes, neural cells, and mast cells (Izumi et al. 1995, Goldberg & Smith 2004, Hahn & 
Liewehr 2007, Hahn & Liewehr 2007).  
1.1.3.1 Odontoblasts 
Odontoblasts are organised as a dense tight cell layer located peripherally at the pulp and 
there they form the dentine (Goldberg et al. 2011, Goldberg & Hirata 2017). 
Odontoblasts are highly specialised long-living, terminally differentiated, post mitotic cells 
that are located at the dentine‐pulp interface, where they maintain pre‐dentine and dentine 
conjunction (Bleicher 2014). The odontoblasts’ cytoplasmic processes extend into the dentinal 
tubules within the dentine. Within the coronal pulp, they form a single layer of tall columnar 
and highly polarised cell bodies while in the radicular pulp they are square or flattened (Ricucci 
& Siqueira 2013, Sloan 2015). An active odontoblast cell body is characterised by a large oval 
nucleus located in its basic region that may contain up to four nucleoli, while inactive 
odontoblasts have a decreased number of organelles and become shorter. Odontoblasts produce 
collagen type I and non-collagenous proteins such as dentine phosphoproteins, proteoglycans, 
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and glycoproteins (Kawasaki & Weiss 2008). In addition, odontoblasts synthesize dentine 
proteins, dentine sialoprotein (DSPP) and dentine matrix protein (DMP)‐1, and these proteins 
are specific markers of odontoblasts (Narayanan et al. 2006). 
Alteration in the morphology of odontoblasts can occur due to their function, irritants and 
age. As the tooth ages, typically the highly polarised cell bodies of the odontoblasts become 
flattened and reduce in size (Couve et al. 2013). When pulpal inflammation starts and before 
the manifestation of inflammatory changes in the pulp, odontoblast cell bodies will be disrupted 
with reduction in overall number and cell size and aspiration of nuclei into the dentinal tubules 
due to outward movement of dentinal fluid. The cell may be irreversibly damaged which causes 
the release of inflammatory molecules close to the irritant site (Bulut et al. 2004, Yu & Abbott 
2007, Abi-Ramia et al. 2010, Lazzaretti et al. 2014, Ahmed et al. 2017).  
Low or moderately intense irritation to the dental pulp may cause acute inflammation after 
the removal of irritants or stimulation. Then, this is followed by formation of reactionary 
dentine. With increased severity of external noxious irritation to the toot there is a reduction in 
the number of odontoblasts in the affected area due to their apoptosis (Kitamura et al. 2003, 
Smith et al. 2003, Ricucci et al. 2014). 
The secretory function of odontoblasts can be upregulated after injury to the pulp-dentine 
complex. The cells will secrete a tertiary dentine matrix at a specific area related to injury (Sloan 
2015). 
1.1.3.2 Fibroblasts  
Fibroblasts are located centrally in the dental pulp and they are responsible for formation 
and the turnover of the pulp ECM. They produce collagen, mainly collagen type I and collagen 
type III, as well as non-collagenous ECM components such as proteoglycans and fibronectin. 
Fibroblasts maintain collagen turnover in the dental pulp by producing and maintaining ECM 
proteins and are able to phagocytose collagen. The early differentiating fibroblasts are 
characterised as polygonal and they are distributed within the ground substance. In the mature 
pulp, fibroblasts appear as flattened spindle-shaped cells (fibrocytes) (Yildirim 2013, Keijo et 
al. 2016, Goldberg & Hirata 2017).  
Fibroblasts play an essential role in the proliferative phase of wound healing, through the 
production and deposition of the ECM (Reinke & Sorg 2012, Landén et al. 2016), and they are 
involved in tissue fibrosis (Bainbridge 2013, Ronchetti et al. 2013, Darby et al. 2014). Fibrosis 
is the abnormal thickening of ECM and collagen due to inflammation or irritation (Ronchetti et 
al. 2013). Pulpal fibroblasts are also responsible for the production of many inflammatory 
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mediators in response to caries-related bacteria (Sloan 2015). In addition, they have been shown 
to express TLR2, 3, 4 and 5, which have an important function in innate immunity (Keller et 
al. 2010). 
1.1.3.3 Dental Pulp Stem Cells  
Within dental pulp there is a small sub-population of undifferentiated cells that are stem and 
progenitor cells which are able to differentiate in to several cell types (Friedlander et al. 2009). 
Dental pulp stem cells (DPSCs) are ectoderm-derived stem cells, originating from migrating 
neural crest cells. DPSCs have mesenchymal stem cells (MSCs) properties, such as the ability 
to adhere to a plastic surface, a fibroblast-like morphology and express mesenchymal surface 
markers (da Silva Meirelles et al. 2006, Martens et al. 2013, Pisciotta et al. 2015). These dental 
pulp stem cells are also characterised by their self-renewal ability and multilineage potential 
(Atari et al. 2012). Under particular molecular and environmental signals, they may 
differentiate into more specialised cells, such as fibroblasts, neural or endothelial cells to 
contribute to healing (Tecles et al. 2005).   
1.1.3.4 Immunocompetent Cells 
It is well established that the normal (healthy) dental pulp contains immunocompetent cells, 
which contribute to immunosurveillance within the dental pulp. Immune cells are present both 
in normal and inflamed dental pulps. In the normal pulp, the immune cells are known to regulate 
cell density, control cell proliferation and apoptosis, while in the inflamed pulp, they may 
contribute to immune regulation (Goldberg et al. 2015). 
These immune cells have a very important role in the maintenance of dental pulp tissue 
homeostasis, as well as their role in host defence during dental injury. Exposure of the dental 
pulp to noxious irritants will lead to the release of inflammatory mediators and cytokines and 
result in the upregulation of the inflammatory pathways. Both immunohistochemistry (IHC) 
and immunofluorescence (IF) studies have shown that non-inflamed and inflamed dental pulp 
contains DCs under the odontoblast layer with macrophage-like cells and a small number of T 
lymphocytes in the centre of the dental pulp (Farges et al. 2003, Goldberg et al. 2008, Cooper 
et al. 2014, Gaudin et al. 2015, Zanini et al. 2017).  
Macrophages have a regulatory role in the dental pulp immune system even in the absence 
of inflammation (Miyauchi et al. 2010). During inflammation, macrophages have three roles. 
Firstly, they act as antigen presenting cells (APCs), secondly they participate in phagocytosis 
and their third role is their responsibility for immunomodulation by producing different growth 
factors and cytokines (Fujiwara & Kobayashi 2005, Park et al. 2017). In irreversible pulpitis, 
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there is a significant increased expression of tumour necrosis factor (TNF)-α and interleukin 
(IL)1 (Pezelj-Ribaric et al. 2002, Elsalhy et al. 2013). IL1 is localized in macrophages and in 
the pulp connective tissue stroma (Silva et al. 2009). Activation of macrophages will lead to 
the activation of the adaptive immune response in association with the activation of DCs which 
secrete a range of cytokines that influence both innate and adaptive immune responses. The 
DCs are located under the odontoblast layer and form approximately 8% of the total pulp cells 
(Keller et al. 2010). They migrate to the regional lymph nodes and activate T lymphocytes 
(Farges et al. 2015).  
T lymphocytes are recognised as normal resident immune cells of dental pulp (Farges et al. 
2003). Their number, especially T helper (Th) lymphocytes, is increased in pulpal inflammation 
(Gaudin et al. 2015). A minor population of T lymphocytes, known as T regulatory (Treg) cells 
play an important function in regulating the immune and inflammatory responses by secreting 
of transforming growth factor (TGF)-β and anti-inflammatory cytokines (Chen et al. 2003). 
Regulatory T cells are a heterogeneous family of cells, known to regulate the host response by 
regulation the response of Th cells. Tregs have an important role to modulate immune 
responses, induct and maintain of immune tolerance, and to prevent autoimmune diseases 
(Nakajima et al. 2005, Teixeira‐Salum et al. 2010). They are characterised by the expression 
of a transmembrane protein known as the fork head/winged helix transcription factor (FOXP3) 
which is considered as a specific marker of Treg cells (Chen et al. 2003, Zheng & Rudensky 
2007, Campos et al. 2015). Treg cells have been identified in human periodontal disease, in 
inflamed dental pulp and in periapical lesions associated with pulpal infection (Nakajima et al. 
2005, AlShwaimi et al. 2009, Bruno et al. 2010, Yang et al. 2014) where they may prevent 
disease development and inhibit the immune response (Shevach 2002, Alvarez et al. 2018). 
Treg cells also have a role in the suppression of T cell activation and expansion and inhibit 
activated effector T cells, memory CD4 T cells, CD8 T cells, B cells, APCs, and natural killers 
(NKs) (Alroqi & Chatila 2016). The suppressive mechanism of Tregs can summarised by four 
mechanisms: (1) modulate the APCs maturation or function, (2) kill targeted cells, (3) metabolic 
disruption, and (4) inhibit cytokines (Liberal et al. 2015). Besides the immuno-suppression 
activity, Tregs may promote wound healing processes and help tissue-repair process (Zhang et 
al. 2017).  
1.1.4 Dental Pulp as a Connective Tissue 
Dental pulp is classified as a loose connective tissue. The dental pulp cells are in contact 
with macromolecules secreted extracellularly which form the ECM (Yildirim 2013). The ECM 
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provides a scaffold for the dental pulp tissues. The ECM is a major constituent of connective 
tissue and includes fibrillar proteins and ground substance. The ECM is composed of 
proteoglycans (chondroitin sulfate, heparan sulfate, hyaluronic acid, and phospholipid), 
collagenous proteins (mainly collagen type I and III, elastin), and non-collagenous proteins 
(sialoprotein, tenascin, and fibronectin). 
Collagen comprises approximately 34% of the total ECM proteins, especially collagen type 
I and type III. Collagen type I is the main collagen fibril in dental pulp (56%) and is essential 
for dental pulp tissue architecture stabilisation, while collagen type III comprise 41% and have 
a role in tissue elasticity. Other fibrillar collagens such as V, VI, and XI, and microfibrillin are 
also found in the dental pulp, while non-fibrillary type II collagen is not found (Goldberg & 
Smith 2004).  
Collagen is formed and secreted by both odontoblasts and fibroblasts which differ in their 
properties. The collagen secreted by odontoblasts subsequently mineralizes, while that 
produced by fibroblasts normally does not calcify. They also differ in their basic structure, in 
hydroxylysine content and their degree of cross-linking (Pashley et al. 2002).  
The ground substance provides the soft gel-like properties of the dental pulp due to its non-
collagenous protein content (characterised by the presence of proteoglycans), along with the 
water content. The ground substance is the medium which surrounds, supports structures and 
also through it the metabolic and wastes products are transferred from and to cells and vessels 
(Sloan 2015).  
1.1.5 Clinically Normal Dental Pulp and Inflamed Dental Pulp 
Based on the patients’ signs, symptoms, and objective examination findings, several clinical 
pulpal conditions are described: 1) normal, 2) reversible pulpitis, 3) symptomatic and 
asymptomatic irreversible pulpitis, 4) pulp necrosis, 5) previously treated, and 6) previously 
initiated therapy (American Association of Endodontists 2013). The term ‘clinically normal 
pulp’ is a clinical diagnostic term used to describe an asymptomatic pulp that has no clinical or 
radiographic signs or symptoms of disease and is normally responsive to pulp testing. The 
“clinically” normal pulp has “a mild or transient response to thermal cold testing, lasting no 
more than one to two seconds (secs) after the stimulus is removed” (Abbott & Yu 2007, 
American Association of Endodontists 2013). A clinically normal pulp does not show a 
lingering response to thermal stimuli. Furthermore, palpation and percussion tests will not 
induce tenderness (Abbott & Yu 2007). When the dental pulp is exposed to irritants, pulpal 
inflammation will follow. Dental pulp inflammation is diagnosed clinically according to signs 
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and symptoms into; (1) reversible pulpitis (short sharp pain elicited by a stimulus such as cold 
or sweet, normal radiographic findings), and (2) irreversible pulpitis (spontaneous or lingering 
pain after removal of a stimulus and may be accompanied by tenderness to percussion). The 
correct clinical diagnosis of the dental pulp is important and in part, can inform the possible 
histological pulp status and guides endodontic treatment planning.  
1.1.6 Dental Pulp Response to Irritants 
It is well known that the innate immune system responds to pathogens via the identification 
of pattern recognition receptors (PRRs) and pathogen-associated molecular patterns (PAMPs). 
It is now, however, also known that PRRs can be activated by non-microbial signals, which are 
known as damage-associated molecular patterns (DAMPs) (Sims et al. 2009, Chen & Nuñez 
2010). Damage-associated molecular patterns are endogenous factors or molecules that are 
normally found intracellularly, and they can be released extracellularly due to cellular stress or 
injury. Inflammation is important for the host defence against invasive pathogens, tissue injury 
and trauma, even with the absence of microorganisms. The presence of tissue inflammation 
with the absence of microorganisms is known as ‘sterile inflammation’ (Chen & Nuñez 2010).  
In response to irritants, various pulp cell types, such as odontoblasts, fibroblasts, DCs, neural 
cells and endothelial cells are involved in the immune response. Odontoblasts are the first line 
of defence in the pulp tissue and they release different chemokines and PRR which trigger the 
pulp inflammatory and immune response (Veerayutthwilai et al. 2007, Farges et al. 2009, 
Mutoh et al. 2009, Keller et al. 2010, Farges et al. 2011, Liu et al. 2014). They are able to detect 
lipoteichoic acid derived from the cell membranes of gram-positive bacteria via TLR2, while 
detecting lipopolysaccharides derived from the cell walls of gram-negative bacteria via TLR4 
(Jiang et al. 2006, Veerayutthwilai et al. 2007, He et al. 2015). 
1.1.6.1 Cellular and Molecular Dental Pulp Respond to Irritants and Inflammatory 
Mediators 
Irritants such as caries, chemicals and dental injury from trauma can affect the pulp. The 
pulp responds to irritants at a cellular and molecular level, and these responses can manifest 
into inflammatory and/or healing or regenerative events (Cooper et al. 2014). The odontoblasts, 
lining the peripheral pulp adjacent to the dentine, are able to detect irritants at an early stage 
(Cooper et al. 2014). In response, they release chemokines and cytokines (Horst et al. 2011). 
The odontoblasts and, thereafter, the pulp fibroblasts, endothelial cells, and stem cells detect 
irritant components via PRRs such as the TLRs, which recognize both PAMP and DAMP. 
Cytokines and chemokines generate signals which bind to cell receptors resulting in the 
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amplification of the inflammatory response within the tissue (Cooper et al. 2014). The best 
characterised cytokines and chemokines expressed in pulp disease are interleukin IL1!, TNF-
" and IL6, and other inflammatory molecular mediators such as S100 proteins (Kokkas et al. 
2011).  
Immune cells are resident in healthy pulp, and their levels are increased in pulpitis (Izumi et 
al. 1995). The migration of the immune cells through the pulp and their activity can cause 
significant host tissue damage. The immune cells release reactive oxygen species (ROS) and 
other potent enzymes, which can cause significant pulp cell and tissue damage. The signals 
released by the dental pulp’s dying cells can lead to increased proinflammatory response via 
toxins (Farges et al. 2015).  
1.1.6.2 Effects of Age, Obesity, and other Co-morbidities on Pulpal Morphology 
With increased age, the dental pulp volume is reduced and characteristically there are 
increased amounts of secondary and tertiary dentine, and dentine tubules become sclerosed (Ge 
et al. 2016). Secondary dentine is formed physiologically, while tertiary dentine is formed as a 
response of pathologic stimuli, such as caries or tooth wear. Dental pulp calcifications/stones 
may also be present in older adults and contribute to the decrease in pulp chamber volume. The 
prevalence of dental pulp stones increases with age although the association remains unclear 
(Turkal et al. 2013, Patil et al. 2018). The age‐related sclerosis of dentinal tubules and reduction 
in pulp chamber volume have also been associated with a reduction in pulp sensibility. Pulp 
sensibility with cold testing relies on osmotic movement of fluid within dentinal tubules and 
with sclerosis this is test becomes unreliable or does not reflect the vitality status of the pulp. 
Further, older patients have fewer nerve branches and greater mineralisation of the dental pulp 
nerves, which frequently presents as a weak or delayed responses to electrical stimuli, thus 
limiting the use of dental pulp sensibility tests and increasing the false‐negative responses 
(Jafarzadeh & Abbott 2010, Jespersen et al. 2014).  
The comorbidities of obesity are associated with tissue inflammation (Suvan et al. 2011). 
Obesity can alter the host immune responses to oral infections (Falagas & Kompoti 2006). 
Thus, proinflammatory molecules and the processes implicated in the pathogenesis of chronic 
oral infections may be influenced by obesity (Falagas & Kompoti 2006). An association 
between diet content in fatty acids and the dental pulp cell population has been suggested 
(Vermelin et al. 1995). Rats with fatty acid deficiency diet showed an increased dental pulp cell 
density (Vermelin et al. 1995) and an increased level of Leptin is associated with T2D 
microvascular complications and endothelial dysfunction (Katsiki et al. 2018). Leptin is 
expressed in human pulp fibroblasts (Linden et al. 2009), odontoblasts (Ide et al. 2011), and in 
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the normal and inflamed human dental pulp (Martín-González et al. 2013). Leptin plays a role 
in the dentine biomineralization process and/or in human dental pulp reparative and immune 
responses (Martín-González et al. 2015). The effect of obesity on dental pulp histology and 
morphology is unclear and warrants further research. 
1.1.6.3 Dental Pulp Fibrosis, Calcification and Stones  
The dental pulp changes from a loose connective tissue into denser fibrous tissue with pulp 
ageing and in response to irritation. The density and number of odontoblasts, and pulp 
fibroblasts decreases with pulp fibrosis (Goldberg 2014).  
Pulp stones are calcified masses in the dental pulps of healthy and diseased teeth. An irritated 
dental pulp may form a dental pulp stone in the presence of chronic inflammation (Ricucci et 
al. 2014). Fibroblasts are involved in soft tissue calcification in response to irritants (Ronchetti 
et al. 2013). Dental pulp stones are similar to other types of ‘stones’ in body tissues, and are 
formed from concentric or diffuse layers of calcified tissue in the ECM (Pashley et al. 2002).  
1.1.6.4 Pulpal Inflammatory Mediators 
Inflammation in the dental pulp has similarities to inflammation in other connective tissues 
in the body. It is mediated by several cellular and molecular factors to minimize the harmful 
effects of the irritating factors. Mild to moderate inflammation is an important prerequisite for 
dental pulp healing and repair (Cooper et al. 2014, Goldberg et al. 2015). However, the pulp is 
unique in that it is enclosed by non-complaint dentine and it does not have a collateral 
circulation. This means pulpal injury and the release of inflammatory mediators frequently 
results in tissue damage. Fibroblasts, and endothelial cells produce inflammatory mediators, 
including cytokines and expression adhesion molecules or PRR and therefore contribute to the 
immune system.  
Cytokines are a large group of secreted soluble proteins which assist immunocompetent 
cells’ communication in the regulation of inflammatory responses and are well recognised as 
markers of inflammation (Borish & Steinke 2003). They are polypeptides secreted by different 
cells and, based on their function, can be classified as proinflammatory and anti‐inflammatory 
cytokines. Proinflammatory cytokines mediate and enhance inflammation, whilst anti‐
inflammatory cytokines suppress inflammation. Inflammatory pathways within the pulp mean 
that many of these cytokines are under regulation of other mediators such as TGF-β1, VEGF, 
IL1β, IL2, IL4, IL10, IFN-γ and TNF-α (McLachlan et al. 2005, Farges et al. 2009, Abd-
Elmeguid et al. 2013, Elsalhy et al. 2013). 
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The expression level of TNF-α, IL1β and IL6 is significantly increased in pulpitis (Silva et 
al. 2009, Elsalhy et al. 2013, Galicia et al. 2016, Hirsch et al. 2017). Interleukin17A (IL17) is 
upregulated in pulpitis, and this occurs due to the activation of nuclear factor-κB (NF-#B) 
(Xiong et al. 2015). 
In cell culture, IL17 increases the expression of IL6 and IL8 mRNA in human dental 
fibroblast (Xiong et al. 2015). IL17 plays a positive regulatory role in pulp inflammation 
through upregulating cytokine expression and mediating monocytes migration (Liu et al. 2019). 
However, the exact role of IL17 in the dental pulp is unclear and understanding largely comes 
from studies involving periodontal and periapical lesions. 
1.1.6.5 The Link Between Inflammation and Regeneration  
The healing process by the dentine–pulp complex in response to injury and the formation of 
tertiary dentine is directed by either the original surviving odontoblasts or by newly 
differentiated odontoblast-like cells (Cooper & Smith 2013). The secretion of tertiary dentine 
is a result of a complex cellular process and is affected by inflammation. Tissue repair or 
regeneration occurs when the inflammation is under control and so there is a balance between 
levels of proinflammatory mediators and tissue regeneration. When higher levels of 
inflammation are present the intense recruitment and activation of immune cells tips the balance 
towards tissue destruction, delayed healing or persistent disease (Friedman 2002, Cooper & 
Smith 2013). High levels of cytokines and growth factors within the pulp may occur secondary 
to the release of growth factors from the dentine matrix (Lara et al. 2003, Tomson et al. 2013). 
The proinflammatory signalling can also inhibit repair by negatively affecting stem cell 
proliferation and activity (Chang et al. 2005). Conversely, inflammation can also be a stimulant 
for repair when a low level of cytokines are released within the tissue which can activate MAPK 
signalling, which promotes DSPP and dentine phosphoprotein (DPP) expression during tertiary 
dentine formation (Paula-Silva et al. 2009). Immune cells such as macrophages and dendritic 
cells, can release low level ROS which stimulate stem or progenitor cell differentiation and 
mineralization processes (Lee et al. 2006), and also can release cytokines which can stimulate 
odontoblast differentiation (Saito et al. 2011).  
Inflammation is necessary for healing, especially when using gold standard pulp capping 
agents, such as Mineral Trioxide Aggregate (MTA) and bioceramic cements, which stimulate 
the formation of tertiary dentine (Nair et al. 2008, Nowicka et al. 2013) 
MSCs may modulate inflammation and promote dental tissue repair. Dental pulp MSCs can 
regulate immunity due to their low-level surface expression of class II Major Histocompatibility 
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Complex (MHC-II) molecules. Their immunomodulatory ability is a result of direct cell-to-cell 
interactions, which leads to the secretion of TGF-β (Wang et al. 2012). In vitro, MSCs have 
been shown to be able to inhibit cell proliferation of T lymphocytes cells, NK, and DC cells 
and can inhibit immune cell functions such as immune cell maturation, cytokine secretion, and 
antigen presentation (Tomic et al. 2011). 
1.2 Type 2 Diabetes 
Type 2 diabetes (T2D) is a metabolic disorder characterised by hyperglycaemia and altered 
lipid metabolism caused by the inability of islet !-cells to secrete adequate insulin (Nolan et al. 
2011). The prevalence of this systemic disease has increased dramatically over the last decade 
and is associated with long-term damage, dysfunction, and failure of different organs, such as 
the heart, eyes, nerves, kidneys, and blood vessels (American Diabetes Association 2020). 
1.2.1 Prevalence and Incidence 
Diabetes mellitus is an international health burden. It is the most common chronic and non-
communicable disease in the world and continues to increase. Type 2 diabetes is one form of 
diabetes and is diagnosed if the fasting plasma glucose is ≥7.0mM/l (126mg/dl) or random 
plasma glucose is ≥11.1mM/l (200mg/dl) (Shah & Vella 2014, American Diabetes Association 
2020).  
The worldwide population with T2D has doubled over the past three decades. In 2010, Shaw 
et al. from Baker IDI Heart and Diabetes Institute in Australia published a global estimation of 
diabetes prevalence for all 216 countries for 2010 and 2030. They estimated the worldwide 
prevalence of diabetes among the adult population in 2010 was 6.4%, affecting 285 million 
adults. This number was predicted to rise to around 7.7% (439 million adults) by 2030 (Shaw 
et al. 2010). According to the latest International Diabetes Federation report in 2019, 463 
million adult people aged 20-79 years were considered to have diabetes, representing 9.3% of 
the global population. This number is predicted to increase to 578 million (10.2%) in 2030 and 
700 million (10.9%) in 2045 (International Diabetes Federation 2019, Saeedi et al. 2019).  
T2D is the predominant type of diabetes mellitus and accounts for 85-91% of all diabetes 
cases (González et al. 2009, Holman et al. 2015, International Diabetes Federation 2019). The 
massive burden of this disorder is due to its destructive damage to many of the body’s organs. 
Consequently, it places a severe economic burden on governments, health systems and 
individuals. 
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The prevalence of T2D varies according to a country’s economic status but in developed 
countries it is more common in those over 60 years of age (Shaw et al. 2010). T2D was seldom 
seen in young people or in pregnant women until 1990, but this changed in recent times 
(González et al. 2009, Colagiuri 2010, International Diabetes Federation 2019). The prevalence 
of T2D in young people in the USA is greater in some ethnic groups, as seen in young African 
American aged 10–19 years. The prevalence of T2D among this ethnic group (per 1,000) was 
1.06 (0.93–1.22) and the annual incidence (per 100,000) was 19.0 (16.9–21.3) (Mayer-Davis et 
al. 2009). 
In New Zealand, the incidence of T2D is significantly higher among Māori and Pacific Island 
populations than in Europeans. The 2018/19 New Zealand Health Survey recorded the 
prevalence of T2D as European 5.3%, Māori 9.1%, Pacific Island peoples 14.5%, and Asian 
Indians 7.9% (Ministry of Health 2019). It is estimated that by 2020, 18% of the New Zealand 
Pacific Island population will be diagnosed with T2D as opposed to 4% of New Zealanders of 
European origin (Coppell et al. 2013). In New Zealand, the adult obesity rate increased from 
27% in 2006/07 to 30.9% in 2018/19. According to last Ministry of Health, New Zealand 
statistic around one in three adults (aged 15 years and over) were obese and the prevalence of 
obesity is higher in Pacific (66.5%) and Māori (48.2%) adults. Adults living in the most 
deprived areas were 1.6 times more likely to be obese compared to adults living in the least 
deprived areas (Ministry of Health 2019). 
1.2.2 General and Oral Health Complications 
Type 2 diabetes is associated with reduced quality of life and reduction in life expectancy. 
Patients with diabetes show macro-or micro-vascular complications such as retinopathy, 
nephropathy, neuropathy, and atherosclerosis. Hyperglycaemia has been shown to cause 
systemic inflammation and increase the oxidative stress which damage tissues and organs 
(Kajitani et al. 2010).  
Oral health is affected by systemic health and diseases such as T2D. Diabetes can worsen 
oral inflammation and infections and vice versa especially the periodontal health in diabetes. 
T2D is associated with many oral health problems and symptoms including, dental caries, dry 
mouth, periodontal disease, and delayed wound healing (Dorocka-Bobkowska et al. 2010, 
Albert et al. 2012, Verhulst et al. 2019, American Diabetes Association 2020). 
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1.2.3 Aetiology and Pathophysiology of Type 2 Diabetes 
The aetiology of T2D is a group of genetic factors such as impaired insulin secretion, insulin 
resistance, and environmental factors such as aging, stress, lack of exercise and obesity. T2D 
occurrence is clearly associated with a family history of diabetes; a family history of a first-
degree relative with T2D increases three-fold the risk of developing diabetes (Weires et al. 
2007). Furthermore, the prevalence of T2D is generally higher in monozygotic twins than 
dizygotic twins. The high prevalence of T2D in some populations supports the role of genetics 
in the aetiology and pathogenesis of T2D (Avery & Duncan 2019).  
Genetic abnormalities can be related to the diabetic pathogenesis and affect the regulation 
of glucose metabolism and insulin secretion (Schäfer et al. 2011).   
The epidemic, both nationally and internationally of obesity largely explains the dramatic 
increase in the incidence and prevalence of T2D over the past 20 years - see Section 1.2.1. 
Obesity can cause insulin resistance and T2D (Kohei 2010).  
1.2.3.1 Pathophysiology of Type 2 Diabetes  
T2D is a syndrome characterised by abnormalities in fat and carbohydrate metabolism. The 
known risk parameters of diabetes are elevated fasting plasma glucose, abnormal glucose 
tolerance test, obesity and impaired insulin action. Insulin is the main hormone that regulates 
blood glucose; normal glycaemia is maintained by the balance between insulin action and 
insulin secretion and hence pancreatic islet !-cell dysfunction is central to the pathogenesis of 
T2D (Cersosimo et al. 2018). 
The abnormal glucose homeostasis in T2D is due to resistance to the action of insulin, 
inadequate insulin secretion and/or increased production of glucose by the liver. Diagnosed 
T2D is characterised by delayed and defective insulin secretion, and abnormal post-prandial 
suppression of glucagon (Cersosimo et al. 2018).  
Insulin resistance occurs when insulin does not act properly to reduce blood glucose levels 
even with its sufficient concentration in the blood. The impairment of insulin action mainly 
occurs in the liver and muscle when the biological effects of insulin are less than expected for 
both glucose disposal in skeletal muscle and the suppression of endogenous glucose production, 
primarily in the liver (Chatterjee et al. 2017, Cersosimo et al. 2018). Insulin resistance is 
associated with obesity and physical inactivity, both significant factors that contribute to the 
emergence of T2D (Kahn et al. 2006). An increased mass of triglyceride in the visceral or 
subcutaneous fat in obese people has large fat cells which are resistant to inhibition of lipolysis 
by insulin. Impaired insulin secretion induces pancreatic β-cell failure and initiates T2D. 
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Impaired glucose tolerance is due to a diminished glucose response in the early-phase insulin 
release from islet cells and reduced insulin secretion after meals is a cause of hyperglycaemia 
(Chatterjee et al. 2017).  
1.2.3.2 Type 2 Diabetes Diagnosis 
Glucose is the essential energy source in the body and is the only source of energy for the 
brain. Glucose homeostasis is controlled, and the normal fasting plasma glucose concentration 
range is 4.0 to 5.4mM/l (Ministry of Health 2011). Hyperglycaemia is the main characteristic 
in T2D (Rawshani et al. 2017, American Diabetes Association 2019).  
The diagnosis of T2D depends on internationally determined standards. For the diagnosis of 
diabetes, one of the following tests can be used: 
1. Fasting plasma glucose (FPG) 
2. 2-hour plasma glucose value during a 75g oral glucose tolerance test 
3. Glycated haemoglobin (HbA1c) 
4. Random blood glucose 
The criteria for a diagnosis of diabetes and the interpretation of the test results are shown in 
Table 1.1. 
Table 1.1: Diagnostic test and results for diabetes and pre-diabetes  
Diagnostic test Diabetes Pre-diabetes 
Fasting plasma glucose*  ≥126mg/dl (7.0mM/l) 100mg/dl (5.6mM/l) to 125mg/dl 
(6.9mM/l) (IFG) 
Oral glucose tolerance** ≥200mg/dl (11.1mM/l) 140mg/dl (7.8mM/l) to 199mg/dl 
(11.0mM/l) (IGT) 
HbA1c ≥6.5% (48.0mM/mol) 5.7-6.4% (39.0-47.0mM/mol) 
Random blood glucose*** >200mg/dl (11.1mM/l) - 
*Fasting plasma glucose is defined as no caloric intake for at least 8 hours.  
**Oral glucose tolerance is performed by using a glucose load containing the equivalent of 75g anhydrous glucose 
dissolved in water. 
*** Random blood glucose is used for the diagnosis of diabetes in a patient with classic symptoms of hyperglycaemia or 
hyperglycaemic crisis.  
HbA1c- glycated haemoglobin; IFG-impaired fasting glucose; IGT: impaired glucose tolerance.  




1.2.4 Intracellular Effect of Hyperglycaemia 
When tissues are exposed to hyperglycaemia and component cells are not capable of 
reducing the transport of glucose, an increased intracellular glucose concentration result. 
Diabetes selectively damages endothelial cells and mesangial cells, whose glucose transport 
rate does not decline rapidly in response to hyperglycaemia, leading to a high intracellular 
glucose level (Brownlee 2005). Increased intracellular glucose levels triggers the production of 
reactive oxygen species (ROS) in the mitochondria and activates four mechanisms that are 
involved in tissue damage: (1) increased polyol pathway flux, (2) activation of protein kinase 
C, (3) increased hexosamine pathway activity, and (4) increased non-enzymatic formation of 
advanced glycation end-products (AGEs) and their receptors RAGEs (Brownlee 2005).  
The non-enzymatic formation of AGEs results from interactions between glucose and lipids, 
nucleic acids or proteins (Singh et al. 2001, Singh et al. 2014). Their accumulation in tissue can 
cause tissue damage by altering intracellular proteins and cellular function (Brownlee 2001). 
AGEs can also diffuse out of the cell and cause dysfunction (Brownlee 2001). After diffusing 
out of the cell, AGEs bind to their receptors RAGE on macrophages and endothelial cells which 
activate proinflammatory cytokines including IL6, IL1 and TNF-α (Ahmed 2005, Brownlee 
2005). These processes cause the vascular damage typically seen in diabetic complications 
(Ahmed 2005, Brownlee 2005, Singh et al. 2014).  
1.2.5 Glycation   
Hyperglycaemia induces the formation of covalent adducts with plasma proteins through a 
non-enzymatic process known as glycation. Glycation is a spontaneous reaction and is 
dependent on different factors such as the duration and degree of hyperglycaemia, the proteins’ 
half-life and the tissues’ permeability to free glucose. Glycated proteins undergo a further 
reaction with time leading to poorly characterised structures called an advanced glycation end 
products (AGEs) as shown in Figure 1.2 (Ahmed 2005). This process is known as the Maillard 
reaction. Advanced glycation end products (AGEs) are a complex and heterogeneous group of 
compounds found in plasma which accumulate in tissues during ageing and at an accelerated 
rate in hyperglycaemia (Singh et al. 2001). The AGEs act in the body and tissues through three 
mechanisms:  
1. Forming cross-links which cause alteration of the structural features of a protein: 
AGEs may crosslink and biochemically modify the structure and functions of different 
proteins, such as the components of the two main types of ECM (connective tissue matrix, 
and the basement membrane). 
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2. Interacting with their receptors (RAGEs): AGEs-modified proteins are recognised by 
several AGEs-binding proteins, including RAGE which will trigger proinflammatory 
intracellular signalling when it binds to AGEs, leading to strong cellular responses (Rojas 
et al. 2013).  
3. Intracellular accumulation: Intracellular AGEs accumulation activates different 
signalling pathways, such as the NF‐κB pathway which leads to increasing expression of 
cytokines and growth factors (Ott et al. 2014). Furthermore, AGEs accumulation is 
associated with increased free radicals, such as ROS and nitric oxide (Goldin et al. 2006, 
Peres et al. 2017). 
 
Figure 1.2: Advanced glycation end products formation (Singh et al. 2014).  
 
Protein glycation reactions leading to AGEs are a major cause of diabetic complications 
(Kalousová et al. 2005, Kajitani et al. 2010). AGEs accumulate over a lifetime in permanent 
and long-living proteins such as collagen. It binds easily to collagen and increases cross-linking 
between collagen fibrils consequently altering the mechanical characteristics of collagen and 
fibrous tissue. Histopathological studies have shown AGEs accumulation in a variety of tissue 
types, body organs and layers (Sasaki et al. 2001, Zizzi et al. 2013).  
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1.2.5.1 Advanced Glycation End Products Receptor  
Advanced glycation end product receptor (RAGE) is a multiligand receptor belonging to the 
immunoglobulin superfamily. RAGE is expressed by different cell types such as lymphocytes, 
smooth muscle cells, endothelial cells, monocytes, and neurons. The biological effect of AGEs 
as mentioned before is mediated by the receptor of AGEs (RAGE) (Schmidt et al. 2000, Nedić 
et al. 2013). This interaction leads to a range of cellular responses such as proliferation of 
vascular smooth muscle cells, aggregation of platelets, stimulation of monocyte chemotaxis, 
osteoclast‐induced bone resorption and stimulation of the secretion of inflammatory cytokines, 
several growth factors and collagenase (Ramasamy et al. 2011). AGEs, via RAGE, activate 
signalling mechanisms that stress the cells, cause cellular dysfunction, and damage target 
tissues and organs, leading to many complications. RAGE interacts with non-AGEs ligands, 
such as S100/calgranulins and high mobility group box (HMGB1) (Taguchi et al. 2000, Kang 
et al. 2015). The binding of ligands to RAGE stimulates expression of RAGE and generates 
oxidative stress and increases the secretion of proinflammatory cytokines (Hofmann et al. 1999, 
Kang et al. 2015). RAGE has been shown to accumulate in diabetic tissues and forms to an 
accelerated degree in hyperglycaemia (Yamagishi et al. 2005). Some studies showed that 
AGEs-induced inflammatory responses increased the expression of proinflammatory cytokines 
such as IL6, IL1!, and TNF-" by activating RAGE, and NF‐κB in different cell lines (Rasheed 
et al. 2010, Yang et al. 2010).  
1.2.5.2 Glycation and the Extracellular Matrix and Blood Vessels 
Crosslinking of AGEs contributes to the rigidity of arterial connective tissues and increases 
when a person is hyperglycaemic (Basta et al. 2004). Collagen in the blood vessel wall has a 
long half-life and it undergoes significant nonenzymatic glycation with the time, which affects 
blood vessels and causes atherosclerosis (Brownlee 2000, Brownlee 2005). The activation of 
endothelial cells by AGEs is reported to increase RAGE’s gene expression by the activation of 
NF-κB (Tanaka et al. 2000). The increased crosslinks between the collagen protein molecules 
reduces collagen susceptibility to enzymatic digestion and decreases collagen solubility (Singh 
et al. 2014). 
1.2.5.3 Advanced Glycation End Products and Wound Healing 
The normal wound healing processes include four phases: haemostasis, inflammation, 
migration and proliferation (Shaikh‐Kader et al. 2019). In diabetes mellitus, many factors can 
lead to healing delay such as increase matrix metalloproteinases (MMPs) expression and 
activity, hypoxia, impaired blood vessel regeneration, fibroblast dysfunction, a higher risk of 
 23 
infection, and increased expression of AGEs and ROS (Guo & DiPietro 2010, Görlach et al. 
2015). Increased MMPs activity leads to increased collagen breakdown and thus impaired 
wound healing (Goova et al. 2001). AGEs-RAGE binding will activate NF‐κB and lead to 
increased cytokine expression and extend the inflammation thus prolonging wound healing 
(Byun et al. 2017). Furthermore, an increase in AGEs accumulation and AGEs/RAGE binding 
stimulates cells such as macrophages and significantly increases expression of VEGF and TNF‐
α, which affects vascular activity (Pertyńska-Marczewska et al. 2004).  
Fibroblasts play an important role in wound healing and collagen production. They migrate 
into the wound site, proliferate and form a new ECM (Gurtner et al. 2008). Increased AGEs 
accumulation and AGEs/RAGE binding impairs wound repair by decreasing the fibroblast 
proliferation and increasing fibroblast apoptosis (Wu & Yen 2005, Huijberts et al. 2008). The 
fibroblasts lose their turnover ability and contractility when RAGE is activated in fibroblasts 
(Kueper et al. 2007).  
During the pulp wound healing process, dental pulp progenitor cells or stem cells from the 
perivascular region in the pulp tissue migrate to the injured site and participate in healing 
(Nakashima & Akamine 2005). Hyperglycaemia could minimize the healing response of the 
dental pulp due to an altered inflammatory response which inhibits dentine bridge formation 
(Garber et al. 2009, Inagaki et al. 2010, Madani et al. 2014, Nakajima et al. 2015).  
1.2.6 Type 2 Diabetes, Advanced Glycation End Products, Advanced Glycation 
End Products Receptor, and Dental Tissues  
1.2.6.1 Type 2 Diabetes and Periodontal Disease 
Diabetes has been associated with oral infections such as periodontal disease, dental caries, 
and candidiasis (Rohani 2019). Mutans Streptococcus, Lactobacilli and Candida species have 
been identified as the predominant microbes from saliva of patients with diabetes (Hintao et al. 
2007). 
Most understanding of AGEs and RAGE in dental tissues has come from the periodontal 
literature where there is increased RAGE levels and their accumulation in the periodontal and 
gingival tissues of people with T2D (Lalla et al. 2001, Rajeev et al. 2011, Zizzi et al. 2013). 
AGEs activate MMP1, by the RAGE-NF-κB pathway and activate the production of 
proinflammatory chemokines and cytokines in gingival fibroblasts (Yu et al. 2012, Xu et al. 
2015). The level of AGEs is increased in the gingival crevicular fluid of patients with T2D and 
this is associated with poor periodontal status (Akram et al. 2019). The stimulation of 
periodontal ligament cells by glycation is associated with the upregulation of TLRs and RAGE, 
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and a high level of oxidative stress and glycemia, resulting in the damage of collagen fibres 
(Chang et al. 2013). Diabetes mellitus and the interaction of AGEs and RAGE are found to 
accelerate bone loss and the dissolution of collagen fibres in the periodontal tissues (Lalla et al. 
2001). Zizzi A et al. investigated in vivo the accumulation of AGEs in gingival tissues in both 
non-diabetes and diabetes participants with periodontitis. Their study showed a high 
accumulation of AGEs in gingival fibroblasts and vessels (Zizzi et al. 2013). They suggest that 
AGEs accumulation increased the severity of the periodontitis.  
1.2.6.2 Type 2 Diabetes and the Dental Pulp  
There is limited understanding of AGEs, RAGE and diabetes in the dental pulp of humans 
with most research coming from animal studies. This is largely due to the difficulty in 
standardising inclusion criteria since T2D patients frequently present with other associated co-
morbidities. In vitro human studies (Miura et al. 2014, Fukushima et al. 2015, Greis et al. 2018) 
have reported increased expression of AGEs in caries-affected dentine, and within the 
predentine there is collagen cross-linking and an increased accumulation of AGEs along 
dentinal tubules and in the intratubular collagenous matrix.  
Calcification has also been observed in association with T2D. Studies have showed that 
thickened predentine and pulp stones were more prevalent in diabetic rats. This due to AGEs 
which stimulate calcification in dental pulp cells (Inagaki et al. 2010, Nakajima et al. 2013). 
The expression levels of AGEs, RAGE, IL1!,	S100A8 and S100A9 were higher in diabetic rat 
pulp tissues and cultured rat dental pulp cells (Nakajima et al. 2013, Nakajima et al. 2015). In 
addition, another study showed that RAGE was increased in dental pulp during inflammation 
(Zhang et al. 2014). The binding of RAGE to S100 protein activates the NF‐κB pathway and 
increases proinflammatory responses (Takeichi et al. 2011).  
RAGE is intensely expressed in odontoblasts and subodontoblast cells, in the predentine 
area, the extracellular pulp matrix and in fibroblasts in pulpal inflammation and pulpitis 
(Tancharoen et al. 2014). Inflamed pulp tissues increase expression of RAGE, which stimulates 
the activity of IL1, IL6 and TNF-α, and affects the migration of pulp fibroblasts (Zhang et al. 
2014).  
In 2018, Ila et al. suggested that AGEs can reach the dental pulp through blood flow, and by 
diffusion from gingival crevicular fluid and dental support structures. They also suggest that 
AGEs act through its receptor RAGE and activate inflammatory mechanism that may affect the 
collagen fibres, and can change the colour and hardness of dental tissues (Ilea et al. 2018).  
 25 
A histological study of the dental pulp in Wistar rats recognised that pulp tissue can be 
affected by diabetes. In the dental pulp of Wistar rats with and without diabetes there was a 
significant reduction in the number of fibroblasts and in collagen fibres density after three 
months of diabetes, when compared with the non-diabetic group. In addition, in the third month, 
a significant reduction in the blood vessel density and increased inflammatory cell density was 
observed in the diabetic group. Pulp necrosis was detected after 3, 6, 9, and 12 months, affecting 
almost all the pulp tissue in diabetic samples (Claudino et al. 2015). This could be due to 
ischemia and damage to the blood circulation in diabetes (Lima et al. 2013). Diabetes may 
thicken dental pulp blood vessel walls (Moraru et al. 2017).  
Vital pulp therapies using biocompatible and bioactive materials are a common treatment to 
promote pulp healing in carious permanent teeth (Gandolfi et al. 2015). Direct pulp capping is 
one of the vital pulp therapies and aims to preserve exposed dental pulp and induce hard tissue 
repair. A histological study in rats found that diabetes affects dental pulp healing after direct 
pulp capping and increases the inflammatory response of the rat dental pulp to capping material 
(Madani et al. 2014). Metabolic changes induced by diabetes in rats modified the response to 
dental caries in particular, inhibition of dentine bridge formation after dental pulp exposure, 
suggesting that hyperglycaemia may reduce the healing response (Garber et al. 2009, Inagaki 
et al. 2010, Nakajima et al. 2015). AGEs may act as a DAMP for diabetic pulp calcification as 
they promote predentine thickening and pulp stone formation in rat dental pulp cells (Inagaki 
et al. 2010, Nakajima et al. 2013). However, no human studies have investigated the effect of 
direct pulp capping in patients who have diabetes. 
Expression levels of RAGE, IL1!, S100A8 and S100A9 were increased in diabetic dental 
pulp tissues (Nakajima et al. 2015). AGEs and lipopolysaccharide cooperatively increased 
proinflammatory chemokine and cytokine production, which resulted in tissue damage and 
increased inflammatory responses (Liu et al. 2009). AGEs accumulation can attribute to pulpal 
inflammation, necrosis and apical periodontitis (Pratha & Jayalakshmi 2016).  
Iwama et al. found that increased obligate anaerobic bacteria significantly reduces 
chemotactic responses of polymorphonuclear leukocytes in infected root canals of rats with 
T2D by comparison with healthy rats (Iwama et al. 2006). Metabolic products in T2D alter 
immune function in patients with diabetes such as decreased leukocyte adherence, chemotaxis 
and phagocytosis and increase microorganisms’ adherence to diabetes cells (Turina et al. 2005, 
Gupta et al. 2007).  
Dental pulp pain in patients with diabetes is called diabetic odontalgia. Patients with diabetes 
may have odontalgia without caries involvement due to pulp arteritis (Bender & Bender 2003). 
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The dental pulp in diabetes is known to have impaired collateral circulation and reduced 
polymorphonuclear leukocyte activity which can increase the risk of ischemia, infection, and 
necrosis. In this situation pulpal infection is known as anachoresis (Bender & Bender 2003, 
Lima et al. 2013). Diabetic odontalgia and anachoresis can be a diagnostic challenge (Bender 
& Bender 2003). 
A patient with medically well-controlled T2D who is free of general complications can be 
treated in the dental clinic the same as a non-diabetic person, and they do not require any extra 
prophylactic measures during dental treatment, including endodontic treatment (McKenna 
2006). Some studies have shown that the rate of success of endodontic treatment is reduced in 
patients with diabetes with pre-operative periapical lesions (Fouad & Burleson 2003). Wang et 
al. found there was a higher incidence of tooth extraction after endodontic treatment in patients 
with diabetes (Wang et al. 2011).  
In general, there is much evidence demonstrating that T2D is associated with pathological, 
immunological and inflammatory changes in the oral cavity, especially the periodontal tissues. 
The effect of T2D on clinically normal human dental pulp remains unresolved and further 
information is required at the molecular level to understand the effect of the disease on dental 
pulp healing in patients presenting for care who have T2D. The aim of this thesis was to provide 













1.3 Research Questions 
The effect of Type 2 diabetes on the clinically normal dental pulp is unknown. The three 
research questions were:  
• How does type 2 diabetes (T2D) affect the clinically normal dental pulp? 
• How does glycation affect clinically normal dental pulp tissue? 
• Does hyperglycaemia affect cultured hDPCs? 
1.4 Aims and Objectives 
• To evaluate the morphological differences of the clinically normal dental pulp from 
non-T2D and T2D participants.  
• To observe the presence of immune cells and cytokine expression in clinically normal 
dental pulp tissue collected from non-T2D and T2D participants. 
• To investigate the glycation process in the clinically normal dental pulp tissue of non-
T2D and T2D participants.  
• Establish primary hDPC lines and an in vitro diabetic cell culture model  
• Determine the effect of various glucose concentrations on hDPCs. 
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Chapter 2  
Participant Information 
2.1 Introduction 
T2D is at epidemic proportions and is one of the most important worldwide chronic diseases 
because of its severe chronic complications. The number of people with T2D increases with 
age, in those who are obese, people who have a family history of diabetes or a previous history 
of gestational diabetes, with physical inactivity, and in certain ethnicities (Sigal et al. 2004). 
Socioeconomic deprivation is associated with poor diet and other adverse lifestyle factors and 
is linked to high rates of diabetes (Gadsby 2002).  
Generally, T2D is more likely in people over 40 years of age but is also found in young 
adults and children, and it is often associated with obesity and a lack of exercise (Sigal et al. 
2004, Norris et al. 2008). The prevalence of T2D in New Zealand increases significantly with 
older age; people 0-24 years have a mean prevalence of 0.33%, while those 75 years and older 
have a mean of 18% (Ministry of Health 2019).  
Many patients with T2D are obese (Body Mass Index (BMI) greater than 30kg/m2) (Centers 
for Disease Control Prevention 2020). 31.6% of New Zealanders aged 15 years and over are 
obese (Ministry of Health 2019). There is a seven times greater risk of diabetes in obese people 
compared with those with a healthy weight, and a three-fold increase in risk for overweight 
people (Abdullah et al. 2010). 
The diagnosis of T2D, as outlined by the New Zealand Ministry of Health, is based on 
HbA1C 48mM/mol, or a fasting plasma glucose level of 7.0mM/l or 2 hours plasma glucose 
11.1mM/l during an oral glucose tolerance test, or the presence of classical symptoms of 
hyperglycaemia and random plasma glucose of 11.1mM/l (Ministry of Health 2011). See 






2.2 Aim  
To collect demographic and clinical data from study participants for experiments in Chapters 
3 and 4.  
2.3 Study Design and Methods 
A questionnaire (Appendix A, Section A.1.5) was used to collect demographic and clinical 
information about participants who provided tissue samples for use in the laboratory 
experiments carried out in Chapters 3 and 4.  
2.3.1 Ethical Approval and Māori Consultation 
Ethical approval for this study was obtained from the University of Otago Human Ethics 
Committee (Health)- (Project Reference H16/069). Māori consultation was undertaken with the 
Ngāi Tahu Research Consultation Committee (Appendix A, Sections A.1.1 and A.1.2). 
2.3.2 Participant Recruitment 
Forty participants (20 non-T2D and 20 T2D) with dental extractions as part of a routine 
treatment plan at the Faculty of Dentistry, University of Otago, Dunedin were recruited for this 
study. All participants met the inclusion and exclusion criteria.  
2.3.2.1 Recruitment of Participants 
The health records of patients on the oral surgery waiting list were reviewed to identify 
potential participants. Patients who met the inclusion criteria were invited to participate in the 
study by completing the questionnaire and donating their tooth after extraction. Informed 
written consent was obtained from participants (Appendix A; Sections A.1.3 and A.1.4). 
2.3.2.2 Inclusion Criteria for Type 2 Diabetes and Non-Type 2 Diabetes Group 
• Non-tobacco smokers  
• Aged 25-65 years  
• Any ethnic group 
• Periodontally healthy or gingivitis 
• Permanent teeth with complete root development 
• Clinically normal dental pulps; the tooth should be asymptomatic, no clinical or 
radiographic signs or symptoms of disease and is normally responsive to pulp testing 
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(mild or transient response to thermal cold testing, lasting no more than one to two 
seconds after the stimulus is removed)  
• Healthy participants with no systemic disease for non-T2D participants  
2.3.2.3 Additional Inclusion Criteria for Type 2 Diabetes Group 
• The same inclusion criteria as described in Section 2.3.2.2 
• Type 2 diabetics diagnosed by a physician with HbA1c of ≥48mM/mol or a fasting 
glucose of ≥7mM/l  
• No other systemic disease  
2.3.2.4 Exclusion Criteria for Type 2 Diabetes and Non-Type 2 Diabetes Group 
• Pregnancy or breastfeeding 
• Antibiotic treatment within the last three months 
• Periodontitis  
• Taking regular anti-inflammatory medication 
2.4 Questionnaire Design  
Participants who met the inclusion criteria were asked to complete a questionnaire prior to 
tooth extraction. The questionnaire consisted of tick boxes and open-ended questions and had 
four main parts:  
• Demographic characteristics  
• Medical history  
• Dental history  
• New Zealand index of socio-economic deprivation for individuals (NZiDep) 
The first section was designed to gather general and demographic data. It included questions 
on gender, age, ethnic group, weight and height. The second section was designed to gather 
general health information and included questions about age, the duration of diabetes, a family 
history of diabetes, management, treatment, diabetes control and tobacco smoking status. The 
third section collected dental history. The final section of the questionnaire gathered socio-
economic data using the non-occupational index of NZiDep. It consisted of eight questions 
created and validated for use in research (Salmond et al. 2006).  
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2.4.1 Data Collection  
The questionnaire collected qualitative and quantitative data to provide a summary of the 
participants from the T2D group and the non-T2D group.  
2.4.2 Data Management 
All questions were given a code for categorical analysis. Participants self-reported their 
height and weight and their BMI was calculated. Obesity was categorized according to the 
WHO and New Zealand Ministry of Health (MOH) BMI cut-off points into four main groups; 
underweight, healthy weight, overweight and obese (Ministry of Health 2015, World Health 
Organization 2017). The BMI classification for adults (over 18 years of age) is shown in Table 
2.1.  
The second part of the questionnaire included general health information for T2D 
participants. In this part, the participants recorded their age when diagnosed with diabetes and 
cited their medications, smoking history and information about their diabetes management and 
control.   
Table 2.1: Classification of adults according to their body mass index 
BMI value (Kg/m2) Classification 
<18.50 Underweight 






2.4.3 Socio-Economic Deprivation Index  
The New Zealand index of socio-economic deprivation for individuals (NZiDep) is a tool 
used for measuring socio-economic deprivation for New Zealand individuals and is a composite 
score based on eight questions (Salmond et al. 2006). The order of the eight questions is not 
important. Scoring of the NZiDep is based on the total number of ‘yes’ answers to the eight 
deprivation questions and typically has five categories (Table 2.2). 
Table 2.2: New Zealand index of socio-economic deprivation score 
Number of deprivation characteristics/variables NZiDep value 
No deprivation characteristics (0) 1 Dep 
One deprivation characteristic (1) 2 Dep 
Two deprivation characteristics (2) 3 Dep 
Three or four deprivation characteristics (3 or 4) 4 Dep 
Five or more deprivation characteristics (≥5) 5 Dep 
NZiDep: New Zealand index of socio-economic deprivation  
2.4.4 Analysis of Data  
Following completion of the survey, the collected data were entered into the Statistical 
Package for Social Sciences (IBM SPSS Statistics for Mac, Version 25.0. IBM) for statistical 
analysis. The characteristics of participants were described as the frequency and percentage for 
categorical variables and means with standard deviations (SD) for continuous variables. A Chi-
square test was used for assessing the relationships between T2D and variables; BMI, and 
NZiDep. Qualitative data from open-ended questions was analysed thematically.  
2.5 Results  
2.5.1 Demographics 
Fifty-six participants, 28 non-T2D and 28 T2D, completed the questionnaire and 48 
participants (28 non-T2D participants and 20 T2D) were included for analysis of the 
questionnaire. Eight T2D participants were excluded after completion of the questionnaire as 
they reported having other systemic conditions which were not recorded previously in their 
health file. Some teeth were used for optimisation of experimental protocols. In the final sample 
20 teeth collected from non-T2D participants, and 20 teeth from T2D participants were used in 
the histological, immunohistochemistry (IHC), immunofluorescent (IF), double 
immunofluorescences (DIF) and qPCR experiments. Four participants from the non-T2D group 
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donated two teeth, one was used for histological, IHC, IF and DIF and the other tooth was used 
for qPCR.  
The gender of participants in the non-T2D group was 9 males and 19 females, and in T2D 
group there were 9 males and 11 females. There was a difference in the mean age of participants 
from T2D and non-T2D groups (31 years old (SD=5.45) and 55 years old (SD=5.75) 
respectively), but the ethnicity of both groups was mainly New Zealand European in both 
groups (Table 2.3). 
2.5.2 Body Mass Index and Socio-Economic Deprivation Index  
Most non-T2D participants had a healthy BMI (75%), while most T2D participants were 
obese (80%) or overweight (20%). No T2D participants were in the healthy weight range (Table 
2.3). 
The socio-demographic characteristics of participants are presented in Table 2.3. Non-T2D 
participants had the lowest deprivation index (1 Dep) of 46.4%, while T2D participants had a 
higher deprivation index (4 and 5 Dep) of 45% and 20%, respectively. 
Type 2 diabetes was associated significantly with obesity and social deprivation. There was 
a significant relationship between the presence of T2D and the BMI score (Chi-square 
P<0.001). A similar relationship was observed between T2D and then NZiDep score (Chi-
square P=0.015). 
2.5.3 Dental Health 
Most participants from both groups had visited the dentist within the last year (75% non T2D 
and 50% T2D). The majority of both groups visited the dentist only when they had a problem 
(78.6% of non-T2D participants and 95% of T2D participants). Participants in the non-T2D 
group were more likely to have a dental check-up than the T2D group (21.4% of non-T2D 
participants and 5% of T2D participants). Removal of third molars was the most common 
reason for extraction for non-T2D participants (89.3%), while T2D participants were likely to 
have teeth extracted in order to accommodate a denture (55%), or extract wisdom teeth (20%) 
or a periodontal problem (20%).  
2.5.4 Glycaemic Control 
All T2D participants had been diagnosed with T2D in the past five years, and only one 
participant reported not being well-controlled. Nearly two thirds had a family history of T2D. 
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Participants were generally under the care of several medical professionals for diabetes 
management. The general medical practitioner most commonly co-ordinated care but practice 
nurses, diabetes physicians and diabetes nurses were sometimes involved. Most of the T2D 
participants managed their diabetes with oral medications e.g. Metformin and Gliclazide, 
combined with diet, exercise and other lifestyle factors (Table 2.4). 
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Male 9 9 
Female 19 11 





Age group (Years) 
Age (25-35) 22 3 
Age (36-45) 5 2 
Age (46-55) 1 9 
Age (56-65) 0 6 
Ethnicity 
NZ European 25 15 
Maori 0 4 
Samoan 0 1 
Cook Island/Maori 0 1 
Tongan 0 0 
Niuean 0 0 
Chinese 1 0 
Indian 1 0 
Other 1 0 
BMI score b 
Underweight 0 0 
Healthy weight 21 0 
Overweight 4 4 
Obese 3 16 
Dental 
History 
Last visit to the dentist 
Within the past year 21 10 
1-2 years 4 4 
>5 years 3 6 
Usual reason for 
visiting the dentist 
Dental examination (check-up) 6 1 
With pain 22 19 
Reason for extraction 
Wisdom teeth 25 4 
Periodontal disease 2 4 
Dental caries 0 1 
Removable prosthodontics 1 11 
NZiDep c NZiDep score 
1 Dep (Not deprived) 13 3 
2 Dep 5 1 
3 Dep 3 3 
4 Dep 6 9 
5 Dep (most deprived) 1 4 
a. Age (mean) 
b. BMI: Body mass index = weight(kg)/high(m)2 
c. NZiDep: New Zealand individuals deprivation index 




Table 2.4: General health of type 2 diabetic participants  
Characteristics Total n (%) 
Age of T2D diagnosis a 51 (SD=5.06) 
T2D duration <1 2 (10%) 
1-5 18 (90%) 
5-10 0 (0%) 
>10 0 (0%) 
Family history of T2D Yes 13 (65%) 
No 6 (30%) 
Don't Know 1 (5%) 
Regular follow up of diabetes with 
professional 
Yes 20 (100%) 
No 0 (0%) 
Health Professional General medical practitioner 10 (50%) 
Diabetes specialist 1 (5%) 
Practice nurse at your general practitioner 0 (0%) 
Diabetes nurse 0 (0%) 
Others 0 (0%) 
General medical practitioner & practice nurse at 
your general practitioner 
4 (20%) 
Diabetes specialist & diabetes nurse 2 (10%) 
General medical practitioner & diabetes 
specialist 
3 (15%) 
Diabetes management No treatment 0 (0%) 
Diet 0 (0%) 
Exercise 0 (0%) 
Insulin injections 0 (0%) 
Tablets/pills 12 (60%) 
Diet, exercise, tablets 5 (25%) 
Diet, tablets 3 (15%) 
Pills/tablet list Gliclazide 2 (10%)  
Metformin 18 (90%) 
Other regular medications Yes 1 (5%) 
No 19 (95%) 
Diabetes Control Well controlled 19 (95%) 
Poorly controlled 1 (5%) 
Other medical conditions associated 
with your T2D 
Yes 0 (0%) 
No 20 (100%) 
Smoking history Yes 0 (0%) 
No 20 (100%) 




This questionnaire collected demographic and clinical information about the participants 
before collecting their teeth for IHC and qPCR laboratory experiments. Questionnaire results 
showed a distinct difference in age between the participants in each group (mean age of non-
T2D participants was 31 years, while the mean age of T2D participants was 55 years). This age 
difference should be considered when reviewing the findings, as it was not known what 
influence this had on the dental pulp and whether or not some of the younger participants would 
have gone on to develop T2D in due course. However, it was difficult to more closely age match 
samples owing to availability of non-T2D participants who had teeth extracted that were not 
inflamed or infected. Generally, T2D has long been regarded as a condition that affects middle 
age and aged people, with most aged 40-59 years at the time of diagnosis (International 
Diabetes Federation 2019). Corda and colleagues studied salivary gland dysfunction in T2D 
patients with a mean age of 68 years (range 26-86 years), while their control group had a mean 
age of 48 (26-86) (Carda et al. 2006). Furthermore, Altamash et al. found the mean ages of 
their study group (diabetes with periodontal disease) and the control group (no diabetes and 
without periodontal disease) was 53 (age range 28-75) and 32 (age range 25-71) respectively 
(Altamash et al. 2016). This was comparable to the age variation in the current study where the 
majority of T2D participants were aged 46-65 years (mean age at diabetes onset was 51 years). 
In this group, T2D prevalence, according to the age groups, was 15% of 25-35 years old, 
compared with 5% of 45-54, 10.8% of 55-64 and 13% of 56-74 years old (Ministry of Health 
2019). The results from the MOH showed a very low percentage of young age groups with 
T2D, while it increased in older age groups. This further explains the challenge to collect 
samples from age-matched participants in this study, particularly in Dunedin which has only 
2.8% of New Zealand’s population. The number of people registered with Southern District 
Health Board as Registered Diabetics in 2017 was 14,355, and 82% of them were European 
and 10% were Māori. The age range of 10% European and 25% Māori diabetic were 65-74 
years old. The 2018/19 NZ Health Survey found that the T2D prevalence in Māori and Pacific 
Island peoples was 2-4 times higher compared with the European population (Ministry of 
Health 2019).  
People with T2D have double the risk of mortality than people without diabetes (Tancredi 
et al. 2015). In a meta-analysis of 698,782 people, diabetes was associated with an increased 
risk of coronary heart disease, ischaemic stroke, and other deaths related to vascular disease 
(Collaboration 2010). So as not to bias results, the inclusion criteria for T2D participants in this 
study was restricted to those who did not have other systemic complications. T2D is associated 
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with macrovascular complications and causes peripheral arterial disease, high blood pressure 
and an increased risk of myocardial infarction and stroke. Furthermore, T2D can cause 
microvascular complications, and lead to lose of vision, kidney disease and nerve problems 
(American Diabetes Association 2020).  
In the current study, the calculated BMI was based on the self-reported weight and height of 
participants and the results showed a significant association between BMI score and T2D. This 
is consistent with international studies that showed a seven times greater risk of diabetes in 
obese people and three times greater risk in people who were overweight compared with those 
of a healthy weight (Abdullah et al. 2010, Gatineau et al. 2014). Obesity is a risk factor for 
diabetes; weight gain increases the risk for new-onset diabetes, and weight loss reduces the risk 
(Wilding 2014). The 2018/2019 NZ Health Survey found that almost one in three adults were 
obese 32%, and a further 35% of adults were overweight. The increasing number of obese and 
overweight people in NZ will double the number of those with T2D (Ministry of Health 2019). 
The questionnaire used in this study may be useful for a study using a larger sample size to 
investigate the association between the different variables, particularly the BMI, NZiDep and 
associated co-morbidities. 
There is an accepted relationship between oral health and general health (Leite et al. 2013, 
Kudiyirickal & Pappachan 2015) and the current study shows oral health appears to be a lesser 
priority for those with T2D. Studies have reported that diabetes patients had significantly fewer 
annual dental check-ups compared with non-diabetes patients (Lalla et al. 2006, Eldarrat 2011, 
Sahril et al. 2014). The current questionnaire results are congruent with these studies where 
diabetics were more likely to attend the dentist for a specific problem than a routine 
examination. The awareness of the relationship between oral health and diabetes were minimal 
in the diabetes population (Bowyer et al. 2011, Valerio et al. 2011, Sahril et al. 2014). In the 
United States, one of the objectives initiated by the Centre for Disease Control was to increase 
the proportion of patients with diabetes who have an annual dental examination by 71% by 
2010 (Centres for Disease Control and Prevention 2005). Their findings emphasised the need 
to increase awareness and support for oral health care among adults with diabetes.	There needs 
to be a preventative approach to managing patients with diabetes by educating patients and 
encouraging at least annual examinations. This enables an early diagnosis of oral disease, 
especially periodontal disease which may impair glycaemic control (Preshaw et al. 2012, Leite 
et al. 2013). A multidisciplinary effort is required to promote the awareness of the bi-directional 
relationship between oral health and diabetes. Raising the awareness is important in providing 
care for these patients.  
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Self-reported diabetes prevalence is twice as high in the most deprived communities of New 
Zealand (Ministry of Health 2019). Diabetes is a chronic disease that needs continuing medical 
care and patient self-management education to prevent any acute complications and to reduce 
the risk of chronic complications. The American Diabetes Association advises diabetes patients 
to receive their medical care from a general medical practitioner. However, for different 
reasons, some diabetes patients and their health care providers do not achieve the desired goals 
of treatment and the latter patients may be referred to specialist diabetes physicians (American 
Diabetes Association 2003). The T2D participants in this study were medically healthy, with 
no associated complications and this may explain why general medical practitioners and 
practice nurses the main co-ordinators of care were.  
The results of current study support that the T2D prevalence is increased in a group of obese 
and socioeconomic deprived people in New Zealand.  
2.7 Conclusion 
There were distinct differences between the two sample groups. T2D participants were older 
than non-T2D participants. Most of the participants in the T2D group had a family history of 
diabetes and had a higher deprivation index. The T2D participants were obese and overweight 
with a high BMI. Furthermore, the current investigation has shown that diabetic participants 
received their general health care from their general medical practitioner. T2D participants were 




Chapter 3  
Inflammation, Diabetes and Dental Pulp 
3.1 Introduction  
Type 2 diabetes (T2D) is a chronic multisystemic disorder which alters the structure and 
functions of many organs and tissues. Diabetes results in changes in collagen within the tissue 
and leads to the development of atherosclerosis, thickening of capillary basement membranes, 
increased arterial wall stiffness, decreased tissue elasticity, sclerosis of the renal glomeruli, 
stiffening of the heart muscle, periarticular rigidity, and osteoarthritis (Verzijl et al. 2002, 
Zieman et al. 2005, Connizzo et al. 2014, Argyropoulos et al. 2016, Giménez et al. 2017). 
There is abundant evidence that diabetes is associated with pathological changes in the oral 
tissues (Kudiyirickal & Pappachan 2015), particularly in the periodontium where it is associated 
with decreased collagen turnover, and impaired neutrophil chemotaxis and phagocytosis 
(Preshaw & Bissett 2013). The gingival tissue in patients with diabetes is characterised by a 
reduction of collagen solubility and distortion of reticular fibres (Silva et al. 2008). The effects 
of high glucose concentration, as well as impaired glucose metabolism, are seen histologically 
with enlarged vessel walls and a narrow vessel lumen which leads to vascular dysfunction 
(Tesseromatis et al. 2009, Preshaw & Bissett 2013). Further, the severity of periodontal disease 
is increased in patients with uncontrolled T2D which frequently leads to early tooth loss in 
patients with diabetes (Mealey & Ocampo 2007, Monea et al. 2012). Delayed wound healing 
of extraction sockets and the presence of enlarged periapical lesions have also been observed 
in patients with T2D (Devlin et al. 1996, Iwama et al. 2003).  
There is scant literature on the effects of T2D on dental pulp and evidence-based 
understanding mainly comes from animal studies where hyperglycaemia results a marked 
reduction in plasma blood flow in the dental pulp of rats (Amatyakul et al. 2003). Histological 
studies indicate that in patients with T2D and periodontal disease there is an associated 
morphological change in dental pulp with an increased amount of fibrous connective tissue with 
thickening and arteriosclerotic change in the walls of blood vessels (Moraru et al. 2017). 
Hyperglycaemia can affect dental pulp repair and healing as evidenced by reduced dentine 
bridge thickness following direct pulp capping with mineral trioxide aggregate (MTA) (Garber 
et al. 2009).  
The dental pulp has a role in immunosurveillance and is able to elicit an inflammatory 
response to irritants (Hahn & Liewehr 2007, Hahn & Liewehr 2007). Pattern recognition 
receptors (PRR), in particular the TLR2 and TLR4, are expressed in healthy and inflamed 
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human dental pulp particularly on odontoblasts (Jiang et al. 2006, Veerayutthwilai et al. 2007, 
Farges et al. 2009, Hirao et al. 2009, Keller et al. 2010). These are important in the innate 
immune response via PAMPs and DAMPs (Brownlee 1995, Sims et al. 2009, Chen & Nuñez 
2010). Hyperglycaemia leads to chronic activation and an unregulated innate immune response. 
In T2D patients, the function of the dendritic, monocytes and neutrophils cells is decreased 
(Lecube et al. 2011, Piątkiewicz et al. 2013, Restrepo et al. 2014). There is an altered immune 
response with associated tissue changes and delayed healing in T2D patients. 
T2D is a metabolic proinflammatory condition associated with increased levels of certain 
inflammatory chemicals such as circulating cytokines (Zozulinska & Wierusz-Wysocka 2006, 
Al-Shukaili et al. 2013, Daniele et al. 2014). Peripheral vascular changes occur, leading to 
reduced immunological capacity of the patient and increased susceptibility for infection. 
Hyperglycaemia has been shown to increase TNF", IL6, IL1! and IL17 (Dandona et al. 2007, 
Hang et al. 2014, Samuel et al. 2019). Patients with T2D have decreased numbers of 
immunosuppressive Treg cells and increased proinflammatory cytokines (Mahmoud & Al-
Ozairi 2013, Qiao et al. 2016). The expression and spatial distribution of Tregs and 
inflammatory cytokines in dental pulp are known, while in T2D dental pulps are not clear. 
The term ‘clinically normal pulp’ is used to describe an asymptomatic pulp that has no signs 
or symptoms of disease (Abbott & Yu 2007). Cells in healthy (normal) tissues are necessary to 
contribute to healing but what is ‘normal’ for a pulp in a patient with diabetes is largely 
unknown. Further information is needed to understand the morphological differences between 
T2D and non-T2D to inform clinical decision-making and enhance understanding of prognosis 
and treatment outcomes. There is a lack of data concerning the level and the role of many 
immune and inflammatory markers in the normal dental pulp of T2D patients. The following 
study will use special stains and immunohistochemistry to answer these questions.  
This chapter will include two sections. The first section analyses the histological appearance 
of the normal dental pulp in T2D and non-T2D samples, and the second section analyses 





3.2 Hypothesis  
T2D will result in altered morphology within a clinically normal dental pulp with increased 
connective tissue and inflammation. 
3.3 Experimental Aims 
The aim of the present study was to use special stains and immunohistochemistry to 
determine the morphology and cellular composition of normal dental pulps from the two groups 
described in Chapter 2. The specific aims are:  
1. To examine the morphology of clinically normal dental pulp in the presence of T2D 
using various histological stains. 
2. Using immunohistochemistry determine the expression and distribution of immune 
cells (anti-CD4, anti-CD68, anti-CD83, anti-FOXP3), transmembrane PRRs (anti-
TLR2 and anti-TLR4) and cytokines (anti-IL1!, anti-IL6, anti-IL17 and anti-TNF-
") in clinically normal dental pulp tissue collected from non-T2D and T2D 
participants. 
3.4 Materials and Methods  
Ethical approval for this study was obtained from the University of Otago Human Ethics 
Committee (Health) - Project Reference H16/069 and Māori consultation entered with the Ngāi 
Tahu Research Consultation Committee (see Appendix A.1). 
3.4.1 Participants and Sample Collection 
Permanent molar teeth which had complete root development and were diagnosed as having 
a clinically normal pulp were collected according to the inclusion and exclusion criteria 
described in Chapter 2 (Section 2.3.2). Teeth were collected from 10 T2D and 10 non-T2D 
participants who were undergoing dental extractions as part of their clinical treatment plan at 
the Faculty of Dentistry at the University of Otago, Dunedin, New Zealand.  
Following extraction, the teeth were sectioned horizontally below the CEJ and the coronal 
portion was immediately placed in 10% neutral buffered formalin for 24 hours to fix the tissues. 
Specimens were decalcified by placing them in 10% EDTA solution (with agitation) at 4℃ 
for 8-12 weeks. The solution was replenished every 2-3 days. Prior to processing and 
embedding them in paraffin, the specimens were trimmed to ensure they were in the correct 
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plane of section and they were agitated in phosphate-buffered saline (PBS) for 24 hours to 
remove excess EDTA. 
Fourteen sections of 4μm thickness were cut from each specimen block using a microtome 
(MicromTM HM 340 E, Thermo Fisher Scientific Inc.) and placed on positively charged 
Histobond® microscope slides (Cat. No. 0810000, Marienfeld Laboratory Glassware). Tissue 
sections were incubated in an upright position at a temperature of 60°C for 2 hours, followed 
by an overnight incubation at 60°C to remove any water trapped under the sections and to 
facilitate tissue adhesion onto the slides. Sections were then stored at 4°C until required for 
special stain and IHC experiments. 
3.4.2 Haematoxylin and Eosin, and Special Stains  
Two sections (the first and last sections) from each specimen block were stained with H&E 
(see Appendix B1.1) for routine histological examination and to verify the level of section. All 
specimens were histologically examined by two Oral Pathologists at the Oral Pathology Centre 
(OPC) to confirm the absence of inflammation. 
Sections were stained with Masson’s trichrome, van Gieson (VG), and silver reticulin special 
stains to identify the presence and location of micro-structures and tissues in non-T2D and T2D 
dental pulp (Appendix B.1). Positive control tissues were run in parallel, kidney for Masson’s 
trichrome, intestine for VG stain, and liver for silver reticulin stain. 
3.4.3 Immunohistochemistry  
3.4.3.1 Primary Antibody Optimisation  
Primary antibody specificity and matched isotype controls are shown in Tables 3.1 and 3.2. 
IHC protocols were optimised for each of the antibodies including primary antibody 
concentration, antigen-retrieval methods, blocking agents and wash buffers. The optimum 
working dilution for each primary antibody was determined using a positive control according 






Table 3.1: Primary antibodies used in this study 
Primary antibody Antigen specificity 
Immune cells 
Anti-CD4 • CD4+ve T cells 
Anti- CD68 • Macrophages 
Anti-CD83 • CD4+ve T cells  
• Dendritic cells 





• Dendritic cells 










• Endothelial cells 
Anti-IL6 • Macrophages 
• Neutrophils 
   Anti-IL17 • IL17+ve cells 
   Anti-TNF-" 
• Macrophages (mainly) 
• CD4+ve T cells 
• NK cells 
• Neutrophils 




Table 3.2: Primary antibody suggested manufacturer’s concentrations, isotype and positive 
control tissue 








  100µg at 0.14mg/ml 
1:100-1:250 
Tonsil 











50µg/ml at 1mg/ml Spleen 
Anti-FOXP3 Sc 130666 






Anti-TLR2 Sc 21759 








100µg at 1mg/ml 
1:100 
Tonsil 




100µg at 2mg/ml 
1:50 to 1:200 
Thymus 




   500µg at 1mg/ml 
0.125µg/ml 
Spleen 




50µg/ml at mg/ml Dentigerous cyst 








3.4.3.2 Immunohistochemistry Optimisation 
All specimens and control slides were labelled. Tissue sections were deparaffinised in xylene 
and rehydrated through descending grades of ethanol. These sections were rinsed in tap water, 
followed by distilled water. A wash in PBS (pH 7.4) for 2-3 minutes (mins) was followed by 
rinsing in distilled water (see Appendix B.6.1).  
3.4.3.3 Antigen Retrieval 
In order to unmask the tissue antigens caused by formalin fixation, a heat-induced antigen 
retrieval (HIAR) technique was used.  
Three antigen retrieval conditions were compared to establish a reproducible working 
method. 
1. No antigen retrieval. 
2. Heat-mediated antigen retrieval was performed on the sections by placing them in a 
pre-heated sodium citrate buffer (pH 6) in a water bath. The temperature of 80°C was 
tested for a 20-minute immersion period. 
3. As for condition 2. but for an immersion period of 15 minutes. 
The sections were placed into a Coplin jar containing 0.01M sodium citrate buffer (pH 6.0). 
The sodium citrate buffer had been prepared earlier (Appendix B.3.1). The Coplin jar was 
covered, then the jar was placed in a preheated water bath (80℃) followed by a PBS wash and 
then allowed to cool down in PBS for 20 minutes to room temperature (RT) and put in tap water 
for two minutes. 
3.4.3.4 Primary Antibody Concentration 
A doubling technique was used to test different concentrations in order to identify the 
concentration that would yield optimal staining with minimal non-specific background staining. 
The antibody data sheets from the respective manufacturers were used and a positive control 
according to the dilution range suggested was used. Positive and negative control specimens 
were used in parallel. 
Positive tissue controls known to express each of the proteins were used to check antibody 
specificity (Table 3.2). The positive control tissue blocks were selected from the archives of 
OPC, at the University of Otago and were prepared in the same manner as the tissue samples 
from non-T2D and T2D dental pulp.  
A negative control, in which the non-specific antibodies immunoglobulin (Ig)-G replaced 
the primary antibody at the same concentration, acted as the negative controls. The IgG isotype 
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control contained Ig, but without an antibody attached, hence it resulted in no staining and 
served as a negative control for each run. Selection of the IgG isotype relied upon the host 
origin of each primary antibody (Table 3.2). 
3.4.3.5 Background Reduction and Primary Antibody Incubation 
The endogenous peroxidase enzyme activity in the tissue sections was blocked to prevent 
non-specific background staining. This was done by submerging the tissue sections in 3% 
hydrogen peroxide (H2O2) in methanol, followed by two 10-minute washes in 0.01M PBS at 
pH 7.4 (Table 3.3 and Appendix B.6. 2).  
3.4.3.6 Signal Amplification  
The binding of the antigen-antibody signal was amplified manually using one drop (30μl) of 
the secondary reagent EnVision™+ Dual Link System-HRP for both the anti-mouse and anti-
rabbit (Cat. No. K4063, Agilent Dako). This system is based on a horseradish peroxidase (HRP) 
labelled polymer which is conjugated with secondary antibodies. The labelled polymer does 
not contain avidin or biotin. Consequently, nonspecific staining resulting from endogenous 
avidin-biotin activity is eliminated or significantly reduced. All tissue sections were incubated 
with a secondary antibody for 30 minutes at RT in the humidified chamber. All tissue sections 
were washed with PBS for 10 minutes. 
3.4.3.7 Visualisation  
Following signal amplification, the enzyme-labelled antibodies were visualised using 3,3’-
diamino-benzidine (DAB) (Cat. No. D3939, Sigma Aldrich) as the chromogen. The DAB 
solution was prepared by mixing one drop of DAB substrate with 1ml of supplied buffered 
solution. 100µl of DAB solution was pipetted onto each slide and left for 5-10 minutes (varied 
between antibodies). Following this, the slides were immediately washed with PBS for 10 
minutes. Finally, the sections were counterstained with Gill’s haematoxylin for 30 seconds, 
followed by running tap water (until clear) and after that they were dipped into Scott’s tap water 
for 30 seconds. The sections were then dehydrated with a series of graded alcohols, followed 
by xylene for 5 minutes twice (Appendix B.6). 
The slides were cover-slipped individually in a fume hood using a mounting media. All the 




Table 3.3: Optimised antigen retrieval and primary antibody concentration for dental pulp 












Anti-CD4 1.41µg/ml 1:100 Heat 80℃ 20 mins Overnight No background 
Anti-CD68 0.05µg/ml 1:50 Heat 90℃  20 mins Overnight No background 
Anti-CD83 4µg/ml 1:50 Heat 80℃  20 mins Overnight No background 
Anti-FOXP3 20µg/ml 1:50 Heat 80℃  20 mins Overnight No background 
Anti-TLR2 10µg/ml 1:20 Heat 80℃ 20 mins Overnight No background 
Anti-TLR4 10µg/ml 1:100 Heat 80℃  20 mins Overnight No background 
Anti-IL1! 10µg/ml 1:200 Heat 80℃  20 mins Overnight 
15 min H2O2,  
10 min milk 
Anti-IL6 10µg/ml 1:100 Heat 80℃  20 mins Overnight 
15 min H2O2,  
10 min milk 
Anti-IL17 2µg/ml 1:100 
Heat 80℃ 
15 mins 
Overnight 15 min H2O2,  10 min milk 
Anti-TNF" 1µg/ml 1:100 Heat 80℃  20 mins Overnight 
15 min H2O2,  
10 min milk 
Min/Mins; minute(s)  
 
3.4.4 Digital Capture and Analysis 
Digital images of each slide were taken at 40x magnification by using the Aperio Scanscope 
CS2 image capture device (Aperio CS2, Aperio Technologies, Leica Biosystems). Digital 
analysis of these images was carried out using the ImageScope (Aperio ImageScope Version 
12.4.3, Aperio Technologies, Leica Biosystems) and Adobe Photoshop CC 2018 (Adobe 
Photoshop CC 2018, Version 18, Adobe Systems Inc.) software packages. 
3.4.5 Data Analysis 
3.4.5.1 Haematoxylin and Eosin Analysis 
Five representative sections of each specimen for each stain were randomly selected, two 
from the centre and three at the corners, to be analysed under a light microscope at varying 
magnifications up to 40x (Leica DM Digital Microscope, CTR 5000, Leica Microsystems). 
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3.4.5.1.1 Qualitative Analysis: Four Zones of the Dental Pulp 
The microscopic analysis focused on the presence and morphologic preservation of the 
following parameters: blood vessels, nerve bundles, and ECM components of the pulp 
(fibroblasts, fibrosis and calcification). Fibrosis was defined as an increased collagen fibre 
concentration. It was noted as present or absent. The presence of pulp calcification was also 
noted. The density (the number per field area) of blood vessels was analysed on H&E slides at 
20x and 40x magnifications. Dentine was evaluated for the presence or absence of tertiary 
dentine. The appearance of the predentine width was described for both groups.  
3.4.5.1.2 Quantitative Analysis 
Quantitative evaluation of cells and blood vessels was performed in all pulp zones at a 
magnification of 20x for each image area of (0.12mm2). Five sections in the centre of the pulp 
with the greatest number of cells from each tooth were selected for cell and blood vessel number 
analysis. Cell counting was performed manually under high-power fields (20x) at five different 
locations in the tooth specimens. 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 7 for Mac OS X (GraphPad Prism 
7.0a Macintosh Version, 2016). A student’s t-test was used to determine whether there were 
significant differences between the total cell, arteriole, venule and capillary numbers in T2D 
and non-T2D samples. One-way ANOVA was used to compare between the non-T2D and T2D 
dental pulp samples. P-value <0.05 was considered statistically significant.  
3.4.5.2 Special Stains 
3.4.5.2.1 Qualitative Analysis 
The Masson’s trichrome, van Gieson (VG), and silver reticulin special stains were examined 
to qualitatively identify collagen structures in non-T2D and T2D dental pulp. The distribution 
of staining was compared between the two groups. Samples were analysed visually with the 
non-T2D group used as the baseline for comparison.  
3.4.5.3 Immunohistochemistry Analysis 
Sections were examined using a light microscope (Leica CTR5000, Leica Microsystems) at 
10x, 20x and 40x objective magnification. Photomicrographs of the representative fields in the 
correct orientation were taken at 40x magnification using the Aperio Scanscope CS2 image 
capture device (Aperio CS2, Aperio Technologies, Leica Biosystems). Digital analysis and 
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images of these scanned slides were carried out using the ImageScope (Aperio ImageScope 
Version 12.4.3, Aperio Technologies, Leica Biosystems). Immunopositivity was defined as 
distinct and clear brownish DAB chromogen staining within a cell. Qualitative and semi-
quantitative analyses were performed to assess the protein expression in the specimens. 
3.4.5.3.1 Qualitative Analyses 
A descriptive analysis of microscopic findings was performed for the non-T2D and T2D 
specimens and compared with the control specimens using a light microscope (Leica CTR5000, 
Leica Microsystems) under various magnifications up to 40x. 
The parameters of qualitative analysis were: 
1. Presence of staining (positive/negative) 
2. Distribution (focal/diffuse) 
3. Location within dental pulp (peripheral and/or central of dental pulp) 
4. Staining pattern (classified as cell membrane and/or cytoplasmic or nuclear) 
3.4.5.3.2 Semi-Quantitative Analysis 
Cell counting was performed from ten selected areas within the specimen. The hotspot areas 
with high immunopositive cell density in each sample were selected. Immunopositive cells 
were counted using a digitally superimposed square graticule grid board and the “Grid” tool 
followed by the “Cell-counter” tool in the ImageScope (Aperio ImageScope version 12.4.3, 
Aperio Technologies, Leica Biosystems). Final cell counts were expressed as positively stained 
cells per unit area. Each area was viewed at a size corresponding to a square viewing field of 
200μm×140μm=0.028mm2 at 40x zoom magnification.  
Statistical Analysis 
The data obtained from the cell counting for each antibody were tabulated and analysed 
using GraphPad Prism 7 for Mac OS X (GraphPad Prism 7.0a Macintosh Version, 2016) to 
obtain the average value of the scores of each slide. The difference in expression in between 
the T2D groups was analysed using the unpaired student t-test. A P-value of <0.05 indicated 
data of statistical significance. 
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3.4.6 Results 
3.4.6.1 Gross Appearance of Dental Pulp Tissue  
Gross evaluations of the pulp from non-T2D participants showed that it was pink, soft in 
consistency, and resilient, whereas those obtained from the T2D patients were hard in 
consistency, friable, and the hard tissue required two weeks longer to decalcify. 
3.4.6.2 Histology 
3.4.6.2.1 Histological Characteristic of Dental Pulp 
H & E staining showed the morphology of the ‘clinically normal’ dental pulp collected from 
non-T2D participants to be uninflamed with only occasional cells in some fields that 
morphologically resembled lymphocytes. It consisted of loose fibrous connective tissue 
surrounded by dentine. Within the pulp chamber, the pulp had well-defined zones from the 
peripheral to the central region. Clearly defined zones could be seen in the normal dental pulp. 
The peripheral pulp presented three typical areas: the odontoblastic zone, the CFZ and the CRZ. 
The odontoblast layer was well defined, continuous, and uninterrupted with a single layer of 
columnar odontoblast with polarised nuclei. The odontoblast junction line with predentine was 
regular and well defined. The CFZ, which is located below the odontoblast layer, was clearly 
defined and separated the odontoblast layer from the CRZ. The CRZ was well defined with 
numerous small thin-walled blood vessels and fibroblasts. More centrally, the pulp contained 
cells, blood vessels, nerve fibres and the ECM. The central pulp was characterised by a large 
number of spindle-shaped fibroblast loosely arranged within connective tissue. The blood 
vessels were well defined with a thick, or thin walled lumen lined with endothelial cells. Small 
blood vessels or capillaries were most consistently seen in the CRZ and with a single endothelial 
cell layer. The nerve fibres were well defined as wavy shaped bundles and most associated with 
blood vessels to form a well-defined neurovascular bundle (Figure 3.1).  
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Figure 3.1: H&E stain of a non-T2D dental pulp. Photomicrograph of normal dental pulp of non-
T2D sample from molar teeth of a 41 year old participant showing (A) Histological appearance of 
coronal non-T2D dental pulp with well-defined dental pulp zones (2x magnification, scale bar, 1mm). 
(B) Dental pulp zones and regular dentinal tubules (H&E, 20x, scale bar 100µm). (C) Central pulp (20x 
magnification, 200µm). (D) Central pulp region with well-defined blood vessels at higher power view 
of central pulp (40x scale bar 50µm).  
D-dentine, PD- predentine, O-odontoblast, P- central pulp, N-nerve bundles, NVB- neurovascular bundle, CFZ-




The general histology was similar in both groups. However, some clear variability was 
observed in the T2D samples compared with non-T2D samples. There was a clear definition of 
pulp zones in both groups. The odontoblast layer was less well defined, discontinuous in some 
regions, with clear changes in the position and orientation of the odontoblastic nuclei in T2D 
samples. Odontoblasts were more cuboidal compared with those in the non-T2D dental pulp. 
Furthermore, the movement of the odontoblastic nuclei towards the dentinal tubules was more 
evident than in the control samples. The junction between the odontoblasts and predentine was 
irregular. The predentine was identified as pale pink in colour, located from the outer border of 
the odontoblastic cell layers of the pulp to the borderline of the dentine. The predentine in T2D 
participants was characterised by irregular outline with changes in thickness along the 
odontoblast layer (Figure 3.2).  
 
Figure 3.2: H&E stain of a T2D dental pulp. Photomicrograph of normal dental pulp of T2D from a 
molar tooth of a 53 year old participant (A) showing histological appearance of coronal T2D dental pulp 
with well-defined dental pulp zones (2x, scale bar, 1mm). (B) Dental pulp zones and tertiary dentine 
deposition (4x, scale bar 500µm). (C) Peripheral part of T2D dental pulp (20x, 100µm). (D) Central 
pulp region with thick-walled small blood vessels (40x scale bar 50µm). (blood vessel: yellow arrow) 
D-dentine, PD- predentine, O-odontoblast, P- central pulp, N-nerve bundles, CFZ-cell free zone, CRZ-cell rich 
zone, BV-blood vessels, F-fibroblast, TD- tertiary dentine. 
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Irregular tertiary dentine-like tissue was observed in eight samples of T2D dental pulp. 
However, this was not found in any of the non-T2D dental pulps. Calcification was commonly 
seen within the pulp chamber. Pulp stones were found in eight of the 10 T2D dental pulp tissues 
examined. The size and location of the pulp stones was variable (Figure 3.3). 
 
Figure 3.3: H&E stain of a T2D dental pulp. Photomicrograph of normal dental pulp from molar teeth 
of different T2D samples (A) and (B) pulp stones in peripheral pulp region (10x & 20x, scale bar 200µm 
&100 µm respectively), (C) and (D) Pulp stones in central pulp. Blood vessels of T2D pulp with 
thickening walls with fewer endothelial cells (20x, scale bar 100µm). 
D-dentine, PD-predentine, O-odontoblast, N-nerve bundles, BV-blood vessels, S-pulp stone. 
 
In the T2D pulp, there was less definition between the CFZ and CRZ, and CRZ was less 
cellular with fewer blood vessels and fibroblasts. The central pulp showed a greater density of 
fibrous connective tissue than in non-T2D specimens. 
The pulp was less cellular and less vascular. Most vessels in the T2D pulp had thickened 
and irregular walls with few endothelial cells. The small blood vessels or capillaries were 
frequently occluded with blood cells and often visualised in the odontoblast and subodontoblast 
layer (Figures 3.4 and 3.5).  
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Figure 3.4: H&E stain of a T2D and non-T2D dental pulp. Photomicrograph of clinically normal 
dental pulp from molar teeth of T2D and non-T2D participants showing sub-odontoblast capillaries 
(yellow arrows) in (A) T2D dental pulp. (B) non-T2D dental pulp. (20x, scale bar 100µm) 
 
 
Figure 3.5: H&E stain of a T2D dental pulp. Photomicrograph of blood vessels of normal dental pulp 
of (A) & (C) T2D dental pulp and (B) & (D) Non-T2D dental pulp showing a range of blood vessels 





In the T2D pulp tissue, nerve fibres and neurovascular bundles were less distinct in most 
samples of the T2D dental pulp (Figure 3.6). 
 
Figure 3.6: H&E stain of a T2D and non-T2D dental pulp. Photomicrograph of blood vessels and 
nerves of normal dental pulp from molar teeth of T2D and non-T2D samples. (A-C) showing the blood 
vessels, nerves and neurovascular bundles in T2D dental pulp. (D-F) show the blood vessels, nerves and 
neurovascular bundle in non-T2D dental pulp. (A, B, D, E, F; 20x, scale bar 100µm) and (C; 40x, scale 
bar 50µm). 
N-nerve bundles, NVB-neurovascular bundle, BV-blood vessels, S-pulp stone. 
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3.4.6.2.2 Morphometric Evaluation  
T2D samples were significantly less cellular than non-T2D samples (P<0.001). In T2D 
dental pulp, the mean total cells/image area count was (776.60 cells ± 42.44) with a SD of 
134.2, while the mean in non-T2D dental pulp was 1005 ± 31.66 SD 100.1 (Figure 3.7). 
 
Figure 3.7: Total cell count. The mean total cells/sample count in T2D and non-T2D dental pulp 
samples using an unpaired student t-test (*P-value <0.001). The error bar indicates standard deviation. 
 
The mean number of blood vessels was significantly lower in the T2D dental pulp group 
(P=0.03) (Table 3.4).  
Table 3.4: Mean blood vessels in non-type 2 diabetic and type 2 diabetic dental pulp 
 





















Non-T2D dental pulp 
(n=10) 
T2D dental pulp 
(n=10) P-value 
(Mean ± SEM) SD (Mean ± SEM) SD 
Total blood vessels 197.8 ± 5.75 18.17 180.8 ± 4.85 15.32   P=0.03* 
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3.4.6.3 Special Stains 
3.4.6.3.1 Masson’s Trichrome Stain 
Masson’s trichrome differentiates collagen from muscle. In the central pulp, the connective 
tissue consisted of regularly arranged collagen fibres which appeared to be denser in dental 
pulp of T2Ds samples compared with non-T2Ds. The blood vessels in the central pulp from 
both groups were large and lined with dark blue stained endothelial cells. Moreover, the smooth 
muscle of the blood vessel walls was stained blue/purple. The pulp stones were dark purple and 
were free in the pulp or were close to blood vessels. The blood vessels in the central pulp of 
T2D samples had thicker walls and were more strongly stained (Figure 3.8). 
 
Figure 3.8: Masson’s trichrome stain. Photomicrograph of dental pulp from (A and C) T2D and (B 
and D) non-T2D participants. The intensity of blue collagen stain in central region of dental pulp and 
around blood vessels (yellow arrows) was increased in T2D group. Endothelial cells, black stain (red 
arrows), lining the blood vessel lumen. (A & B; 20x, scale bar 100µm), (C, & D; 40x, scale bar 50µm) 
BV-blood vessels, F-fibroblast, S-pulp stone. 
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3.4.6.3.2 Van Gieson Stain 
The van Gieson’s stains collagen and connective tissue and also elastic fibres found in blood 
vessels. The organic component of dentine of the non-T2D dental pulp stained intensely red 
and the tubular structure of the dentine was visible. The dental pulp was predominantly 
composed of regular connective tissue, as indicated by the red stained collagen fibres. This stain 
highlighted the elastin lining the large blood vessels wall in the central pulp. The T2D dental 
pulp had a distinctively different pattern of collagen fibre staining with stronger intensity and 
fewer cells compared with non-T2D dental pulp. Elastin fibres in arteriole walls stained brown 
with VG. Pulp stones seen in the T2D specimens stained densely red (Figure 3.9). 
 
Figure 3.9: Van Gieson stain. Photomicrograph of dental pulp from (A and C) T2D and (B and D) 
non-T2D participants. The collagen staining was intense in T2D dental pulp especially around blood 
vessels compared with the non-T2D dental pulp. (A & C; 20x, scale bar 100µm), (B &D; 40x, scale bar 
50µm)  
N-nerve bundles, NVB-neurovascular bundle, BV-blood vessels 
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3.4.6.3.3 Silver Reticulin Stain 
Silver reticulin stains reticulin fibres found in nerves and blood vessels. Reticulin stain uses 
silver impregnation to detect reticulin fibres composed of collagen type III. The fibres appear 
black against a grey to light pink background. The reticulin fibres were prominent in the 
odontoblast layer and in blood vessel walls. The blood vessels in the central pulp were large 
and round, while smaller vessels were seen in the CRZ. In T2D specimens, blood vessel walls 
were irregular and reticulin fibres were most evident in the thickened vessel walls, while the 
reticulin fibre arrangement was less prominent in the odontoblast zone. T2D dental pulp 
reticular fibres showed less staining intensity in vessel walls and few were detected in the 
odontoblast layer compared with the non-T2D dental pulp (Figure 3.10). 
 
Figure 3.10: Silver reticulin stain. Photomicrograph of dental pulp from (A and C) T2D and (B and 
D) non-T2D participants. Fewer fine black lines which represent the reticulin fibres (blue arrows) in the 
odontoblast layer, BV wall, fibroblast cells cell wall was found in dental pulp of T2D compared with 
non-T2D dental pulp. (A-D; 40x, 50µm)  
N-nerve bundles, NVB-neurovascular bundle, BV-blood vessels, S-pulp stone 
 
 
3.4.6.4 Immunohistochemistry Results 
3.4.6.4.1 Immunohistochemistry Qualitative Analysis 
Table 3.5: Summary of qualitative findings of Immunohistochemistry  
 Non-T2D T2D 
Antibody Staining pattern Spatial distribution Cell expression Staining Pattern Spatial distribution Cell expression 
CD4 • Cell membrane 
• Cytoplasm 
• Scattered centrally • Lymphocytes • Cell membrane 
• Cytoplasm 
• Scattered centrally • Lymphocytes 
CD68 
• Cell membrane 
• Cytoplasm 
• Scattered centrally 
• Subodontoblast region 
• Macrophages  
• Endothelial cells 
• Cell membrane 
• Cytoplasm 






• Cytoplasm  




• Scattered centrally 
• Subodontoblast region 
• Odontoblasts 
• Odontoblasts 
• Dendritic cells 
• Cytoplasm 














• Scattered centrally 
• Odontoblasts 
• Lymphocytes • Nuclear Cytoplasm • Scattered centrally 
• Odontoblasts 
• Lymphocytes 
TLR2 • Cell membrane 
• Cytoplasm 
• Scattered in 
Odontoblasts 
• Odontoblasts • Cell membrane 
• Cytoplasm 




• Cell membrane 
• Cytoplasm 
• Scattered in 
Odontoblasts 
• Odontoblasts • Cell membrane 
• Cytoplasm 








• Cell membrane 
• Cytoplasm 
• Scattered centrally 
• Diffuse in Odontoblasts 
• Odontoblasts 
• Fibroblasts 
• Endothelial cells 
• Nerve fibres 
• Cytoplasm • Scattered centrally  




• Endothelial cells 
• Nerve fibres 
IL6 
• Cytoplasm • Scattered centrally 




• Cytoplasm • Scattered centrally 







 Non-T2D T2D 





•  Centrally and 
Odontoblasts 
• Lymphocytes  
• Odontoblasts 
• Cytoplasm 
• Extracellular matrix 














• Extracellular matrix 










3.4.6.4.1.1 CD4 Immunostaining  
The 51 kDa surface marker CD4 expressed on CD4+ve T cells was visualised as dark staining 
in the cell membrane and cytoplasm in both the dental pulp of T2D and non-T2D specimens. 
Positive staining of the anti-CD4 antibody was found on scattered cells in the centre of the 
dental pulp. Lymphocytes in human tonsil tissue were used as a positive control. The negative 
control used non-specific rabbit IgG antibody to replace the primary antibody (Figure 3.11).  
 
Figure 3.11: Photomicrograph showing immunohistochemistry staining with anti-CD4. (A) Dental 
pulp of T2D specimens and (B) Dental pulp of non-T2D specimens showing immunopositive staining 
of CD4+ve T cells (arrows). (C) Positive control tissue: human tonsil. (D) Negative dental pulp control 




3.4.6.4.1.2 CD68 Immunostaining  
The anti-CD68 antibody was used to identify macrophages. Cells in the dental pulp of T2D 
and non-T2D specimens showed positive staining to the anti-CD68 antibody in the 
subodontoblast region and centrally within the pulp. CD68 protein was scattered on occasional 
cells in the subodontoblast region and in the central pulp. Macrophages in human inflamed 
dentigerous cyst tissue were used as a positive control. The negative control used non-specific 
mouse IgG antibody to replace the primary antibody (Figure 3.12). 
 
Figure 3.12: Photomicrograph showing immunohistochemistry staining with anti-CD68. (A) 
Dental pulp of T2D specimens and (B) Dental pulp of non-T2D specimens showing immunopositive 
staining of macrophages (arrows). (C) Positive control tissue: inflamed dentigerous cyst. (D) Negative 




3.4.6.4.1.3 CD83 Immunostaining 
The anti-CD83 antibody was used to identify dendritic cells. Cells in the dental pulp of T2D 
and non-T2D specimens showed positive cell membrane and cytoplasmic staining with anti-
CD83 antibody. Occasionally CD83+ve cells were scattered amongst the odontoblasts, in the 
subodontoblast region and within central part of the dental pulp. Dendritic cells within spleen 
tissue were used as a positive control. The negative control used non-specific mouse IgG 
antibody to replace the primary antibody (Figure 3.13).  
 
Figure 3.13: Photomicrograph showing immunohistochemistry staining with anti-CD83. (A) 
Peripheral dental pulp of T2D samples and (B) Peripheral dental pulp of non-T2D samples showing 
immunopositive staining of dendritic cells (squares). (C) Positive control tissue: human spleen. (D) 





3.4.6.4.1.4 FOXP3 Immunostaining 
The anti-FOXP3 antibody was used to identify regulatory T cells (Tregs). Cells within the 
central and peripheral dental pulp of T2D and non-T2D specimens were positively stained with 
anti-FOXP3 antibody. Tregs were present adjacent to endothelial cells, nerve cells, and 
odontoblasts. Tregs within tonsil tissue was used as a positive control, while the negative 
control used non-specific mouse IgG antibody to replace the primary antibody (Figures 3.14 
and 3.15). 
  
Figure 3.14: Photomicrograph showing immunohistochemistry staining with anti-FOXP3. 
Peripheral dental pulp of (A) T2D specimens and (B) non-T2D specimens showing immunopositive 
staining of regulatory T-cells (shown in squares). (C) Positive control tissue: human tonsil. (D) Negative 
dental pulp control with non-specific mouse IgG isotype. (A-C; 40x magnification, scale bar 50μm), (D; 




Figure 3.15: Photomicrograph showing immunohistochemistry staining with anti-FOXP3. Central 
dental pulp of (A) T2D specimens and (B) non-T2D specimens showing immunopositive staining of 
regulatory T-cells (squares). (C) Positive control tissue: human tonsil. (D) Negative dental pulp control 




3.4.6.4.1.5 TLR2 Immunostaining 
The TLR2 antibody detects transmembrane PRRs that are expressed on several cell types, 
including monocytes, macrophages, dendritic cells, PMNs and odontoblasts. Occasional 
odontoblasts of both groups showed positive staining to the TLR2 antibody with faint brown 
cell membrane and cytoplasmic staining, but no other cells were positive. Tonsil tissue was 
used as a positive control and dental pulp tissue of non-T2D was used as a negative control by 
using the non-specific mouse IgG antibody to replace the primary antibody (Figure 3.16). 
   
Figure 3.16: Photomicrograph showing immunohistochemistry staining with anti-TLR2. (A) The 
dental pulp of T2D specimens and (B) Dental pulp of non-T2D specimens showing immunopositive 
staining of TLR2 in the odontoblast of the dental pulp specimens (arrows). (C) Positive control tissue: 
human tonsil. (D) Negative dental pulp control with non-specific mouse IgG isotype. (20x 




3.4.6.4.1.6 TLR4 Immunostaining 
The TLR4 antibody also detects transmembrane PRRs, found on many cells such as 
macrophages, endothelial and odontoblasts and this protein expression indicates TLR4 provides 
an initial line of defence against bacterial irritants. The dental pulp of T2D and non-T2D 
specimens showed positive TLR4 staining, with greater number of positive cells in T2D 
specimens compared with non-T2D specimens. Tonsil tissue was used as a positive control and 
dental pulp tissue of non-T2D was used as a negative control by using the non-specific mouse 
IgG antibody to replace the primary antibody (Figure 3.17).  
 
Figure 3.17: Photomicrograph showing immunohistochemistry staining with anti-TLR4. (A) 
Dental pulp of T2D group and (B) Dental pulp of non-T2D group showing immunopositive staining of 
TLR4 in the peripheral pulp (arrows). (C) Positive control tissue: human tonsil (D) Negative dental pulp 
control with the non-specific mouse IgG isotype. (A and B; 40x magnification, scale bar 50µm) and (C 




3.4.6.4.1.7 IL1! Immunostaining 
The anti-IL1! antibody was used to identify IL1 expressing cells. The dental pulp of T2D 
and non-T2D specimens showed positive staining for the IL1! antibody on macrophages, 
fibroblasts, nerve and endothelial like-cells. IL1! protein was diffusely distributed in both the 
odontoblasts and central dental pulp, with more staining in the T2D samples. (Figure 3.18).  
 
Figure 3.18: Photomicrograph showing immunohistochemistry staining with anti-IL1". (A) 
Dental pulp of T2D specimens and (B) Dental pulp of non-T2D specimens showing immunopositive 
staining of IL1!. (C) Positive control tissue: human thymus (D) Negative dental pulp control with non-
specific mouse IgG isotype. (A and B; 40x magnification, scale bar 50µm) (C and D; 20x magnification, 




3.4.6.4.1.8 IL6 Immunostaining 
The anti-IL6 antibody was used to identify IL6 expressing cells. The dental pulp of T2D and 
non-T2D specimens showed positive cytoplasmic staining to the anti-IL6 antibody in 
odontoblasts, macrophages, fibroblasts, nerve, and endothelial like-cells throughout the pulp. 
(Figure 3.19). 
 
Figure 3.19: Photomicrograph showing immunohistochemistry staining with anti-IL6. Peripheral 
dental pulp of (A) T2D specimens and (B) non-T2D specimens showing immunopositive staining of 
IL6 (squares). (C) Positive control tissue: human spleen (D) Negative dental pulp control with non-
specific mouse IgG isotype. (A, C and D; 40x magnification, scale bar 50µm) (B; 20x magnification, 




3.4.6.4.1.9 IL17 Immunostaining 
The anti-IL17 antibody was used to identify IL17 expressing cells. Positive 
immunoreactivity was detected in the cytoplasm of odontoblasts and cells scattered throughout 
the dental pulp (Figure 3.20).  
 
Figure 3.20: Photomicrograph showing immunohistochemistry staining with anti-IL17. Peripheral 
dental pulp of (A) T2D specimens and (B) non-T2D specimens showing immunopositive staining of 
IL17 (squares). (C) Positive control tissue: inflamed dentigerous cyst. (D) Negative dental pulp control 




3.4.6.4.1.10 TNF-$ Immunostaining 
The anti-TNF-" antibody was used to identify TNF-"	expressing cells within the pulp. T2D 
and non-T2D specimens showed positive staining to the anti-TNF-" antibody in the cytoplasm 
of odontoblasts, endothelial cells, lymphocyte-like and macrophage-like cells and in the ECM 
throughout the pulp. (Figure 3.21).  
 
Figure 3.21: Photomicrograph showing immunohistochemistry staining with anti-TNF-$. Central 
dental pulp of (A) T2D specimens and (B) non-T2D specimens showing immunopositive staining of 
TNF-$	(squares). (C) Positive control tissue: spleen tissue (D) Negative dental pulp control with non-
specific mouse IgG isotype. (A and B; 40x magnification, scale bar 50µm) (C and D 20x magnification, 




3.4.6.4.2 Immunohistochemistry Semi-quantitative Analysis  
The IHC semi-quantitative analysis showed that T2D resulted in an increased expression of 
markers for CD4+ve cells, macrophages and dendritic cells and decreased expression of Tregs. 
Furthermore, T2D samples had increased expression of TLR2 and TLR4. The IHC results 
showed increased expression of cytokines (IL1!, IL6, IL17 and TNF") in T2D samples 
compared with non-T2D samples. 
The semi-quantitative analysis of protein expression included the positively stained cells per 
image area.  
3.4.6.4.2.1 Positively Stained Cells 
The mean number of stained immune cells within the hotspot selected area (anti-CD68, anti-
CD83, anti-FOXP3), PRRs (anti-TLR2 and anti-TLR4) and expression of cytokines (anti-IL1!, 
anti-IL6, anti-IL17 and anti-TNF-") was significantly higher in the dental pulp of T2D 
compared with non-T2D group. Not all reached significance (Table 3.6).  
Table 3.6: Mean number of positively stained cells per sample  
 
  
Antibodies Non-T2D T2D P-value 
Mean SD Standard 
error 
Mean SD Standard 
error 
CD4 120.40 45.45 14.37 137.30 36.17 11.44 0.37 
CD68 74.80 28.09 8.88 144.00 41.74 13.20 <0.001 
CD83 59.30 31.49 9.96 85.40 21.67 6.85 0.04 
FOXP3 164.30 42.96 13.58 122.50 21.70 6.86 0.01 
TLR2 28.00 9.17 2.90 64.10 21.65 6.85 <0.001 
TLR4 26.00 13.20 4.17 53.30 12.23 3.87 <0.001 
IL1! 80.70 38.55 12.19 121.00 23.45 7.42 0.01 
IL6 139.50 27.79 8.79 236.40 42.84 13.55 < 0.0001 
IL17 52.90 17.78 5.62 115.20 19.10 6.04 <0.0001 
TNF-" 97.00 18.69 5.91 124.6 24.84 7.86 0.01 
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3.5 Discussion 
Diabetes alters the structure and functions of many organs and tissues, including dental pulp. 
Furthermore, this disease can influence the outcome of endodontic treatment (Catanzaro et al. 
2006, Ferreira et al. 2014, Madani et al. 2014). The effect of general health on oral health is 
evident when observing the dental pulp (Huang & Chen 2016) and the present study showed 
the effect of T2D on the dental pulp. The results of the current study accept the hypothesis that 
T2D will result in altered tissue morphology with increased connective tissue and inflammation 
within a clinically normal dental pulp. 
A significant finding in this study was evidence of an increased amount fibrous connective 
tissue in the T2D samples compared with non-T2D. The connective tissue appeared to have 
more collagen and with fewer reticular fibres altering the characteristic appearance of the dental 
pulp from loose connective tissue to a more fibrous tissue. This change in connective tissue has 
been reported in other body sites (Aneja et al. 2008, Hill 2009, Castellar et al. 2011, Hsu et al. 
2014). Another important histological finding was the thickening of blood vessel walls in the 
dental pulp of participants with T2D. These results are consistent with Moraru et al. (2017) 
who used histology to evaluate changes in dental pulp collected from periodontal patients with 
diabetes (Moraru et al. 2017).  
The current results showed significant histological differences in the pulp vasculature from 
T2D participants with some indicators of microscopic arteriosclerosis particularly in thicker 
blood vessel walls. It is known that hyperglycaemia causes vascular wall changes which may 
accelerate arteriosclerosis (Catanzaro et al. 2006) and long term diabetes causes vascular 
sclerosis in periodontal tissues (Mr et al. 2014) so there may be similar processes occurring in 
the dental pulp.  
T2D is associated with altered fibrous connective tissue particularly collagen metabolism 
which may impair healing (Ferreira Martinez et al. 2000, Mr et al. 2014). These fibrotic changes 
in the pulp have been attributed to ischemia that occurs following changes in blood vessels (Mr 
et al. 2014). Several studies have shown that blood flow is reduced in the dental pulp in patients 
with diabetes (Bender & Bender 2003, Ferreira et al. 2014). The present study found that the 
collagen sheaths around the blood vessels and collagen fibres were thickened in T2D dental 
pulp, but reticulin fibres were reduced. It is clear that diabetes mellites affects wound healing, 
collagen synthesis and collagen degradation by prolonging the inflammation and delaying 
proliferation and then formation of granulation tissue which consequently affects collagen 
deposition (Lioupis 2005, Haycocks et al. 2013). These findings also would suggest that pulp 
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preservation following injury and healing following direct pulp capping may be impaired. 
Further research is required to identify the precise mechanism by which diabetes effects 
collagen production and fibrosis of dental pulp tissue.  
Pulpal calcifications are related to metabolic disturbances due to age, pathological responses 
in the dental tissues, and systemic disease (Huang & Chen 2016). Dental pulp tissues of patients 
with diabetes are associated with pathologic calcifications such as diffuse calcification and pulp 
stones (Amatyakul et al. 2003, Bender & Bender 2003, Inagaki et al. 2010, Nakajima et al. 
2013). Moreover, a positive correlation between T2D and pulp stones has been found in a 
number of clinical cases which were assessed by radiographs (Nayak et al. 2010). Whether 
patient age correlates with increased pulpal calcification or pulp stones has been examined 
previously, with inconsistent results. A number of studies suggest it does (Turkal et al. 2013, 
Huang & Chen 2016, Hsieh et al. 2018), however, others have reported it does not (Kannan et 
al. 2015, Patil et al. 2018). It has been reported that AGEs can stimulate mineralization activity 
in rat dental pulp cells (Nakajima et al. 2013, Nakajima et al. 2015). 
Predentine thickness reflects the rate of mineralisation and is affected by various 
pathological, systemic and metabolic conditions. Caries, high sucrose diet, age and trauma may 
all alter the predentine thickness (Autio et al. 1997, Basandi et al. 2015). Studies in animals 
have found that diabetes is associated with thickened predentine in diabetic rats (Inagaki et al. 
2010, Nakajima et al. 2013) and the present study has now shown that diabetes may elicit a 
similar response in humans.  
Diabetes may exacerbate pulp inflammation which can adversely affect pulp healing 
following pulp capping with MTA (Garber et al. 2009) possibly due to disruption of the 
vasculature (Sen et al. 2006, Guo & DiPietro 2010). It is well known that dental pulp tissue 
repair is followed by the formation of tertiary dentine-like tissue as a response to the injury 
(Cooper et al. 2010, Ricucci et al. 2014). Our results showed that T2D samples had thickened 
irregular tertiary dentine-like tissue lining the pulp chamber and reduced vascularity, suggesting 
hyperglycaemia may be a contributing factor. 
Immunohistochemistry of the clinically normal dental pulp showed that T2D resulted in 
increased expression of cytokines (IL1!, IL6, IL17, TNF-"), increased immune cells (CD4, 
CD83, CD68), TLR2+ and TLR4+ cells, but decreased Tregs when compared to the dental pulp 
of non-T2D patients. The expression of inflammatory cytokines plays an important role in the 
development of diabetic complications and are markers of immune activation in patients with 
diabetes (Mahmoud & Al-Ozairi 2013). T2D results in altered immune‐inflammatory responses 
at local and/or systemic levels. However, to date there is little data concerning the cascade of 
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immune‐inflammatory mediators in the dental pulp of patients with T2D (Catanzaro et al. 2006, 
Garber et al. 2009, Moraru et al. 2017). 
To my knowledge, this is the first study to investigate the expression of cytokines in human 
dental pulp of T2D in the absence of other oral disease. In 2017, Moraru et al. studied the 
histology and immunohistology of the dental pulp from diabetes patients who had periodontal 
disease (Moraru et al. 2017). Their study only examined the soft pulp tissue and so did not 
identify the altered morphology of odontoblasts and dentine. 
The use of axial sections for the specimens preserved the anatomy of crown and dental pulp 
so was helpful to study the morphological changes and spatial distribution of immune and 
inflammatory cells. The use of positive control tissue for IHC is important to ensure the positive 
staining obtained in each experimental run is a true representation of the targeted antigen rather 
than a general background reaction. 
In the current study, all the included samples were obtained from well controlled non-insulin 
dependent diabetics who had been diagnosed for less than 5 years. However, this information 
was self-reported by participants and individual differences in blood glucose levels may have 
contributed to some variability between the samples. Moraru et al. (2017) included samples 
from insulin and non-insulin dependent diabetics who had been diagnosed at least seven years 
and found similar variability. 
The expression of TLR2 and TLR4 was significantly increased in T2D dental pulp. TLRs 
identify both PAMPs and DAMPs in the earliest phase of the host innate immune response and 
induce the expression of various immune and inflammatory genes via NF-κB stimulation 
(Brownlee 1995, Sims et al. 2009, Chen & Nuñez 2010). IHC labelling found TLR2 and TLR4 
positivity distributed among the odontoblast and subodontoblast region confirming the findings 
of others (Jiang et al. 2006, Mutoh et al. 2007, Veerayutthwilai et al. 2007). Odontoblasts in 
the peripheral pulp are an important cell in the first line of pulp defence (Farges et al. 2009). 
The results of our study clearly show this by formation of tertiary dentine-like tissue as a 
protective barrier against irritants and increased expression of TLR2 and TLR4 in dental pulp 
of T2D samples. The expression of TLR2 and TLR4 is increased in gingival and periodontal 
tissues in the presence of inflammation in patients with diabetes (Rojo-Botello et al. 2012, 
Promsudthi et al. 2014) and our findings would suggest that hyperglycaemia increases TLR 
expression in the clinically normal dental pulp. TLR2 and TLR4 are upregulated in the presence 
of dental caries and inflammation (Takeda et al. 2003). However, the present study excluded 
these cases and indicates that hyperglycaemia may act as a DAMP and activate TLR2 and TLR4 
in dental pulp in the absence of microbial irritant.  
 77 
The dental pulp mounts an inflammatory reaction to irritants to stimulate repair. Microscopic 
examination of an inflamed dental pulp shows increased numbers of inflammatory cells (Izumi 
et al. 1995, Goldberg 2009, Ivkovska et al. 2017, Naseri et al. 2017). In this study significantly 
more immune cells (CD4+ve T cells, macrophages and dendritic cells) were present in the 
clinically normal dental pulp of TD2 samples compared with non-T2D samples. The subsequent 
activation of these cells leads to the production of cytokines such as TNF-" and IL1! (Chen & 
Nuñez 2010) and the present study found these cytokines were increased in dental pulp of T2D 
group. 
The elevated immune and inflammation activity in T2D can be caused by the decreased 
immunosuppressive function of Tregs. The results have shown FOXP3 expression, a specific 
marker of Treg, was reduced in dental pulp of T2D participants. It is well known that Tregs 
have a vital role in resistance to autoimmune disease and self-tolerance by down-regulation of 
the innate and adaptive immune effector cells’ function (Zeng et al. 2012, Mahmoud & Al-
Ozairi 2013) and the findings of this study suggest that the effect of T2D on the dental pulp 
may be similar to other body sites. Macrophage activation is one of the important causes of 
diabetic complications (Lopes-Virella & Virella 2003). Therefore, with fewer Tregs cells there 
is less immunosuppressive effect on macrophages leading to inflammation and potentially 
enhancing diabetic complications (Zeng et al. 2012). Tregs control the inflammatory process 
in part by decreasing the Th17 response. The present study found there was increased presence 
of IL17 in the T2D dental pulp which may be a result of reduced Treg expression. 
Cytokines induce an inflammatory response to various noxious stimuli (Dinarello 2000) 
such as glucose and RAGE ligands (AGE and S100 proteins) which have been known as 
diabetes-related endogenous DAMPs. The present study showed dental pulp of T2D 
participants showed increased expression of IL1! and TNF-" by comparison with non-T2D. 
Although IL1! and TNF-" are known as a key regulators of proinflammatory responses in the 
dental pulp in response to infection (Farges et al. 2015), this study demonstrated that diabetes 
can also induce their expression. The findings coincide with other studies that showed elevated 
levels of cytokines such as IL6, TNF-" in patients with diabetes (Alexandraki et al. 2006, 
Dandona et al. 2007, Mirza et al. 2012, Wang et al. 2012, Mahmoud & Al-Ozairi 2013). 
Individuals with T2D have elevated accumulation of AGEs in their serum and gingival tissue. 
This is associated with increased oxidative stress which accelerates tissue injury (Takeda et al. 
2006). The interaction of AGEs with its receptors RAGE stimulate the production of 
proinflammatory proteins (Javed et al. 2012) but its expression in the pulp is unclear.  
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The evaluation of protein expression by IHC is one of the most appropriate methods for 
evaluation of dental pulp inflammation (Zanini et al. 2017). The semi-quantitative analysis of 
protein expression included counting the number of immunopositive cells. A large SD was 
found across the samples which may be the result of the biological variability, the small sample 
size and the possible effect of variable hyperglycaemic control of participants at a molecular 
level. Another limitation of the present study is the age range of the participants although our 
findings are consistent with other studies which also had a wide age range (Moraru et al. 2017). 
However, future studies should consider the use of age-matched groups to further validate our 
observations. Variability in glucose control at a molecular level, will be examined in Chapter 5 
by use of primary cell culture diabetic model in order to mimic the diabetic status of the body 
and control other factors.  
3.6 Conclusion 
This study has shown distinct morphological differences between normal dental pulp in non-
T2D patients and those with T2D. The use of histology and special stains suggests the response 
in the dental pulp is similar to other tissues in the body with increased fibrous connective tissue 
and reduced vascularity which may influence the dental pulp’s healing response to 
inflammation and infection. This study focused on morphological changes in normal dental 
pulp to further understand the effect of T2D on diseased dental pulp, a study of the 
morphological changes in inflamed dental pulp would be of value. Moreover, this study 
highlights the complexity of the inflammatory process in the pulp, and for individuals who have 
T2D and shows that it may vary according to their systemic status. Hyperglycaemia may act as 
a chronic irritant to dental pulp and lead to an increased innate and adaptive immune response 
with an increased production of cytokines and subsequent fibrosis. Hyperglycaemia in T2D 
changes the vascular responses and alters immune responses in diabetes patients and pulp 
healing may be impaired in these patients. Pulp calcifications create challenges during root 
canal treatment and so it is important to be vigilant with a good radiographic assessment prior 
to treatment. Within the limits of the present study, the results suggest that the normal pulp in 
T2D has features seen with increasing age including tissue fibrosis, reduced vascularity and an 




Chapter 4  
Glycation in the Dental Pulp 
4.1 Introduction  
Hyperglycaemia has been shown to persistently induce systemic low‐grade inflammation 
and inflammation‐induced oxidative stress damages various organs and tissues through 
different pathways including glycation (Kalousová et al. 2005, Kajitani et al. 2010). Glycation 
is a biological process occurring in body proteins through the Maillard reaction which leads to 
the formation of non-reversible products known as advanced glycation end products (AGEs) 
(Singh et al. 2001). AGEs are a complex and heterogeneous group of compounds found in 
plasma which accumulate in tissues during ageing. They occur at an accelerated rate in diabetes 
(Singh et al. 2001, Thomas 2011), accumulate in permanent and long-living proteins such as 
collagen (Jeanmaire et al. 2001) and bind to collagen. They act as a cross-link between collagen 
fibrils and accumulated AGEs cross-linking alters the mechanical characteristics of collagen-
rich tissues. Histopathological studies have shown AGEs accumulation in a variety of body 
sites including periodontal and gingival tissues (Lalla et al. 2001, Sasaki et al. 2001, Rajeev et 
al. 2011, Zizzi et al. 2013). The Maillard reaction has been reported in healthy dentine and is 
increased in caries-affected dentine with collagen cross-linking occurring within the predentine 
(Miura et al. 2014, Fukushima et al. 2015, Greis et al. 2018). Increased AGEs accumulation 
occurs in the intratubular collagenous matrix of the predentine and along dentinal tubules and 
is associated with hardness and discolouration of dentine with age (Miura et al. 2014). It has 
been suggested increased AGEs in rat dental pulp may be a stimulatory factor for diabetic intra-
pulpal calcification due to AGEs-stimulated release of inflammatory IL1! and S100 proteins 
(Inagaki et al. 2010, Nakajima et al. 2013, Nakajima et al. 2015). 
The effects of AGEs are regulated by the interaction of AGEs and its receptor, RAGE 
(Schmidt et al. 2000, Nedić et al. 2013). AGEs-RAGE interactions affect the metabolism of 
collagen tissue by the activation of NF‐κB pathways which results in an increase in the 
expression of the inflammatory cytokines such as IL1β, IL6 and TNF‐α (Takeda et al. 2006, 
Liu et al. 2010, Rasheed et al. 2010, Yang et al. 2010, Chen et al. 2017). The co-expression of 
AGEs-RAGE is suggested to play a role in cellular activation and mediated periapical tissue 
destruction (Takeichi et al. 2011). The mRNA level for the RAGE gene is significantly higher 
in the inflamed human dental pulp compared to non-inflamed dental pulp (Tancharoen et al. 
2014, Zhang et al. 2014, Khorasani et al. 2017) but the effect of systemic disease on this 
expression is unknown. Immunostaining of RAGE in pulpitis samples shows the protein is 
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expressed in odontoblasts, stromal pulp fibroblasts, and endothelial cells (Tancharoen et al. 
2014). RAGE also interacts with S100 calcium binding proteins which belong to the DAMP 
superfamily (Sirois et al. 2013). S100A12 has an important role during inflammation (Pietzsch 
& Hoppmann 2009). S100A12 interacts with RAGE on the surface of lymphocytes, 
macrophages and endothelial cells which activate the receptor and results in the activation of 
NF‐κB resulting in the secretion of proinflammatory mediators (Pietzsch & Hoppmann 2009, 
Kang et al. 2015). However, the expression of RAGE, S100A12 and NF‐κB in the clinically 
normal dental pulp of T2D patients has not been previously studied. 
RAGE is the most studied receptor for AGEs. Another group of cell surface receptors, 
AGER1, AGER2 and AGER3 (galectin 3) appear to regulate endocytosis and the degradation 
of AGEs, and counteract the effects of RAGE (Vlassara 2001). Galectin 3 (Gal-3) is known to 
uptake and remove AGEs, maintain glucose homeostasis and prevent the deleterious activation 
of the adaptive and innate immune response (Pugliese et al. 2014). Gal-3 is involved in a variety 
of physiological and pathological processes including tissue fibrosis, modulation of the 
immune/inflammatory response regulating the activity in both innate and adaptive immunity, 
and remodelling activity (Iacobini et al. 2003, Pugliese et al. 2014, Lala et al. 2018). However, 
the expression and role of Gal-3 in the dental pulp is unclear.  
In diabetes, glycation affects collagen fibrils and changes their characteristics by increasing 
stiffness and reducing the solubility of collagen (Yan et al. 2003, Avery & Bailey 2006, 
Loughlin & Artlett 2009). Furthermore, AGEs have been found to modify and affect other 
proteins such as vimentin in fibroblasts (Jeanmaire et al. 2001, Kueper et al. 2007). Vimentin 
is a cytoskeletal protein, which is highly expressed in the dental pulp, especially in the 
cytoplasm of dental pulp fibroblasts (Byers et al. 2004, Kadar et al. 2009, Miyagi et al. 2010, 
Murakami et al. 2012). It is well known that vimentin plays a role in the maintenance of the 
cytoarchitecture and tissue integrity (Eriksson et al. 2009) and it is involved in adhesion, 
migration, and cell signalling (Ivaska et al. 2007, Minin & Moldaver 2008, Hu et al. 2011). 
Vimentin is the major target of glycation in human fibroblasts (Kueper et al. 2007). The co-
expression of RAGE and vimentin in skin fibroblasts is well known (Lohwasser et al. 2006, 
Loughlin & Artlett 2010) but it is not clear if pulpal fibroblasts have similar expression. 
Moreover, diabetes increases the intracellular expression level of RAGE in Th lymphocytes 
(Akirav et al. 2012). However, the understanding of how T2D influences the co-expression of 
RAGE/vimentin and RAGE/Th lymphocytes in the dental pulp is unclear. 
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This study aimed to better understand the glycation process in the clinically normal dental 
pulp of T2D patients, the phenotype of cells involved in this process, and the role of glycation 
in tissue destruction.  
4.2 Hypothesis  
Type 2 diabetes modifies clinically normal dental pulp through glycation with increased 
expression of AGEs and RAGE on several cell types. 
4.3 Experimental Aims  
1. To examine the expression of AGEs and RAGE proteins in the clinically normal 
dental pulp of mature permanent teeth from non-T2D and T2D participants using 
IHC. 
2. Using immunofluorescence to evaluate the accumulation of AGEs in the normal 
dental pulp of T2D and non-T2D participants. 
3. To investigate the co-localisation of RAGE with CD4 (CD+ve T cells) and vimentin 
(fibroblasts) in the clinically normal dental pulp of T2D and non-T2D participants 
using double labelled immunofluorescence staining. 
4. Validate a gene which is constitutively expressed in T2D dental pulp suitable for 
qPCR assay cDNA input normalisation. 
5. To determine the mRNA expression levels for RAGE, Gal-3, 100A12, NF‐κB, and 
COL1A1 in the clinically normal dental pulp tissue of non-T2D and T2D patients 
using qPCR.  
4.4 Materials and Methods  
Ethical approval for this study was obtained from the University of Otago Human Ethics 
Committee (Health)- (Project Reference H16/069), and Māori consultation was entered with 
the Ngāi Tahu Research Consultation Committee (see Appendix A.1). 
4.4.1 Sample Preparation 
Study specimens used in this section were the same as those used in the previous chapter 
(see Section 3.4.1). Permanent molar teeth with complete root development which were 
clinically diagnosed as normal and uninflamed were collected, cut, prepared, sectioned, fixed 
and decalcified for IHC, immunofluorescence (IF) and double labelled immunofluorescence 
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(DIF) as previously described (see Section 3.4.1). Three dental pulp sections from non-T2D 
participants and three from T2D were used for IF, while five sections from non-T2D and five 
sections from T2D were used for DIF. One additional section from each group was used as a 
negative control. 
4.4.2 Immunohistochemistry  
4.4.2.1 Primary Antibody, Immunohistochemistry Optimisation, Antigen Retrieval  
Primary antibody specificity, recommended manufacturer’s concentrations and isotype 
matched controls are shown below (Table 4.1).  
Table 4.1: Immunohistochemistry primary antibodies and isotypes matched controls 
Antibody Catalogue 
number 
Isotype Clonality Manufacturers 
recommended 
concentration 



























• Endothelial cells 
• CD+ve cells 




IHC optimisation was performed manually for both AGEs and RAGE primary antibodies 
using a positive control (thymus and lung respectively) with the optimal working dilutions 
determined using the positive controls and a dilution range suggested by the manufacturer.  
The specimens and control slides were labelled, deparaffinised in xylene and rehydrated 
through descending grades of ethanol (see Appendices B.6.1 and B.6.2). Heat-induced antigen 
retrieval (HIAR) technique was used with anti-RAGE (see Section 3.4.3.3). No HIAR was 
required for anti-AGEs.  
The specificity of the antigen-antibody binding was confirmed using positive tissue controls 
known to express AGEs and RAGE. Positive and negative tissue was selected in similar way 
as in Section 3.4.3.4.  
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4.4.2.2 Background Reduction and Primary Antibody Incubation  
The endogenous peroxidase enzyme activity in the tissue sections was blocked to prevent 
non-specific background staining in the similar technique used in Section 3.4.3.5. Additionally, 
Tween 20 was used for anti-AGEs. See Table 4.2 for comparison. 













Anti-AGE 0.025µg/ml 1:40000 No retrieval 20 mins  30 min H2O2 + 
methanol, 30 min 
milk + Tween 20 
Anti-RAGE 10µg/ml 1:100 Heat 80℃, 20 
mins 
Overnight 30 mins H2O2, 10 
min milk 
 
4.4.2.3 Signal Amplification and Visualisation  
The signal amplification was achieved in the same manner as previously mentioned see 
Section 3.4.3.6 and Appendix B.6.  
4.4.3 Immunofluorescence and Double Immunofluorescence  
4.4.3.1 Antibodies and Negative Controls  
To examine the expression of AGE, IF was performed using anti-AGE, while DIF was 
performed to identify the co-localisation of RAGE with anti-CD4 and anti-vimentin antibodies 
(Table 4.3). To prevent cross-reaction(s) between individual detection methods, antibodies 
from different species were used (mouse-rabbit monoclonal combination) (Table 4.4). 
4.4.3.2 Deparaffinisation and Antigen Retrieval 
Section were deparaffinised and rehydrated in the same manner as for IHC (see Section 
3.4.3.3 and Appendix B.7). The conventional HIAR technique was used to unmask the antigen 
for anti-RAGE and anti-AGE as used in IHC Section 3.4.3.3 and Section 4.4.2.1 (Table 4.2). 
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Table 4.3: Primary antibodies used in Immunofluorescence and Double Immunofluorescence 
and matching isotype controls 
Antibody Clonality Isotype Catalogue 
number 

































0.235 - 0.264mg/ml 



























































Donkey Mouse 1:200-1:2000 Red RAGE/ mouse 
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4.4.3.3 Double Immunofluorescence Staining  
Following deparaffinisation and antigen retrieval, the IF and DIF was performed following 
the method in Appendix B.7. The final staining protocols and optimum incubation time for all 
the selected antibodies are summarised in Table 4.5. 
Table 4.5: Summarised protocol for Immunofluorescence and Double Immunofluorescence 
using AGE, RAGE, CD4, and vimentin antibodies 





1 hr at RT) 


















Alexa Fluor® 594 
 
4.4.4 Gene Expression 
4.4.4.1 Sample Collection 
Permanent molar teeth with complete root development clinically diagnosed as normal were 
collected from 24 participants. Ten teeth from participants with confirmed T2D (n=10) and 
fourteen from non-T2D controls were included in this experiment (n=14).  
Following extraction by an oral surgeon, the tooth was immediately immersed in saline. 
Using a high-speed diamond bur, the tooth was cut transversely 2-3mm below the CEJ and the 
coronal pulp excavated and transferred to a 1.5ml nuclease-free microcentrifuge tube 
containing RNAlater® (Cat. No. R0901, Sigma Aldrich) and stored at -20°C until required.  
4.4.4.2 RNA Extraction  
All the equipment used for the purification of RNA was RNase-free or was rinsed with 
RNase Away agent (Cat. No. 10328011, InvitrogenTM, Life Technologies). 
It was found the texture of the dental pulp tissue from the T2D samples was very fibrous. 
Dental pulp from the non-T2D samples was successfully homogenised using TRIzol® and 
scissors. However, it was necessary to use a more aggressive approach for the more fibrous 
T2D patient dental pulp. The softer non-T2D tissue was incubated with 500μl of TRIzol® 
reagent (Cat. No. 12183018A, InvitrogenTM, Life Technologies) in a laminar flow-hood at RT 
for five minutes in a 1.5ml microcentrifuge tube. Using a pair of sterile suture scissors, the 
tissue was cut into smaller pieces to facilitate better penetration of the TRIzol® reagent, and a 
plastic pestle was used to aid the complete dissolution of the tissues. The very fibrous dental 
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pulp from the T2D patient required a more aggressive tissue grinding protocol. To achieve this, 
the Precellys Evolution tissue homogeniser was used (Cat. No. P000062-PEVO0-A, Bertin 
Corp. Technologies). A Cryoly’s Evolution (Cat. No. P000671-CLYS1-A, Bertin Corp. 
Technologies), cooling unit was attached to the homogeniser which ensured the dental pulp 
tissue maintained a temperature 4℃ during the grinding process. The dental pulp tissue was 
placed into a 2ml CKMix50-R tube (Precellys Lysing Kit; Cat. No. P000922-LYSK0-A, Bertin 
Corp. Technologies) according to the manufacturer’s advice. The reinforced tube contained 
ceramic (zirconium oxide) mix beads of 2.8mm and 5.0mm diameter which were recommended 
by the company to prevent tube breakage. The grinding protocol included 3 cycles of 30 
seconds with 20 seconds hold between each cycle run at 7800rpm. 
4.4.4.3 RNA Purification  
Total RNA was extracted from the tissue homogenates, using the TRIzol® Plus RNA 
Purification Kit (Cat. No. 12183018A, Invitrogen™, ThermoFisher scientific) according to 
manufacturer’s instructions. Chloroform (100μl) was added and vigorously agitated by hand 
horizontally for 15 seconds and the sample left to incubate for 2 minutes. Following 
centrifugation at 12,000xg for 15 minutes at 4°C, approximately 300μl of the clear upper-phase 
containing the RNA was transferred to a fresh RNase-free tube. An equal volume of 70% 
ethanol (made used RNA-free water) was added and vortexed for 10 seconds and then 
transferred to a spin cartridge with a collection tube and centrifugated at 12,000xg for one 
minute at RT. With the RNA bound to the spin cartridge, the genomic DNA was removed using 
an on-column PureLink™ DNase set (Cat. No. 12185010, Invitrogen™, ThermoFisher). A 
master mix was prepared containing a DNase reaction buffer (8μl), DNase (10μl) and RNase-
free water (62μl). The master mix (10μl) was applied to the spin column and left to incubate 
for one minute at RT. Wash buffer I (350µl) was added and the spin column centrifuged for 
one minute at 12,000xg. The flow-through was discarded. Two further washes were carried out 
using Wash buffer II with centrifugation for one minute at 12,000xg. The membrane-bound 
RNA was eluted with RNase-free water (50μl) following a one-minute incubation at RT and 
centrifuged at 12,000xg for 2 minutes at RT. The purified total RNA was stored at -20°C.  
4.4.4.4 RNA Quality and Quantity Assessment  
The quantity and quality of the purified total RNA was spectrophotometrically assessed, 
using a NanoVue Spectrophotometer (NanoVue Plus™, GE Healthcare Life Sciences) or a 
Nano Photometer (IMPLEN NanoPhotometer® P-Class, Implen GmbH). The RNA quantity 
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was measured as ng/ml and the RNA quality was estimated from the A260/A280 ratio. A ratio 
between 1.8 to 2.1 is indicative of high-quality RNA.  
4.4.4.5 RNA Concentration 
Purified RNA samples with a concentration <15ng/ml were concentrated using the GeneJET 
RNA Clean and Concentration Micro Kit (Cat. No. K0841, Life Technologies, Thermo 
Scientific) according to the manufacturer’s instruction (see Appendix B.11.2). 
4.4.4.6 cDNA Synthesis  
Purified RNA was transcribed into complementary deoxyribonucleic acid (cDNA) using a 
High Capacity Reverse Transcription Kit (Cat. No. 4368814, Life Technologies). A 2X RT 
master mix 10μl/sample was prepared and combined with the RNA (100-500ng/µl). A thermal 
cycler (Cat. No. 6331000068, Mastercycler gradient, Eppendorf, Eppendorf South Pacific Pty. 
Ltd.) was used to carry out reverse transcription, with incubation temperature as follows: 10 
minutes at 25℃, two hours at 37℃, followed by five minutes at 85℃. The resulting cDNA 
were stored at -20℃ until required (see Appendix B.11.3). 
4.4.4.7 Quantitative Polymerase Chain Reaction  
4.4.4.7.1 qPCR Assay Specifications   
TaqMan® Gene Expression Assays (Life Technologies) were used to determine the mRNA 
expression level for each of the following genes: RAGE, S100A12, NF‐κB, COL1A1 and Gal-
3 (Table 4.6). 
Table 4.6: TaqMan® Gene Expression Assays used in this study 
Gene symbol Gene Name Reporter Dye Assay ID 
RAGE Advanced glycation end-product-specific receptor FAM Hs00179504_m1 
S100A12 S100 calcium binding protein A12 FAM Hs00942835_g1 
NF‐κB 1 Nuclear factor kappa B subunit 1 FAM Hs00765730_m1 
COL1A1 Collagen type I alpha 1 FAM Hs00164004_m1 
Gal-3 Lectin, galactoside binding soluble 3 FAM Hs00174774_m1 
 
4.4.4.7.2 qPCR Amplification 
Each qPCR reaction (10µl) was prepared in 0.2ml qPCR MicroAmp® tubes (Cat. No. 
4358293, Applied biosystem™) and contained the TaqMan® Gene Expression Assay (various 
20X; 0.1µl), cDNA (5ng), TaqMan® Fast Universal Master Mix (2X) (Cat. No. 4352042, 
Applied Biosystems™) and nuclease-free water. 
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qPCR amplification for each cDNA sample were run in duplicate. An osteoblast cell line 
cDNA library (OA) was used as a positive control. The use of a positive control and the 
identification of reference genes helps to identify any error in the process, monitor loss of 
mRNA target, assess the quality of nucleic acid extraction and to determine the false negative 
results. A negative control included water only. The amplification was performed using a 
QuantStudio 6 Flex system (Applied biosystem™ by Life Technologies). Thermal cycling 
parameters used were according to the manufacturer’s instructions: polymerase activation (hot 
start) at 95°C for 20 seconds, 40 cycles at 95°C for 3 seconds and annealing and extension at 
60°C for 30 seconds. The threshold value was set at 0.05 and the background cycles were set 
at 3-10 cycles.  
Following amplification and real-time data acquisition, the threshold and Cq value were 
calculated using the software on the Quantstudio™ 6 Flex machine (Life Technologies, 
ThermoFisher). 
4.4.4.7.3 cDNA Input Normalisation Reference Gene Validation 
HPRT, B2M and ACTB were identified from the literature as the three most commonly used 
dental pulp reference genes for qPCR normalisation. mRNA expression for these genes was 
determined for each of the 24 prepared dental pulp RNA samples, using TaqMan® Gene 
Expression Assays listed below (Table 4.7).  
Table 4.7: Normalisation gene expression assays 
 
4.5 Data Analysis 
4.5.1 Immunohistochemistry Analysis 
4.5.1.1 Digital Capture and Analysis 
All IHC stained slides were scanned at 40x magnification by an Aperio Scanscope CS2 
image capture device (Aperio CS2, Aperio Technologies, Leica Biosystems) and digitalised. 
Digital analysis of these images was carried out using the ImageScope (Aperio ImageScope 
Version 12.4.3, Aperio Technologies, Leica Biosystems).  
Gene symbol Gene Name Reporter Dye Assay ID 
HPRT 1 Hypoxanthine phosphoribosyltransferase1 VIC Hs02800695_m1 
B2M Beta-2-microglobulin VIC Hs00985689_m1 
ACTB Actin, beta VIC Hs00357333_g1 
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4.5.1.2 Immunohistochemistry Staining Assessment, Qualitative and Semi-Quantitative 
Analysis 
Qualitative and semi-quantitative analyses were performed to assess the protein expression 
in each tissue sample following the method detailed in the previous chapter (Section 3.4.5.3). 
4.5.2 Immunofluorescence and Double Immunofluorescence Qualitative Analysis  
Immunofluorescence sections for AGEs were viewed under a fluorescent microscope 
(Olympus AX70, Olympus Corp.) with magnification up to 200x. Images were taken with a 
camera (Go-3, QImaging, Surrey) mounted on a microscope and image capture software (Q 
Capture Suite, QImaging). DIF sections for RAGE, vimentin and CD4 were viewed and imaged 
taken using the EVOS M5000 Inverted Fluorescent Microscope (Cat. No. AMF5000, Life 
Technologies, ThermoFisher Scientific). The images were captured for each fluorescent 
wavelength, green (Alexa Fluor 488®) or red fluorescence (Alexa Fluor 595®) and images 
were combined using Image J software (ImagJ, Version 1.52j). The staining was examined and 
qualitatively identify the proteins and merge in non-T2D and T2D dental pulp. In IF, the 
expression of AGEs, was identified by presence of green fluorescence (Alexa Fluor 488®) 
staining and the distribution in dental pulp samples was described. In DIF, the co-localization 
of both proteins (RAGE/vimentin and RAGE/CD4) in a cell was identified when the merged 
imaged of cell showed both red fluorescence (Alexa Fluor 595®) and green (Alexa Fluor 488®) 
on the cell membrane and/or cytoplasm or the merged image showed yellow colour. 
4.5.3 qPCR Data Analysis 
The raw data on the cycle threshold or quantification cycle (Cq) value for all GOIs and 
reference genes were obtained from the PCR instrument. Data analysis was performed using 
GraphPad Prism software 7 for Mac OS X (GraphPad Prism 7.0a Macintosh Version, 2016). 
To determine the most suitable reference gene Cq values for each of the selected 
normalisation genes were compared using BestKeeper©-Version1 software. The BestKeeper 
algorithm is a good tool to estimates the expression stability of candidate genes by calculating 
and comparing the variation, including the coefficient of variance (CV) and standard deviation 
(SD) (Pfaffl et al. 2004). The most stable reference gene was selected, based on the size of the 
SD value. The SD values of the candidate reference genes and the stability of the gene were 
negatively correlated, this means when the results of lowest SD value are correlated with the 
highest stability. 
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The comparative Cq method was employed to compare the mRNA expression levels (Livak 
& Schmittgen 2001, Schmittgen & Livak 2008). The raw Cq value for each GOI was 
normalised against the Cq of the reference gene where ∆Cq = Cq (GOI) - Cq (reference). The 
normalised relative gene expression level, expressed as 2-∆Cq, was then used to compare 
expression levels in each group using unpaired student’s t-test and the P-value <0.05 was 
considered as statistically significant. The fold difference (FD) for each gene was calculated 
using the average 2-∆Cq value for each group where 2-∆∆Cq = 2-∆Cq(T2D) / 2-∆Cq(non-T2D)  
The association between the age of participants and the level of mRNA for each GOI was 
determined using a correlation r test. 
4.6 Results 
4.6.1 Immunohistochemistry  
4.6.1.1 Qualitative Analysis Results 
The results of qualitative analysis are shown in Table 4.8.  
 
 
Table 4.8: Summary of qualitative findings of Immunohistochemistry 
 Non-T2D  T2D 
Antibody Staining pattern Spatial distribution Cell expression Staining Pattern Spatial distribution Cell expression 
Anti-AGE 
• Cell membrane 
• Extracellular matrix 
• Diffuse centrally 
• Odontoblasts 
• Collagen fibres 
• Fibroblasts 
• Endothelial cells 
• Lymphocytes 
• Macrophages  
• Cell membrane 
• Extracellular matrix 
• Diffuse centrally 
• Odontoblasts 
• Collagen fibres 
• Fibroblasts 
• Endothelial cells 
• Lymphocytes 
• Macrophages   
Anti-RAGE 
• Cell membrane 
• Cytoplasm 
• Scattered centrally 
• Odontoblasts 
• Fibroblasts 
• Endothelial cells 
• Macrophages 
• Neurons 
• Cell membrane 
• Cytoplasm 
• Scattered centrally 
• Odontoblasts 
• Fibroblasts 
• Endothelial cells 
• Macrophages 




4.6.1.1.1 AGE Immunostaining 
The dental pulp of T2D and non-T2D specimens showed positive staining with the anti-AGE 
antibody. The positive immunoreactivity (brown staining) for AGE was seen on the cell 
membrane of odontoblasts, endothelial cells, fibroblasts, lymphocyte-like cells and 
macrophage-like cells. AGE protein was diffusely distributed through the collagen fibres and 
was seen through the odontoblasts and in the central dental pulp. Thymus tissue was used as a 
positive control and dental pulp tissue from non-T2D was used as a negative control with a non-
specific mouse IgG antibody to replace the primary antibody (Figure 4.1).  
 
Figure 4.1: Immunohistochemistry staining with anti-AGE. Peripheral dental pulp of (A) T2D 
specimen and (B) non-T2D specimen showing immunopositive staining of AGE (squares). (C) Positive 
control tissue: human thymus. (D) Negative dental pulp control with non-specific rabbit IgG isotype. (A 




4.6.1.1.2 RAGE Immunostaining 
RAGE is the receptor of AGE. The dental pulp of T2D and non-T2D specimens showed a 
positive expression of the RAGE protein. Positive immunoreactivity (brown staining) for 
RAGE was seen within the cytoplasm and on the cell membrane of endothelial cells, neuronal 
cells, fibroblasts, lymphocyte-like cells and macrophage-like cells. The RAGE protein was 
scattered throughout the central dental pulp. Lung tissue was used as a positive control and 
dental pulp tissue from non-T2D was used as a negative control with a non-specific mouse IgG 
antibody to replace the primary antibody (Figure 4.2).  
 
Figure 4.2: Immunohistochemistry staining with anti-RAGE. Central dental pulp of (A) T2D 
specimens and (B) non-T2D specimens showing immunopositive staining of RAGE (squares). (E) 
Positive control tissue: human lung tissue. (F) Negative dental pulp control with non-specific mouse 





4.6.1.2 Semi-Quantitative Analysis Results  
Semi-quantitative analysis of protein expression included counting the total number of 
positive stained cells/image area.  
4.6.1.2.1.1 Positively Stained Cells 
The mean number of stained immune cells within the hotspot selected area indicated anti-
AGE and anti-RAGE cells were significantly higher in in the dental pulp of T2D compared 
with non-T2D group (Table 4.9).  
Table 4.9: Mean number of positively stained cells per sample 
 
Antibodies 
Non-T2D (n=10) T2D (n=10) 
P-value 
Mean SD SE Mean SD SE 
AGE 49.00 44.31 14.01 191.70 52.91 16.73 <0.0001 
RAGE 139.20 57.05 18.04 270.90 155.90 49.29 0.02 
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4.6.2 Immunofluorescence and Doubled-Labelled Immunofluorescence  
4.6.2.1 AGEs 
Accumulated AGEs could be seen as green fluorescence within the pulp tissue of non-T2D 
and T2D samples and there was a similar pattern of distribution. AGEs, were more prominent 
in T2D samples, particularly associated with odontoblasts, around blood vessels and centrally 
within the ECM of the pulp. (Figure 4.3).  
 
Figure 4.3: Peripheral dental pulp AGE immunofluorescence. (A-C) Non-T2D and (D-F) T2D 
dental pulp tissue (20x, scale bar; 200µm)  
O: odontoblast, D: dentine, BV: blood vessels. No green fluorescence could be seen in the negative controls. 
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Contrasting nuclei DAPI staining showed the central dental pulp of T2D samples to be less 
cellular compared to non-T2D samples (Figure 4.4).  
 
Figure 4.4: DAPI immunofluorescence. (A) Non-T2D and (B) T2D dental pulp tissue (20x, scale bar; 
200µm).  
































4.6.2.2 RAGE and Vimentin 
RAGE (red fluorescence) was expressed in both non-T2D and T2D dental pulp tissue with 
increased levels in T2D samples. RAGE expression was observed on the cell surface of 
mesenchymal cells in non-T2D dental pulp, while within the T2D dental pulp, expression was 
diffuse and associated with ECM collagen and blood vessel walls. Vimentin (green 
fluorescence) expression was found in both the T2D and non-T2D dental pulp, with increased 
expression in the non-T2D dental pulp (Figure 4.5). Co-localisation of RAGE and vimentin 
could be seen in the T2D samples on cell membranes, the cytoplasm, nuclei of the mesenchymal 
cells and fibroblasts (Figure 4.6). 
 
Figure 4.5: Immunofluorescence of vimentin. Nuclei DAPI (blue colour) and vimentin (green colour) 
in (A) & (B) dental pulp of non-T2D samples, and (C) & (D) dental pulp from T2D samples. The white 
arrows show morphological changes of fibroblast like cells (100x, scale bar; 50µm). 
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Figure 4.6: Double immunofluorescence of RAGE and vimentin. RAGE (red colour) and 
Vimentin (green colour). The white and blue arrows show the co-expression of RAGE and vimentin. 




Immunofluorescence showed that the fibroblast morphology in the dental pulp of T2D was 
changed compared with the dental pulp of non-T2D samples (Figure 4.7). Contrasting nuclei 
DAPI staining showed the central dental pulp of T2D samples was more fibrous compared with 
non-T2D samples (Figure 4.7).  
 
Figure 4.7: DAPI immunofluorescence. Nuclei DAPI staining of dental pulp (A) Non-T2D and (B) 




4.6.2.3 RAGE and CD4 
CD4+ve cells were present in both non-T2D and T2D dental pulp samples. Co-localisation 
of RAGE and CD4 was showed by double positive cells and its more prominent in the T2D 
samples with RAGE localised to the cell surface and nuclei of CD4+ve cells. The 
immunofluorescence staining of CD4+ve cells was similar for both groups. However, Th 
lymphocytes within the dental pulp of T2D samples showed morphological changes compared 
with non-T2D samples (Figure 4.8 and Figure 4.9).  
 
Figure 4.8: Immunofluorescence of CD4. Nuclei DAPI (blue colour) and CD4+ve T cells (green 
colour) in (A) & (B) dental pulp of non-T2D samples, and (C) & (D) dental pulp from T2D samples. 
The white arrows show the morphological changes of CD4+ve T cells between the two groups. (100x, 
scale bar; 50µm). 
 101 
 
Figure 4.9: Double immunofluorescence of RAGE and CD4. The merged image showing RAGE (red 
colour) and CD4 (green colour). The white and blue arrows show the co-expression of RAGE and 
CD4+ve cells. (20x, scale bar; 200µm). 
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Contrasting nuclei DAPI staining showed the central dental pulp of T2D samples were more 
fibrous with fewer cells compared with non-T2D samples. T2D dental pulp cells showed some 
morphological changes compared to non-T2D (Figure 4.10).  
 
Figure 4.10: DAPI immunofluorescence. Dental pulp (A) Non-T2D and (B) T2D samples (40x, scale 




4.6.3 mRNA Gene Expression 
4.6.3.1 Sample Selection 
Twenty-four clinically normal dental pulp samples were collected from non-T2D (n=14) and 
T2D (n=10) participants. The mean age of the patients from the non-T2D group was 34 years 
(range 26-47 years) and the T2D group was 45 years (range 30-58 years) (Table 4.10).  
Table 4.10: Patient demographics data  
Sample ID Group Age 
(years) 
Sex Tooth No. Duration of diabetes 
(years) 
H1 Non-T2D 35 F 28 - 
H3 Non-T2D 45 F 48 - 
H5 Non-T2D 26 M 38 - 
H6 Non-T2D 31 M 38 - 
H7 Non-T2D 41 F 38 - 
H8 Non-T2D 29 F 28 - 
H9 Non-T2D 27 F 17 - 
H10 Non-T2D 47 F 48 - 
H11 Non-T2D 26 F 38 - 
H12 Non-T2D 31 F 18 - 
H13 Non-T2D 40 F 48 - 
H14 Non-T2D 28 F 38 - 
H15 Non-T2D 28 M 18 - 
H16 Non-T2D 37 F 48 - 
D2 T2D 55 M 17 5 
D3 T2D 45 M 28 3  
D4 T2D 33 M 26 5 
D5 T2D 49 F 27 5 
D6 T2D 58 M 26 5  
D7 T2D 55 F 36 5  
D8 T2D 48 M 36 4 
D9 T2D 43 M 38 5  
D10 T2D 35 M 28 5  




4.6.3.2 RNA Yield and Quality  
Spectrophotometric RNA analysis showed the purified RNA quantity ranged from 720 to 
5600ng, with a A260/A280 ratio of 1.79–2.17 (Table 4.11).  
Table 4.11: RNA yield and quantity 




Total RNA yield 
(ng) 
H1 2.10 0.015 1.89 60.0 3000 
H3 0.68 0.036 1.80 26.8 1340 
H5 1.14 0.074 1.93 34.8 1740 
H6 0.07 0.039 1.97 28.0 1400 
H7 6.87 0.395 1.86 22.4 1120 
H8 1.19 0.064 1.98 73.6 3680 
H9 6.39 0.368 1.87 15.2 760 
H10 2.47 0.211 1.82 71.6 3580 
H11 0.61 0.032 2.00 21.2 1060 
H12 0.62 0.035 1.96 21.6 1080 
H13 0.69 0.048 2.01 14.4 720 
H14 0.41 0.025 1.80 23.6 1180 
H15 0.75 0.043 2.00 33.2 1660 
H16 1.62 0.095 1.91 54.8 2740 
D2 0.86 0.042 2.00 34.4 1720 
D3 2.80 0.201 1.80 112.0 5600 
D4 2.77 0.204 1.81 110.8 5540 
D5 2.31 0.231 1.79 92.4 4620 
D6 0.92 0.049 2.17 35.7 1785 
D7 2.10 0.021 1.82 73.3 3666 
D8 6.57 0.321 1.89 75.2 3760 
D9 7.70 0.470 2.06 42.4 1220 
D10 0.42 0.380 1.80 65.6 3200 





4.6.3.3 Reference Gene Validation  
B2M, ACTB and HPRT1 Cq duplicate values were averaged and used for BestKeeper© 
analysis. B2M was determined to be the best with the lowest SD value (1.50) compared with 
ACTB (1.76) and HPRT1 (1.64) (Table 4.12).  
Table 4.12: BestKeeper© descriptive statistics for reference genes analysis (n=16) 
Parameters 
Gene 
ACTB HRPT B2M 
Geo mean [CP] 25.04 31.29 20.29 
Ar mean [CP] 25.14 31.35 20.40 
Min [CP] 21.90 28.07 16.35 
Max [CP] 30.76 35.68 24.55 
SD [±CP] 1.76 1.64 1.50 




4.6.3.4 mRNA expression 
The expression level (2-∆Cq) for each gene of interest (GOI) was calculated using the 
comparative Cq method (Figure 4.11). All Cq values can be found in Appendix B.11.6. 
 












































































































The gene most affected by T2D was NF-!" with a highly significance increase in tissue 
expression of 1180.80-fold difference (P<0.0001). RAGE expression was also significantly 
higher in the T2D tissues compared to the non-T2D tissue samples (2660.38-fold difference; 
P<0.0001), along with S100A12 (804.35-fold difference; P<0.0001) and collagen type I 
(929.85-fold difference; P<0.0001). There was no significance difference in the mRNA 
expression for Gal-3 (2.40-fold difference; P=0.37) (Table 4.13).  
Table 4.13: Relative gene expression by comparative Cq method 









 Non-T2D T2D T2D/Non-T2D  
NF-!" 0.00195 2.31 1180.80 <0.0001 
RAGE 0.00053 1.41 2660.38 <0.0001 
S100A12 0.00092 0.74   804.35 <0.0001 
COLIA1       1.34 1246   929.85 <0.0001 
Gal-3      0.05 0.12      2.40 0.37 
 
4.6.3.5 Age of Participants and mRNA Expression Level Correlation  
Transformed Cq values (2-∆Cq) for each of the GOI were compared with the ages of the 
patients in each group. No association between the age of patients and the level of mRNA 
expression for any of the GOI could be shown (Table 4.14).  
Table 4.14: Correlation r test values between the non-T2D group and the T2D group do not 
show a linear correlation between the age of participants compared with the level of mRNA gene 
expression 
 RAGE S100A12 NF-!" COL1A1 Gal-3 
Non-T2D 0.79 0.34 0.30 0.24 0.94 










The results of IHC on non-T2D and T2D samples showed that AGEs accumulated in both 
groups within the ECM and collagen of the dental pulp. They were significantly increased in 
T2D samples and this was confirmed with IF staining which demonstrated intense AGEs and 
RAGE fluorescence in the dental pulp. These findings are congruent with other studies which 
found an accumulation of AGEs in collagen in other tissues (Jeanmaire et al. 2001, Mr et al. 
2014, Argyropoulos et al. 2016, Talakatta et al. 2018). AGEs are accumulated at many sites of 
the body including the heart, large blood vessels, gastrointestinal tract, retina micro- and macro-
vessels, optical nerve of diabetes patients (Amano et al. 2001, Kase et al. 2011, Chen et al. 
2015). Furthermore, AGEs are accumulated in periodontal and gingival tissue of non-T2D and 
T2D patients and their accumulation increases the severity of periodontal disease in diabetes 
more than in non-diabetic patients (Katz et al. 2005, Rajeev et al. 2011, Zizzi et al. 2013, Akram 
et al. 2019). Collagen is the main component of ECM of the dental pulp, and the glycation of 
collagen can increase its intermolecular and intramolecular crosslinks of collagen. This leads 
to structural alterations of collagen, increased stiffness and reduced elasticity within the 
connective tissues and vessel walls of patients with diabetes (Gonzalez et al. 2014, 
Argyropoulos et al. 2016). Furthermore, AGEs accumulation changes the physiochemical 
properties of ECM resulting in decreased solubility and susceptibility to enzymes and 
proteolytic digestion. These changes contribute to the development of diabetic complications, 
including cardiovascular disease, retinopathy, nephropathy, indurated skin and joint stiffness 
(Shah et al. 2015). Diabetes is well known to disturb the structural features of periodontal 
connective tissue including collagen content, fibroblast density and mobility, and mechanical 
strength (Breen et al. 2008, Balci Yuce et al. 2019).  
This study showed that in the pulp, T2D may result in AGEs not only accumulating in 
collagen and ECM, but also in blood vessel walls. Intra-pulpal calcifications were more 
common. Thicker blood vessel walls associated with an accumulation of AGEs indicates that 
AGEs may contribute to pathological changes in the vasculature of diabetics similar to 
physiological aging processes. The crosslinking of AGEs with collagen type I increases the 
stiffness of blood vessels (Zieman et al. 2005).  
The mRNA results showed that mRNA expression level of collagen type I gene increased in 
the dental pulp of T2D samples. Previous investigators have demonstrated that high glucose 
concentration stimulates collagen type I synthesis mRNA levels in different cells and tissues 
(Westermann et al. 2007, Tang et al. 2008, Li et al. 2010, Law et al. 2012). The diabetes and 
glycation of dental pulp by AGEs can be considered as an irritant to dental pulp which leads to 
 109 
fibrosis of dental connective tissue and an increase in collagen type I gene expression level. 
Arteriosclerosis and thickening of the vascular wall by increasing its collagen sheath of the wall 
is known in the dental pulp of patients with diabetes with periodontal disease (Moraru et al. 
2017). The stiffness of vascular walls may affect the small vessels and lead to hypoxia which 
increases the mineralisation activity in dental pulp (Amemiya et al. 2003, Li et al. 2011). The 
IHC results showed that RAGE was expressed in the normal dental pulp of both non-T2D and 
T2D and mainly in cells resembling fibroblasts, endothelial cells, macrophages and neuronal 
cells which corresponded with others (Sims et al. 2009). The expression of RAGE in 
endothelial cells lining blood vessel walls may contribute to increased tissue injury and blood 
vessel stiffness.  
The binding of AGEs to RAGE activates oxidative stress, stimulates production of 
inflammatory cells and promotes secretion of cytokines (Hofmann et al. 1999, Tanaka et al. 
2000, Kierdorf & Fritz 2013). It is possible that AGEs may affect the dental pulp similarly via 
RAGE resulting in increased oxidative stress (Schmidt & Stern 2000, Singh et al. 2001).  
Hyperglycaemia and the AGEs pathway can lead to aggressive tissue destruction and injury 
(Kalousová et al. 2005, Kajitani et al. 2010). The current study suggests that hyperglycaemia 
associated with T2D also affects the clinically normal dental pulp through the increase 
accumulation of AGEs and AGEs-RAGE interactions.  
The IHC findings, described in Chapter 3, showed that the expression of cytokines was 
increased in the dental pulp of T2D samples compared with non-T2D. The increased cytokines 
may be due to AGEs and RAGE upregulation and activation of NF-κB pathways associated 
with hyperglycaemia (Liliensiek et al. 2004, Yang et al. 2017). In this study, the increased 
expression of RAGE in macrophage-like cells in the dental pulp of T2D samples indicates 
hyperglycaemia may stimulate the inflammation process and increase cytokine expression 
(Liliensiek et al. 2004, Mallidis et al. 2007). The results of gene expression showed an increased 
expression level of S100A12 and NF‐κB in dental pulps of T2D compared with non-T2D. 
S100A12 can be considered as a marker for inflammatory periodontal disease in T2D patients 
(Pradeep et al. 2014). Furthermore, it has been shown that mRNA expression of S100A12 was 
detected in the inflamed dental pulp tissue (McLachlan et al. 2004, Khorasani et al. 2017). The 
results demonstrated that diabetes does upregulate the expression of S100A12 mRNA in 
clinically normal dental pulp of T2D group, indicating that the S100A12 gene may have a role 
in inflammation within the clinically normal dental pulp in patients with T2D. S100A12/RAGE 
binding leads to the activation of intracellular signalling that causes activation of NF‐κB (Kang 
et al. 2015). Studies showed that NF‐κB expression is increased in tissues and cells of diabetics 
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(Bierhaus et al. 2001, Ha et al. 2002, Catrysse & van Loo 2017). Thus, hyperglycaemia of T2D 
can increase the glycation intensity in clinically normal dental pulp of T2D by accumulation of 
AGEs and by interaction of RAGE with AGEs and S100A12 and activation of NF-κB pathways 
(Lalla et al. 2001, Catrysse & van Loo 2017).  
The results of DIF identified that RAGE is co-localized within the intermediate filament 
protein vimentin in human clinically normal dental pulps of non-T2D and T2D. Vimentin was 
used as a marker of dental fibroblasts and is also expressed in endothelial cells of capillaries 
and neurons (Lucotte et al. 2015). In T2D samples, RAGE expression was mainly observed 
within blood vessel walls of the pulp. Within the central dental pulp, RAGE was co-expressed 
with vimentin on fibroblasts. This localisation is consistent with other studies in animal models 
that have identified that cells expressing vimentin also express RAGE (Barile & Schmidt 2007). 
The RAGE was detected in fibroblasts and it has shown to be associated with collagen 
production (Mallidis et al. 2007). The results of DIF showed a decrease of vimentin-specific 
fluorescence in dental pulp connective tissue of T2D samples and in capillaries, respectively, 
which may result in impaired pulp healing. Vimentin is a very important protein in healing 
(Ivaska et al. 2007, Minin & Moldaver 2008, Murakami et al. 2012, Cheng et al. 2016), and a 
loss or lack of vimentin leads to delayed wound healing (Matsuyama et al. 2013, Cheng et al. 
2016) with delayed fibroblast migration and collagen contraction necessary for healing (Eckes 
et al. 2000, Menko et al. 2014, Cheng et al. 2016, Antfolk et al. 2017).  
Fibroblasts are involved in tissue fibrosis (Bainbridge 2013, Darby et al. 2014). Tissue 
fibrosis is caused by the hyperproliferation of fibroblasts, which also produce abnormally large 
amounts of ECM (Speca et al. 2012). These hyperactive fibroblasts have the capacity to become 
activated by inflammatory cytokines to myofibroblasts that further increase ECM production 
(Darby et al. 2014). The decreased expression of vimentin and fibroblasts in the dental pulp of 
T2D with increased collagen deposits may indicate the presence of myofibroblasts which are 
more susceptible to hyperglycaemia (Law et al. 2012, Darby et al. 2014). Immunofluorescence 
showed that the fibroblast morphology in the dental pulp of T2D was changed. Together, the 
findings of the current study suggest that hyperglycaemia may activate the transition of 
fibroblasts to myofibroblasts resulting in an increased production of ECM and collagen type I 
which can result dental pulp fibrosis and blood vessel atherosclerosis.   
The DIF staining showed co-expression of RAGE with CD4+ cells in clinically normal dental 
pulp of non-T2D and T2D participants. RAGE plays a role in activation and differentiation of 
T lymphocytes (Moser et al. 2007, Chen et al. 2008, Akirav et al. 2012). Akirava et al. showed 
that RAGE was expressed in Th lymphocytes isolated from patients with diabetes but not 
 111 
healthy patients (Akirav et al. 2012, Akirav et al. 2014). The co-localization of RAGE and 
CD4+ cells implicates RAGE’s role in adaptive immune responses of the clinically normal 
dental pulp but further investigation at a molecular level is warranted. 
There was no significant difference in the expression of GOI even when age was considered. 
This indicates that although there was some disparity in age of participants between the groups 
this did not greatly influence the gene expression levels.  
mRNA gene expression demonstrated for the first time the expression of Gal-3 in clinically 
normal dental pulp of non-T2D and T2D patients. However, there was no significant difference 
between the groups. This result is contrary with others who found Gal-3 was significantly 
increase in the blood serum of patients with diabetes compared with non-T2D (Weigert et al. 
2010, Yilmaz et al. 2015). Gal-3 plays a protective, anti-inflammatory role by removing AGEs 
(Iacobini et al. 2003). Furthermore, Gal-3 protects the tissue when AGEs level increases by 
inducing tissue inflammation and injury (Pugliese et al. 2001, Iacobini et al. 2005). Recently, 
Tan and his group found that increased Gal-3 in the serum was associated with progression of 
T2D complications (Tan et al. 2018). Others have found that the Gal-3 absence accelerates the 
diabetic complications e.g. diabetic nephropathy (Pugliese et al. 2001, Pugliese et al. 2014). 
Gal-3 had different effects in different organs dependent on or independent of the AGEs binding 
function of this protein (Pugliese et al. 2014). The lack of difference between T2D and non-
T2D may be due to the small samples size and the self-reported nature of glycaemic control. 
Future studies using a larger sample size and similar HbA1c levels would be beneficial to 
ascertain if Gal-3 has a role in pulp health and inflammation.  
qPCR was used to analysis the gene expression in dental pulp tissue collected from non-T2D 
and T2D patients to better understand what is happening at a molecular level. The use of 
molecular techniques has improved understanding of pulp disease and healing (McLachlan et 
al. 2005, Staquet et al. 2008, Khorasani et al. 2017, Alvarez et al. 2019, Charoenpong et al. 
2019). Gene arrays are useful for screening the expression of a number of genes simultaneously. 
Genetic information stored in DNA is translated into proteins through the intermediate of 
mRNA, and proteins are directly involved in almost all processes of life by carrying out various 
biological functions. In this study, qPCR was used to analysis groups of genes which were 
different from the groups of proteins which were identified in the dental pulp by using IHC. 
Proteins are essential to life processes and their expression provides important information 
about what is happening in at a tissue level. Accordingly, both protein expression and mRNA 
studies are valuable and supportive to each other (Guo et al. 2008).  
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The results of current study accept the hypothesis of “type 2 diabetes modifies clinically 
normal dental pulp through glycation with increased expression of AGEs and RAGE on several 
cell types. 
4.8 Challenges and Limitations  
The dental pulp from T2D samples was challenging to prepare for the gene expression study. 
The preparation and grinding of T2D dental pulp tissue samples for RNA extraction was 
difficult compared with the non-T2D samples. The T2D dental pulp had a hard-fibrous texture, 
compared with dental pulp from non-T2D samples. The plastic mortar-pestle which used to 
grind the dental pulp was not effective in T2D samples. This finding was consistent with other 
studies which found that collagen fibrils in diabetic tissue are stiffer and harder than intact and 
well-organized collagen fibrils in non-diabetic tissue (Aneja et al. 2008, Argyropoulos et al. 
2016). The method of grinding the dental pulp from T2D was modified and a homogeniser 
machine was used to improve the yield and amplification of the nucleic acid in the tissue. This 
technical difficulty reflects the findings of Chapter 3 which demonstrated morphological 
differences and increased collagen and fibrous tissue within the dental pulp of T2D samples. 
This was also associated with a reduction in mRNA quality in dental pulp of T2D samples, 
which may in part be due to the effect of inflammation which is known to reduce RNA 
(McLachlan et al. 2004).  
This study had several limitations. The sample sizes in this study were relatively small and 
was limited by funding. Further, biological variability between samples is also inherent when 
conducting in vivo studies. 
Future research with a larger number of samples would assist in reducing the significance of 
biological variability and would validate the findings for generalisation to larger cohorts. In 
addition, some results may reach statistical significance. Further studies are needed to 
determine the different roles of RAGE and RAGE related factors, such as oxidative stress 
markers and cell adhesion molecules in dental pulp of T2D. Moreover, the assessment of other 
AGEs pathways besides the receptor-dependent mechanisms may help gain a better 
understanding of glycation in dental pulp. Collagen formation and degradation in the dental 
pulp need further investigation with a match of age between non-T2D and T2D samples to rule 
out the effect of age on pulpal calcification and fibrosis. 
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4.9 Conclusion 
Hyperglycaemia affects the dental pulp via the AGEs/RAGE pathway which can lead to 
aggressive tissue destruction and injury. AGEs reflect the glycation process in dental pulp 
which affects its collagen structure of the dental pulp. The interaction between RAGE and its 
ligands AGEs can result in activation of NF-κB pathways and increases dental pulp 
inflammation and fibrosis. Hyperglycaemia and RAGE ligands such as AGEs and S100 
proteins can be considered as DAMPs within the dental pulp in T2D patients. RAGE has a role 
in the adaptive immune response and can activate myofibroblasts in dental pulp in T2D. 
Understanding the nature of dental pulp in patients with diabetes may help clinicians translate 
this knowledge and make more informed treatment planning decisions. In conclusion, T2D is 
associated with glycation and RAGE which may play an important role in the tissue destruction 




Chapter 5  
In Vitro Diabetic Model 
5.1 Introduction  
In vivo studies have some limitations particularly the inability to precisely control glucose, 
while in vitro models allow precision and repeatability and facilitate study of the 
pathophysiological aspects at the cellular and molecular levels (Apfel 2006). A number of in 
vivo and in vitro models mimicking hyperglycaemia in humans have been designed to 
investigate the pathophysiological mechanisms of diabetes (Srinivasan & Ramarao 2007, 
Okamura et al. 2009, Jaiswal et al. 2010, Al-Qarakhli et al. 2019).  
Diabetic cell culture models provide a mechanism for investigating the effects of 
hyperglycaemia in a controlled environment (Sango et al. 2006). The effect of hyperglycaemia 
can be evaluated in vitro using different glucose concentrations, which clinically mimics T2D 
(Matteucci et al. 2015). In vitro models studying hyperglycaemia have used primary cell 
cultures of dorsal root ganglia neurons, neuroblastoma cells, neural crest cells, cortical neurons 
and retinal cells (Hattangady & Rajadhyaksha 2009, Matteucci et al. 2015). A range of cell 
types have been used to evaluate the effect of hyperglycaemia on cell proliferation including 
mesenchymal stromal cells (Al-Qarakhli et al. 2019), endothelial cells (Morss & Edelman 
2007), periodontal stem cells and periodontal ligament cells (Kim et al. 2006, Kato et al. 2016), 
epithelial cells (Samikkannu et al. 2006), osteoblasts (Linxi et al. 2015), gingival fibroblasts 
(Buranasin et al. 2018), cardiac myofibroblasts (Neumann et al. 2002), and most recently, stem 
cells from apical papilla (Wang et al. 2019). When human skin fibroblasts have been cultured 
in different glucose concentrations their cell morphology and viability was altered 
(Raeisossadati & Daneshimehr 2011). Further, high levels of glucose in cell culture have been 
found to downregulate collagen type I synthesis in pulp tissue (Valikangas et al. 2001). Only 
one identified study has considered the effect of glucose on hDPCs and this showed that 
hyperglycaemia increased cell proliferation and mineralization nodules were evident (Okamura 
et al. 2009). These studies have enhanced our knowledge but the influence of elevated glucose 
on gene expression remains unclear.  
The present study uses an in vitro cell culture model to investigate the effect of 
hyperglycaemia on hDPCs from mature third molars with specific interest in cell viability and 
expression of genes associated with inflammation and healing.  
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5.2 Hypotheses 
An in vitro diabetic cell culture model treated with different glucose concentrations can be 
effective for investigating the effect of glucose on hDPCs.  
Culturing of cells in the presence of high glucose concentrations alters cell behaviour and 
gene expression. 
5.3 Experimental Aims  
To examine cultured hDPC responses in vitro in the presence of various glucose 
concentrations which mimic the blood glucose concentration of T2D patients. 
5.3.1 Specific Objectives 
1. Establish hDPC cell lines from dental pulp tissue explants. 
2. To examine the phenotype of hDPCs cultured in high glucose environments.  
3. Determine the effect of glucose concentration on hDPCs viability. 
4. Examine the effect of normal and high glucose concentrations on mRNA expression.  
5.4 Material and Methods  
5.4.1  Study Participants  
Healthy adults were recruited who were having mature unerupted third molars extracted as 
part of their treatment plan at the Oral Surgery Clinic, University of Otago. Ethical approval 
for this study was gained from the University of Otago Ethics Committee (Project Reference 
H18/077) and Māori consultation was entered with the Ngāi Tahu Research Committee. 
Approvals can be found in Appendices A.2.1 and A.2.2.   
Participants who met the inclusion criteria were asked to read the information sheet and 
written consent was obtained. See Appendices A.2.3 and A.2.4. 
5.4.2 Inclusion and Exclusion Criteria 
Teeth were collected according to specific inclusion and exclusion criteria.  
Inclusion criteria: 
• Healthy participants (no systemic diseases) 
• Age 15-30 years, of any ethnicity 
• Unerupted third molar with a closed apex  
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• Healthy gingival and periodontal tissues (<3mm probing) 
Exclusion criteria:  
• Diabetic: diagnosed by a physician HbA1c  ≥48mM/mol or a fasting glucose 
≥7mM/ml  
• Prediabetic: diagnosed by a physician HbA1c 39-47mM/mol or a fasting glucose 5.6-
6.9mM/ml  
• Any systemic disease 
• Pregnancy  
• Smoking  
• Taking anti-inflammatory medication 
5.4.3 Tooth Collection 
Immediately following extraction, the tooth was collected and sectioned 2-3mm horizontally 
below the CEJ using a long fissure bur in a high-speed handpiece. The crown was transferred 
to a falcon tube containing 10ml prepared of supplemented DMEM media (containing 25mM 
glucose) and transferred on ice within two hours to the tissue culture facility. The tooth roots 
were discarded as usual using the protocols for normal tissue waste. 
5.4.4 Glucose Concentration  
The glucose concentrations were chosen to mimic blood glucose levels and are listed in 
Table 5.1.  
Table 5.1: Glucose concentrations used in diabetic cell culture model and corresponding glucose 
level in blood 
Clinical diagnosis 
Fasting plasma glucose Glucose level used in model 
mM/l mg/dl mM/l mg/dl 
Normal 3.9-5.6 70-100 5.5 99 





Hyperglycaemia >16.67 >300 25 450 
 
5.4.5 Supplemented Culture Media 
DMEM medium was supplemented with 10% foetal bovine serum, penicillin (100UI/ml), 
streptomycin (100µg/ml), amphotericin B (0.25µg/ml), and gentamycin (0.25µg/ml). When 
required, media containing no glucose, 5.5 and 25mM D-glucose, osmotic and L-glucose 
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control media were prepared using the supplemented medium. See Appendix B.12.5 for media 
preparation protocols.  
Unless specified otherwise, glucose used in the current study was D-glucose, a natural form 
of glucose and it utilized in the cells. The osmotic control was checked by using L-glucose, 
which is produced synthetically, and it is not utilized in the cells.  
5.4.6 Experimental Media Preparation 
Media containing various concentrations of D- and L-glucose were prepared according to 
Table 5.2 and compared with commercially available glucose products. 
Table 5.2: List of media used in this study 
Medium Glucose Content Commercial/Prepared Protocol 
Zero No glucose Commercially available   Appendix B.12.5 
Normal 5.5mM D-glucose Commercially available   
Appendix B.12.5 
High  25mM D-glucose Commercially available   
D1 5.5mM D-glucose Prepared from: 




D2 10mM D-glucose 
D3 15mM D-glucose 
D4 25mM D-glucose 
L2 
5.5mM D-glucose  
+ 4.5mM L-glucose 
Prepared from:  
• Zero glucose DMEM 




5.5mM D-glucose   
+ 19.5mM L-glucose 
 
5.4.6.1 Primary Pulp Cell Line Explant Procedure 
Supplemented DMEM containing 25mM D-glucose was used to establish the hDPCs (Ferro 
et al. 2014, Daniela Ferreira Araújo et al. 2018). In a Class II cell culture hood, the dental pulp 
was removed using a sterile dental excavator and transferred to a petri dish containing a drop 
of supplemented DMEM. The tissue was cut into four pieces using a scalpel blade and each 
piece of tissue transferred to the well of a 24-well tissue culture plate (Cat. No.662160, Greiner 
Bio-One). Each well had been previously scratched with the tip of sterile tweezers to encourage 
cell adhesion. The tissue was made smaller and minced using two scalpel blades. Culture 
medium (300µl) was then added to each well and tissue incubated at 37°C in 95% air and 5% 
CO2. The next day, 500µl of the prepared medium was added to each well, followed by 200µl 
on the third day, to a final volume of 1ml. On day 7, 80% of the media was replaced and then 
100% of media replaced every 3-4 days until a monolayer of cells had formed. An average of 
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21 days (range: 18–28) was required for each of the seven hDPCs populations to reach 80% 
confluence before cell expansion was undertaken. 
5.4.6.2 Cell Passaging 
When cells reached 80% confluence, they were detached using 0.25% trypsin-EDTA and 
transferred to a T-25 flask. After 8–15 days, the hDPCs were expanded into a T-75 flask. The 
supplemented DMEM medium was replaced every 2-3 days. See Appendix B.15 cell passaging 
protocol.  
5.4.7 Cell Counting  
Viable cells were counted using a Neubauer Haemocytometer. A 0.4% solution of Trypan 
Blue in PBS, pH 7.2–7.3 was used to stain dead cells blue while the cells with intact cell 
membranes remained clear. See Appendix B.16 for detailed cell counting protocol. 
5.4.8 Cell Cryopreservation 
When sufficient cells were present at passage 3, the cells were suspended in freezing media 
and stored in liquid nitrogen until required for experiments. The cell cryopreservation protocol 
and freezing medium preparation can be found in Appendix B.17. 
5.4.9 Thawing Cells  
Thawing cells is a sensitive procedure. After the cells were removed from the liquid nitrogen, 
they were carefully placed into a 37°C water bath without submerging the cap on the Eppendorf 
tube. When the cells were partly defrosted, they were gently transferred to a T-25 flask 
containing 3ml supplemented culture medium containing 25mM D-glucose. See Appendix 
B.18. All the cells were used in the following experiments were at passage 5.  
5.4.10 Human Dental Pulp Cells Seeding for Diabetic Model Experiment 
The hDPCs were seeded at 5 x103 cells/well in 96-well plates (Nunclon™ Delta Surface; 
Cat. No.167008, Thermo Fisher Scientific) with 200µl supplemented DMEM media containing 
5.5mM glucose and maintained at 37°C in 95% air and 5% CO2 for 24 hours (hrs). The next 
day the medium was replaced with the experimental diabetic model medium. 
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5.4.11 Cell Viability  
5.4.11.1 Experiment Design  
Cell viability was determined for four cell populations over five days in the presence of 
different glucose concentrations. The hDPCs were cultured for 24hrs in DMEM containing 
5.5mM glucose the medium then it was replaced with 100µl of either commercially prepared 
5.5mM and 25mM glucose, diabetic model media (D1-D4) (see Table 5.2) or osmotic media 
controls (L2 and L4) (see Table 5.2). The three plates were incubated at 37°C in 95% air and 
5% CO2 with cell viability measured at days 1, 3 and 5. The plate layout is shown below (Figure 
5.1). 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 5.5 25 D1 D2 D3 D4 L2 L4   D0 No cell 
B 5.5 25 D1 D2 D3 D4 L2 L4   D0 No cell 
C 5.5 25 D1 D2 D3 D4 L2 L4   D0 No cell 
D            
 
E         
   
 
F    





        
 
H 
           
 
Figure 5.1: 96-well plate layout used in viability analysis. The same layout was used three times for the three 
time points (1, 3, 5 days).  
 
5.4.11.2  PrestoBlue® Assay 
PrestoBlue® is a cell permeable resazurin-based solution that functions as a cell viability 
indicator. It uses the reducing power of living cells to quantitatively measure resazurin- based 
dyes that are able to penetrate the cell membrane and viable cells are able to enzymatically 
reduce the dye to resorufin, a fluorescent pink compound, which is then secreted into the 
medium and can be measured spectrometrically. PrestoBlueTM Cell Viability Reagent (10µl) 
(Cat. No. A13261, InvitrogenTM) was added directly to the cells in 100µl medium and incubated 
for two hours at 37℃ in the dark. The cell medium was then transferred to a new 96-well plate 
(Cat. No.662160, Greiner Bio-One) and the resulting fluorescence measured using a Synergy™ 
2 multi-mode microplate reader (BioTek Instruments) at 535nm excitation/615nm emission 
wavelengths.  
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5.4.11.3 Viability Data Analysis  
Data analysis was performed using GraphPad Prism (Prism 8 Version 8.4.2, 2020) and Excel 
(Version 16.37, 2020) software for Mac OS Catalina (Version 10.15.4). The data are presented 
as mean and SD. A student’s t-test was used and the differences between the groups were 
considered significant when P-value<0.05.  
5.4.12 mRNA Expression  
5.4.12.1 Experiment Design 
Two concentrations of commercially prepared glucose 5.5 and 25mM, were compared with 
mRNA expression levels determined following 1, 3 and 5 days of culture. The four hDPCs 
populations were again seeded at 5 x103 cells/well of 96-well in triplicate in DMEM containing 
5.5mM glucose which was replaced after 24 hrs with fresh DMEM containing 5.5mM or 25mM 
glucose. One plate was prepared for each timepoint. 
5.4.12.2 Cell RNA Recovery, cDNA Synthesis and mRNA Expression Analysis 
The TaqMan® Fast Cells‐to CT™ Kit (Cat. No. A35377, Thermo Fisher Scientific, 
InvitrogenTM) was employed for mRNA expression determination. The kit includes reagents 
for cell lysis, RNA recovery, cDNA synthesis and TaqMan® qPCR assays.  
The culture medium was discarded from the wells and the cells rinsed with sterile PBS. One 
well was randomly selected from each of the triplicates for mRNA analysis. The ‘Lysis 
Solution’, containing DNase I (50µl), was added to the cells and incubated for 5 mins at RT, 
followed by the addition of the ‘Stop Solution’ (5µl) and a further incubation for 2 mins at RT. 
cDNA synthesis was carried out using 10μl of the total 55μl cell lysate which was combined 
with 40μl of 2X RT master mix. The reaction was placed into a thermal cycler (Cat. No. 
6331000068, Mastercycler gradient, Eppendorf, Eppendorf South Pacific Pty. Ltd.) and 
incubated for 30 mins at 37℃, 5 mins at 95℃, and kept at 4℃ until removed and stored at -
20℃ until required. The reverse transcription details, master mix components and thermal 
cycler are described in Appendix B.21.2. 
5.4.12.3 Quantitative Reverse Transcription PCR (qRT-PCR) Array Gene Expression 
Analysis 
To determine the cellular response at 1, 3, and 5 days when the hDPCs were cultured in 
5.5mM and 25mM glucose, a comparison of mRNA expression levels was carried out using 
quantitative real-time PCR. Two pre‐designed customised [16 gene x 6 samples] TaqMan® 
gene expression assay 96-well array plates were used (Thermo Fisher Scientific, InvitrogenTM).  
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The phenotype characterisation array plate contained 13 qPCR gene assays for dental pulp 
cell gene markers CD34, PTPRC, PECAMI, NES, DLX2, VIM, and DSPP. The assay also 
included another six gene markers which were not included in the experiments. Three reference 
genes; (r18S, B2M and GAPDH) were included on the plate. The second array plate contained 
13 qPCR gene assays for diabetes-related genes and included the AGE receptors; (RAGE and 
LGALS3BP), cytokine genes; (IL1", IL6, TNF-$, NF-%", S100A12), ECM genes; (COL1A1, 
COL3A1, MMP1, MMP8, VEGF) and a mineralization gene marker; (ALPL). The same 
reference genes were included (see Table 5.3 for RT-qPCR gene expression assays). For 96-
well plate assay layout see Figures 5.2 and 5.3. 
Table 5.3: Gene list used in the experiment 
 Gene symbols Gene name Gene alias 
Hematopoietic 
CD34 CD34 molecule CD34 
PTPRC Protein tyrosine phosphatase, receptor type C CD45 
PECAM1 Platelet and endothelial cell adhesion molecule CD31 
Neural marker and 
cytoskeleton-related markers 
DLX2 Distal-less homeobox 2 TES-1; TES1 
VIM Vimentin CTRCT30; HEL113 
NES Nestin Nbla00170 
Mineralization marker 
DSPP Dentine sialophosphoprotein DFNA39 
ALPL Alkaline phosphatase AP-TNAP 
Dental pulp 
 
COL1A1 Collagen type I alpha 1 EDSC 
COL3A1 Collagen type III alpha 1 chain EDS4A 
MMP1 Matrix metallopeptidtidase 1 CLGN 
MMP8 Matrix metallopeptidtidase 8 CLG1 
VEGF Vascular endothelial growth factor A VEGF 
AGE receptors 
RAGE Advanced glycation end-product-specific receptor RAGE 
LGALS3BP Galectin 3 binding protein gp90 
Inflammatory and cytokine 
markers 
NF-#B1 Nuclear factor kappa B subunit 1 NF-kappa-B 
S100A12 S100 calcium binding protein A12 CAAF1 
IL6 Interleukin 6 BSF-2 
IL1" Interleukin 1 beta  IL1F2 






1 2 3 4 5 6 7 8 9 10 11 12 
A 18s rRNA THY1 18s rRNA THY1 18s rRNA THY1 18s rRNA THY1 18s rRNA THY1 18s rRNA THY1 
B CD44 NES CD44 NES CD44 NES CD44 NES CD44 NES CD44 NES 
C MCAM VIM MCAM VIM MCAM VIM MCAM VIM MCAM VIM MCAM VIM 
D CD34 PTPRC CD34 PTPRC CD34 PTPRC CD34 PTPRC CD34 PTPRC CD34 PTPRC 
E PECAM1 ENG PECAM1 ENG PECAM1 ENG PECAM1 ENG PECAM1 ENG PECAM1 ENG 
F NT5E DLX2 NT5E DLX2 NT5E DLX2 NT5E DLX2 NT5E DLX2 NT5E DLX2 
G DSPP COL2A1 DSPP COL2A1 DSPP COL2A1 DSPP COL2A1 DSPP COL2A1 DSPP COL2A1 
H GAPDH B2M GAPDH B2M GAPDH B2M GAPDH B2M GAPDH B2M GAPDH B2M 
 Day 1 
Normal glucose  
(5.5mM D-glucose) 
Day 1 
High glucose  
(25mM D-glucose) 
Day 3 




 (25mM D-glucose) 
Day 5 
Normal glucose  
(5.5mM D-glucose) 
Day 5 
High glucose  
(25mM D-glucose) 
Figure 5.2: hDPC phenotype characterisation gene assay 96-well plate layout.  
Note: The strikethrough lines indicate the genes were included in the plate but not included in the experiments 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 18s rRNA GAPDH 18s rRNA GAPDH 18s rRNA GAPDH 18s rRNA GAPDH 18s rRNA GAPDH 18s rRNA GAPDH 
B B2M LGALS3BP B2M LGALS3BP B2M LGALS3BP B2M LGALS3BP B2M LGALS3BP B2M LGALS3BP 
C NF-!B1 RAGE NF-!B1 RAGE NF-!B1 RAGE NF-!B1 RAGE NF-!B1 RAGE NF-!B1 RAGE 
D S100A12 COL1A1 S100A12 COL1A1 S100A12 COL1A1 S100A12 COL1A1 S100A12 COL1A1 S100A12 COL1A1 
E COl3A1 ALPL COl3A1 ALPL COl3A1 ALPL COl3A1 ALPL COl3A1 ALPL COl3A1 ALPL 
F VEGF IL6 VEGF IL6 VEGF IL6 VEGF IL6 VEGF IL6 VEGF IL6 
G IL1B TNF IL1B TNF IL1B TNF IL1B TNF IL1B TNF IL1B TNF 
H MMP1 MMP8 MMP1 MMP8 MMP1 MMP8 MMP1 MMP8 MMP1 MMP8 MMP1 MMP8 
 Day 1 
Normal glucose  
(5.5mM D-glucose) 
Day 1 
High glucose  
(25mM D-glucose) 
Day 3 




 (25mM D-glucose) 
Day 5 
Normal glucose  
(5.5mM D-glucose) 
Day 5 
High glucose  
(25mM D-glucose) 





5.4.12.4 qPCR Amplification 
To each array plate well, a master mix containing TaqMan® Fast Advanced Master Mix 
(5μl), cDNA (1μl or 5ng) and PCR-grade water (4μl) was added. The manufacturer’s suggested 
thermo‐cycling conditions were run (2 mins at 50°C hold; 20 secs at 95°C; 40 cycles of 1 sec 
at 95°C and 20 secs at 60°C) on a Quant StudioTM 6 Flex Real-Time PCR System Machine 
(Applied biosystem™ by Life Technologies). The cycle threshold (Cq) values were calculated 
using Quant StudioTM Real-Time PCR Software (Version1.0).  
5.5 qPCR Data Analysis  
The comparative Cq method was employed to calculate the difference in mRNA expression 
between the 5.5mM and 25mM D-glucose concentrations at the 1, 3, and 5 days (see the detailed 
comparative Cq analysis method in Chapter 4, Section 4.5.3). 
The fold difference (FD) for each gene was calculated using the average 2-∆Cq value for 
each time point where 2-∆∆Cq = 2-∆Cq (test) / 2-∆Cq (control). 
1. mRNA expression levels were compared for hDPCs cultured in 5.5mM over time. 
2-∆∆Cq = 2-∆Cq (day3 (5.5mM)) / 2-∆Cq (day1 (5.5mM)) 
2-∆∆Cq = 2-∆Cq (day5 (5.5mM)) / 2-∆Cq (day1 (5.5mM)) 
2. mRNA expression levels were compared for hDPCs cultured in 25mM over time. 
2-∆∆Cq = 2-∆Cq (day3 (25mM)) / 2-∆Cq (day1 (25mM)) 
2-∆∆Cq = 2-∆Cq (day5(25mM)) / 2-∆Cq (day1 (25mM)) 
3. mRNA expression levels were compared for hDPCs cultured in 5.5mM and 25mM 
glucose. 
2-∆∆Cq = 2-∆Cq (25mM) / 2-∆Cq (5.5mM). 
The data analysis was performed using GraphPad Prism (Prism 8 Version 8.4.2, 2020) and 
Excel (Version 16.37, 2020) software for Mac OS Catalina (Version 10.15.4). An unpaired non-
parametric student t-test was used with a difference between the groups considered significant 




5.6.1 Study Participants  
Seven unerupted third molars were collected but it was necessary to exclude two teeth 
because of contamination. Five cell populations were generated from explant tissue. Four cell 
lines cultured from tooth 28 which were extracted from female participants were used for this 
study (C2, C3, C4, C5) see Table 5.4.  
Table 5.4: Participant’s information  
Participant Gender AGE Tooth number Cell ID Include 
1 M 21 18 C1 No 
2 F 22 28 C2 Yes 
3 F 22 28 C3 Yes 
4 F 23 28 C4 Yes 
5 F 22 28 C5 Yes 
6 M 22 28 C6 No 




5.6.2 Human Dental Pulp Cell Characterisation 
5.6.2.1 Human Dental Pulp Cell Morphology 
The hDPCs outgrowth originated from dental pulp tissue explants. Spindle shaped cells 
could be seen migrating from the dental pulp tissue on day 7, with increased numbers by day 
10. Between days 15 and 21 the cells had formed confluent monolayers. The hDPCs were a 
highly proliferative heterogenous cell population with the most prominent being spindle shaped 
cells with fibroblast-like morphology (Figure 5.4).  
 
Figure 5.4: Dental pulp tissue explant outgrowth. Microscopic appearance of human dental pulp cells 
cultures established from impacted third molar tissue. Dental pulp explant on (A) day 2; (B) day 5; (C) 
day 7; (D) day 10; (E) day 14; (F) day 16; (G) day 18; and (H) day 26, where dental pulp cells can be 
seen as a confluent monolayer.  




5.6.2.2 Human dental pulp cells Morphology when Cultured in 5.5 and 25mM D-glucose 
No significant morphological differences were observed after 24 hrs of cells being cultured 
in 5.5 or 25mM D-glucose commercial and prepared media. The hDPCs were heterogeneous in 
shape and were predominantly fibroblast-like, with some appearing cuboidal or polygonal, with 
multiple processes (Figure 5.5).  
 
Figure 5.5: Morphological characterization of hDPCs in various glucose concentrations following 
24hrs of culture. Microscopic appearance (A) 5.5mM D-glucose (commercial) following seeding. After 
24-hrs following the removal of the 5.5mM D-glucose in (B) zero glucose; (C) 5.5mM D-glucose 
(commercial); (D) 25mM D-glucose (commercial); (E) D1; 5.5mM D-glucose (prepared); and (F) D4; 
25mM D-glucose (prepared).  
A-F; 10x magnification. 
 
 127 
5.6.2.3 Phenotype Characterisation of Human Dental Pulp Cells Using Gene Expression 
Analysis 
The reference gene Beta2-microglobulin (B2M) was used to normalise the mRNA 
expression data (Figure 5.6). 
 
Figure 5.6: Reference gene expression. Cq values across all time points were compared. (A) B2M; 
(B) GAPDH (n=4). Error bars indicate mean with SD. 
LG: normal glucose concentration 5.5mMD-glucose, HG: high glucose concentration 25mM D-glucose 
 
mRNA expression for the endothelial-hematopoietic markers CD34, PTPRC (CD45) and 
PECAMI (CD31) were below the limit of detection in all four cell populations when cultured 
in 5.5mM or 25mM D-glucose at all time points (Figure 5.7 A-F). 
Both NES and VIM mRNA, early neural markers, were detected on all three days when the 
































































































Figure 5.7: Gene phenotype characterisation of hDPCs. Scattered plot showing gene markers 
expression in human dental pulp cells; at normal 5.5mM D-glucose on (A) day 1, (C) day 3, and (D) 
day 5, and high glucose 25mM D-glucose on (B) day1, (D) day 3, and (F) day 5. The dotted line indicates 
































































































































































































































































25mM D-glucose on day 3 
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NES mRNA expression decreased significantly over time in 5.5mM glucose on day 3 (4.45-
fold, P=0.02) and day 5 (6.91-fold, P=0.02) compared with day 1, while in 25mM on day 3 and 
5 no significant decrease was detected (7.08-fold, P=0.14 and 4.81-fold, P=0.16 respectively) 
(Figure 5.8).  
 
Figure 5.8: NES neural marker mRNA expression levels. hDPCs were cultured in supplemented 
DMEM containing either 5.5mM or 25mM D-glucose mRNA expression was measured at three-time 
points day 1, 3 and 5. (*P=0.02) (n=4). The dotted line indicates the limit of detection. Error bars indicate 
mean with SD. 
LG: normal glucose concentration 5.5mMD-glucose, HG: high glucose concentration 25mM D-glucose 
 
Distal-less homeobox 2 (DLX2) is a member of the homeodomain family of transcription 
factor and is a neural marker. DLX2 mRNA was positively expressed at all time-points. Its 
expression was affected by increasing time exposure but not concentration of glucose. DLX2 
mRNA expression decreased over time significantly in 5.5mM glucose on day 3 (3.05-fold, 
P=0.001) and day 5 (9.30-fold, P=0.0005), and decreased significantly in 25mM on day 5 (4.24-
fold, P=0.005) (Figure 5.9). The expression level of DLX2 mRNA was decreased in 25mM in 
day 1 (1.09-fold) and increased in 25mM glucose on day 3 and 5 (1.44-fold, and 2.01-fold 
respectively) but none of these differences reached significance (Figure 5.7 A–F). 
mRNA for the odontoblast phenotype marker dentine sialophosphoprotein (DSPP) was not 




















































Figure 5.9: DLX2 neural marker mRNA expression levels. hDPCs were cultured in supplemented 
DMEM containing either 5.5mM or 25mM D-glucose mRNA expression was measured at three-time 
points day 1, 3 and 5. DLX2 mRNA expression was decreased over time significantly in 5.5mM glucose 
on day 3 (**P=0.001) and day 5 (***P=0.0005), and decreased significantly in 25mM on day 5 
(**P=0.005) (n=4). The dotted line indicates the limit of detection. Error bars indicate mean with SD. 
LG: normal glucose concentration 5.5mMD-glucose, HG: high glucose concentration 25mM D-glucose 
 
The greatest change in mRNA expression level over time was found for hDPCs cultured in 
5.5mM glucose for which a number of genes decreased. All the fold changes are shown in Table 
5.5. 




















































Day 3 (5.5mM)/ 
Day 1 (5.5mM) 
Day 5 (5.5mM)/ 
Day 1 (5.5mM) 
Day 3 (25mM)/ 
Day 1 (25mM) 
Day 5 (25mM)/ 










Marker Gene         
CD34 -7.84 0.22 -2.19 0.44 -1.33 0.58 -1.25 0.68 
PTPRC -5.68 0.25 -2.64 0.39 -1.63 0.43 -1.28 0.65 
PECAM1 -13.15 0.20  1.36 0.62 -1.63 0.43 5.03 0.08 
NES -4.45 0.02 -6.91 0.02 -7.08 0.14 -4.81 0.16 
VIM -1.61 0.48 -2.65 0.21 1.01 0.98 -1.71 0.32 
DLX2 -3.05 0.001 -9.30 0.0005 -1.95 0.04 -4.24 0.005 
DSPP -13.15 0.20 -2.50 0.41 -1.18 0.80 -2.94 0.25 
Yellow highlight colour; A fold-difference was considered significant if >2 x <-2 with a P-value <0.05 
Blue highlight colour mark; undetected genes 
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No significant difference was found when mRNA expression levels for 5.5mM and 25mM 
glucoses for each gene was compared across all time points (Table 5.6).  
Table 5.6: mRNA expression fold-change for 5.5 and 25mM D-glucose a comparison for each time 
point 
Gene 
Day 1 (25mM)/ 
Day 1 (5.5mM) 
Day 3 (25mM)/ 
Day 3 (5.5mM) 
Day 5 (25mM)/ 
Day 5 (5.5mM) 
Fold change P-value Fold change P-value Fold change P-value 
Marker Gene       
CD34 -2.84 0.35  2.09 0.25 -1.62 0.64 
PTPRC -2.84 0.35 1.23 0.79 -1.37 0.80 
PECAM1 -2.84 0.35 2.85 0.32  1.30 0.57 
NES  1.08 0.89     -1.48 0.58  1.55 0.37 
VIM -1.38 0.57 1.18 0.82  1.12 0.84 
DLX2 -1.09 0.56 1.44 0.38  2.01 0.13 
DSPP -1.51 0.62 7.38 0.13 -1.78 0.66 
A fold-difference was considered significant if >2 x <-2 with a P-value <0.05 




5.6.2.4 Diabetic Model Validation 
5.6.2.4.1 Cell Viability - Media Composition Commercial V Prepared 
hDPCs were cultured in the commercially prepared supplemented DMEM media (5.5mM 
and 25mM D-glucose) or media which was a commercially prepared supplemented DMEM 
with no glucose to which a concentrated glucose solution was added to a final concentration of 
5.5mM or 25mM D-glucose. The cell viability results in commercial and prepared media were 
similar at each time point. The commercial and prepared media at 25mM both resulted in a 
significant decrease in cell viability at day 5 (P=0.003 and P=0.003). There was very little 
change in cell viability when cells were cultured in media without glucose (Figure 5.10). 
 
Figure 5.10: Diabetic model verification at normal (5.5mM) and high (25mM) glucose. Line graphs 
shows mean fluorescence rate of hDPCs in 5.5mM D-glucose (black) and 25mM D-glucose (red). Error 
bars indicate SD. A significant difference in hDPCs numbers was found between the 5.5mM and 25mM 
D-glucose commercially prepared media (**P=0.003) and 5.5mM and 25mM D-glucose prepared 
media (**P=0.003) on day 5. Error bars indicate mean with SD.  
 
  

















5.5 mM D-glucose (Commercial)
25 mM D-glucose (Commercial)
5.5 mM D-glucose (D1) (Prepared)
25 mM D-glucose (D4) (Prepared)
Zero Glucose
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5.6.2.4.2 Cell Viability - Osmolarity Validation 
The osmolarity effect of the medium containing a high concentration of glucose on the cell 
viability was examined. Osmolality control media, which contained 5.5mM D-glucose with a 
balance of L-glucose had no effect on the number of viable cells suggesting a change in media 
osmolality does not affect the cells but the concentration of available D-glucose does (Figure 
5.11). 
 
Figure 5.11: hDPCs viability and osmotic control media. Line graphs shows mean fluorescence rate 
of hDPCs in 5.5mM D-glucose, 25mM D-glucose prepared diabetic model, and osmotic control 5.5mM 
D-glucose+ 4.5mM L-glucose and 5.5mM D-glucose+ 19.5mM L-glucose. Error bars indicate mean 
with SD.  
 
  

















5.5 mM D-glucose (D1) (Prepared)
5.5 mM D-glucose + 4.5 mM L-glucose 
Zero Glucose
5.5 mM D- glucose + 19.5 L-glucose 
25 mM D-glucose  (D4) (Prepared)
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5.6.2.5 Cell Viability - Various D-glucose Concentrations 
The viability of hDPCs was examined in a diabetic model which included a range of glucose 
concentrations chosen to mimic the in vivo blood glucose levels present in patients with T2D. 
The results show a similar number of viable hDPCs for all concentrations on day 1 and day 3. 
However, by day 5 the hDPC numbers were significantly decreased in the presence of glucose. 
When compared with DMEM media containing 5.5mM D-glucose, there were fewer viable 
cells in media containing 10mM D-glucose (-20.79%; P=0.007), with a further decrease in 
viability for 15mM D-glucose (-30.14%; P=0.006) and 25mM D-glucose (-34.08%; P=0.003) 
(Figure 5.12).  
 
 
Figure 5.12: hDPC viability in different glucose concentrations. Different glucose concentrations 
mimics glucose concentrations in patients with diabetes (D1-D4). A significant difference was found 
when the number of viable cells were compared to each glucose concentration 10mM (**P=0.007), 
15mM (**P=0.006), and 25mM (**P=0.003). Error bars indicate mean with SD. 
 
5.6.3 Functional Gene Expression in the Presence of 5.5mM and 25mM D-Glucose 
Concentrations 
5.6.3.1 Extracellular Matrix and Pulp Healing Genes 
The main macromolecules in dental pulp ECM are collagenous proteins (collagen type I and 
III). The hDPCs were found to express high gene expression levels of collagen type I 
(COL1A1) and type III (COL3A1) mRNA. After normalisation to the B2M reference gene, 

















 5.5 mM D-glucose (D1)
 10 mM D-glucose  (D2)
 15 mM D-glucose  (D3)





both COL1A1 and COL3A1 increased over time when cultured in media containing either 5.5 
or 25mM D-glucose. COL1A1 mRNA expression increased over time, with no significant 
difference between the 5.5mM and 25mM D-glucose supplemented DMEM media (Figure 
5.13A). 
The expression of COL3A1 increased significantly in 25mM on day 1 (19.21-fold, P=0.03) 
and in 5.5mM on day 3 compared with day 1 (6.26-fold, P=0.006) (Figure 5.13B). 
 
Figure 5.13: Dental pulp remodelling mRNA expression levels. hDPCs were cultured in 
supplemented DMEM containing either 5.5mM or 25mM D-glucose mRNA expression was measured 
at three-time points day 1, 3 and 5. (A) collagen type I and (B) collagen type III. (*P=0.03, and 
**P=0.006) (n=4). The dotted line indicates the limit of detection. Error bars indicate mean with SD. 





































































































The dental pulp ECM includes MMPs which are capable of degrading ECM proteins and are 
involved with inflammation. MMP1 and MMP8 can degrade collagen type I and collagen type 
III proteins in the dental pulp connective tissue. These were expressed at low levels. No 
significant difference in gene expression was found in the 5.5mM and 25mM glucose culture 
media at any time points (Figures 5.14A and 5.14B).  
 
Figure 5.14: Dental pulp remodelling mRNA expression levels. hDPCs cultured in supplemented 
DMEM containing either 5.5mM or 25mM D-glucose were measured at three-time points day 1, day 3 
and day 5. (A) MMP1, and (B) MMP8 (n=4). The dotted line indicates the limit of detection. Error bars 
indicate mean with SD. 


































































































Vimentin (VIM), cytoskeleton protein, is a gene marker for fibroblast and mesenchymal 
cells. The expression level of vimentin was not altered in response to the different culture 
environments (Figure 5.15).  
 
Figure 5.15: Dental pulp remodelling mRNA expression levels. hDPCs cultured in supplemented 
DMEM containing either 5.5mM or 25mM D-glucose were measured at three-time points day 1, day 3 
and day (n=4). The dotted line indicates the limit of detection. Error bars indicate mean with SD. 
LG: normal glucose concentration 5.5mM D-glucose, HG: high glucose concentration 25mM D-glucose 
 
Vascular endothelial growth factor (VEGF) is an endothelium-specific secreted protein 
which plays an important role in angiogenesis and repair of damaged tissue. The expression 



















































Alkaline phosphatase (ALPL) is a marker of mineralisation. ALPL mRNA was not detected 
or expressed at very low levels on days 1 and 3 for both glucose concentrations. However, there 
was a significant increase on day 5 for the 25mM glucose media (378.1-fold, P=0.04) which 
was not observed for 5.5mM glucose concentration (Figure 5.16).  
 
Figure 5.16: Dental pulp remodelling mRNA expression levels. hDPCs cultured in supplemented 
DMEM containing either 5.5mM or 25mM D-glucose were measured at three-time points day 1, day 3 
and day. (A) VEGF and, (B) ALPL. ALPL expression was increased significantly (*P=0.04) in 25mM 
on day 5 compared with day 1 (n=4). The dotted line indicates the limit of detection. Error bars indicate 
mean with SD. 
LG: normal glucose concentration 5.5mM D-glucose, HG: high glucose concentration 25mM D-glucose 
 
5.6.3.2 Cytokine Genes 
Nuclear factor kappa B subunit 1 (NF-!B1) is a transcription regulator that is activated by 
various intra- and extra-cellular stimuli. A low level of NF-!B1 mRNA expression was detected 
in all four cell populations with no significant changes in high glucose concentration and over 



































































































S100 calcium binding protein A12 (S100A12) is a calcium binding protein which plays an 
important role in the regulation of inflammatory processes and the immune response. S100A12 
mRNA expression was only detected at very low levels in all four cell populations when 
cultured in supplemented DMEM containing either 5.5mM or 25mM D-glucose (Figure 5.17B).  
 
Figure 5.17: Dental pulp inflammatory response mRNA expression levels. hDPCs cultured in 
supplemented DMEM containing either 5.5mM or 25mM D-glucose were measured at three-time points 
day 1, day 3 and day. (A) NF-"B	 and,	 (B)	 S100A12 (n=4). The dotted line indicates the limit of 
detection. Error bars indicate mean with SD. 


































































































Genes involved with the immune response (IL6, IL1% and TNF-&) were also expressed at 
very low levels at both glucose concentrations. This was observed in all four cell populations 
and expression was unchanged over time (Figure 5.18A-C).  
 
Figure 5.18: Dental pulp immune response mRNA expression levels. hDPCs cultured in 
supplemented DMEM containing either 5.5mM or 25mM D-glucose were measured at three-time points 
day 1, day 3 and day. (A) IL6, (B) IL10	and	(C)	TNF-6 (n=4). The dotted line indicates the limit of 
detection. Error bars indicate mean with SD. 



















































































































































5.6.3.3 Diabetic Response Genes 
RAGE mRNA was detected in hDPCs and increased over time when cultured in either 5.5 
or 25mM D-glucose. RAGE gene expression increased significantly on day 5 in 5.5mM and 
25mM D-glucose concentrations (688.9-fold; P=0.03 and 393.7-fold; P=0.03) respectively 
(Figure 5.19A). 
Galectin-3 (Gal-3) modulates AGE-receptor mediated events. LGALS3BP mRNA 
expression decreased over time when cultured in either 5.5 or 25mM D-glucose with a 
significant decrease on the day 3 in 25mM D-glucose (3.96-fold; P=0.03) (Figure 5.19B). 
 
Figure 5.19: AGE receptors (RAGE and LGALS3BP). hDPCs cultured in supplemented DMEM 
containing either 5.5mM or 25mM D-glucose were measured at three-time points day 1, day 3 and day. 
(A) RAGE	and	(B)	Galectin-3. (*P=0.03) (n=4). The dotted line indicates the limit of detection. Error 
bars indicate mean with SD.  
LG: normal glucose concentration 5.5mM D-glucose, HG: high glucose concentration 25mM D-glucose 
 
No significant difference in hDPC mRNA expression for most of 13 genes examined could 
be found with the exception of COL3A1 mRNA. Expression levels were compared for hDPCs 
cultured in supplemented DMEM (1) 5.5mM and 25mM D-glucose on day 1, 3 and 5 (Table 






































































































Table 5.7: mRNA expression fold-difference for 5.5mM D-glucose compared with 25mM D-
glucose at each time point 
 
Table 5.8: mRNA expression fold-difference compared to 5.5mM D-glucose on day 1 and 25mM 
D-glucose on day 1 
Gene 
Day 1 (25mM)/ 
Day 1 (5.5mM) 
Day 3 (25mM)/ 
Day 3 (5.5mM) 
Day 5 (25mM)/ 
Day 5 (5.5mM) 
Fold change P-value Fold change P-value Fold change P-value 
GOI       
COL1A1       1.88 0.41  2.85 0.35 -1.94 0.54 
COL3A1     19.21 0.03  8.80 0.13 1.36 0.71 
MMP1     14.77 0.28    12.08 0.41 -4.66 0.42 
MMP8       2.26 0.47   2.15 0.45 -303.61 0.06 
VIM      -1.38 0.57 1.18 0.82 1.12 0.84 
VEGF       3.18 0.10  6.65 0.30 1.02 0.98 
ALPL       1.98 0.38  6.08 0.24 6.78 0.12 
NF-!B1      -1.29 0.36 1.81 0.41 -2.93 0.44 
S100A12      -2.53 0.31 -1.16 0.84 -1.35 0.80 
IL6       1.13 0.48  1.38 0.39 1.29 0.40 
IL1"       1.12 0.90 -1.44 0.58 -14.54 0.37 
TNF-#      -4.44 0.38 -1.16 0.84 -5.06 0.40 
RAGE        2.46 0.27 3.46 0.45 1.40 0.73 
LGALS3BP     -11.79 0.28 -1.10 0.87 -2.64 0.44 
Yellow highlight colour; A fold-difference was considered significant if >2 x <-2 with a P-value <0.05 
Name of 
Gene 
Day 3 (5.5mM)/ 
Day 1 (5.5mM) 
Day 5 (5.5mM)/ 
Day 1 (5.5mM) 
Day 3 (25mM)/ 
Day 1 (25mM) 
Day 5 (25mM)/ 










GOI         
COL1A1 2.14 0.38 142.47 0.23 3.25 0.32 39.06 0.11 
COL3A1 6.26 0.006 408.63 0.28 2.86 0.23 28.91 0.09 
MMP1 -1.07 0.95 27.04 0.33 -1.31 0.82 -2.55 0.47 
MMP8 -8.48 0.23 17.73 0.39 -8.91 0.26 -38.68 0.23 
VIM -1.61 0.48 -2.65 0.21 1.01 0.98 -1.71 0.32 
VEGF 1.72 0.54 246.65 0.27 3.60 0.37 79.46 0.24 
ALPL 1.48 0.55 110.40 0.09 4.55 0.27 378.15 0.04 
NF-!B1 -2.38 0.06 1.58 0.66 -1.02 0.98 -1.43 0.10 
S100A12 -10.46 0.16 2.97 0.41 -4.80 0.07 5.57 0.44 
IL6 1.49 0.18 2.46 0.39 1.81 0.90 2.80 0.51 
IL1"	 -8.43 0.17 5.06 0.44 -13.60 0.28 -3.23 0.41 
TNF-#	 -23.28 0.30 1.15 0.91 -6.08 0.08 1.01 1.00 
RAGE  3.59 0.15 688.92 0.03 5.05 0.39 393.79 0.03 
LGALS3BP -42.47 0.25 -9.91 0.29 -3.96 0.03 -2.22 0.08 
Yellow highlight colour; A fold-difference was considered significant if >2 x <-2 with a P-value <0.05 
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5.7 Discussion  
This in vitro study using a novel diabetic cell model examined the effect of glucose 
concentration on four heterogenous hDPCs populations derived from third molar teeth. It 
provides new knowledge about the effect of elevated glucose on hDPCs viability and gene 
expression. The results of this study allow acceptance of the hypothesis that culturing of cells 
in the presence of high glucose concentration results in altered cell behaviour and gene 
expression.  
Primary lines of hDPCs were derived from normal dental pulp tissue and cultured in a range 
of glucose media, to control for the individual biological variability observed in previous 
chapters. The harvesting of ‘normal’ pulp tissue from non-carious unerupted teeth of healthy 
female participants excluded potential bias from gender and inflammation. Further, the use of 
healthy pulp cells provides a baseline for understanding the role of these cells in the healing 
process (Soheilifar et al. 2016, Alkharobi et al. 2017).  
The glucose concentrations chosen to evaluate the hDPCs response in the in vitro model 
were intended to mimic one aspect of clinical diabetes and were based on concentrations used 
in previous studies (Asbun & Villarreal 2006, García-Hernández et al. 2012, Tsai et al. 2013, 
Linxi et al. 2015, Kato et al. 2016). The diagnostic criterion for diabetes is a blood glucose 
concentration of >7mM/l (Ministry of Health 2011). Therefore, in the present study the four 
glucose concentrations used included normal physiological glucose concentration in a non-
diabetic (5mM/l, equivalent to 99mg/dl), a diabetic condition with glucose concentrations (10 
and 15mM/l equivalent to 180mg/dl and 270mg/dl respectively), and a hyperglycaemia glucose 
concentration (25mM/l equivalent 450mg/dl).  
The time points used in this study have been used by others and provided meaningful results 
(Kato et al. 2016). The early effects of high glucose concentration were evaluated by incubating 
the cells for 24 hours, while its prolonged effects of high glucose were evaluated by incubated 
the cells for prolong time 3 and 5 days where the cells were not overcrowded. Exposure of cells 
to high glucose concentration over longer time periods may cause cellular injury leading to 
apoptosis and/or cell death (Samikkannu et al. 2006) and so observations over longer time-
periods would be valuable.  
The validation of the in vitro model compared the viability of the cells in commercially 
available normal (5.5mM) and high (25mM) D-glucose DMEM with manually prepared D1; 
normal (5.5mM) and D4; high (25mM) D-glucose. The observation of similar results for 
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commercial and prepared media were important for validating the feasibility of the diabetic 
model. 
The microscopy of hDPCs during generation of the cell lines showed that the cells had a 
fibroblast-like morphology with other heterogeneous shapes confirming the findings of others 
(Martens et al. 2013, Akpinar et al. 2014). In the early stages of cell expansion, a high glucose 
culture medium did not appear to affect the morphological characteristics of hDPCs suggesting 
that they have the capacity to adapt. This result corresponds in part with a study by Al Qarakhli 
et al., 2019 who showed in an animal study that bone mesenchymal stromal cells cultured in 
(normoglycemic) 5.5mM and (hyperglycaemic) 25mM glucose conditions displayed similar 
morphology over the extended culture expansion period (around 120 days) (Al-Qarakhli et al. 
2019). However, Raeisossadati et al., 2011, found that the morphology of foreskin fibroblasts 
incubated for 48 hours with a wide range of glucose concentrations changed in higher glucose 
concentrations with more nodule formation (Raeisossadati & Daneshimehr 2011). The 
variation in the morphological results in different studies may be attributed to cell types and 
study design such as the seeding cell density used, incubation time, glucose concentration and 
the methodology for analysing cell morphology.  
In this study, cell viability assays were used to evaluate the behaviour of hDPCs in different 
glucose concentrations mimicking patients with T2D. Glucose is essential for cell viability, but 
the current results showed that with a high glucose concentration, cell viability decreases with 
time. Findings of others have been variable. Some have observed that high glucose levels inhibit 
the viability of periodontal stem cells, periodontal ligament cell, gingival fibroblasts, apical 
papilla, osteoblast and epithelial cells (Kim et al. 2006, Samikkannu et al. 2006, Linxi et al. 
2015, Kato et al. 2016, Buranasin et al. 2018). Conversely, human cardiac myofibroblasts 
cultured in high glucose have shown increased cell viability (Neumann et al. 2002). The 
differences in viability behaviour of cells in different studies could be due to a range of effects 
such as the different cell types used in each study, experimental design and plating cell density. 
Glucose is an essential source of cellular energy and at normal levels is an essential substrate 
in protein and lipid synthesis. The very low viability in cells cultured without glucose confirms 
this and indicates that hDPCs are dependent on a supply of glucose for survival in culture. 
Further, glucose acts as fuel to the cells and the proper concentration is important to regulate 
cells’ function and growth (Wood et al. 2005, Robertson & Harmon 2006).  
Chronic hyperglycaemia is associated with the development of diabetic complications. The 
destructive effect of hyperglycaemia can be due to oxidative stress, AGEs, proinflammatory 
cytokines and cellular death. High glucose plays an important role in diabetic complications 
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due to the production of reactive oxygen species (ROS), oxidative stress, and activation of cell 
apoptosis, which leads to cellular death. Oxidative stress represents an important pathway for 
the destruction of cells (Chong et al. 2005). The production of ROS can lead to cell injury via 
destruction of cell membrane lipids and cleavage of DNA (Wang et al. 2003, Maiese et al. 
2007). In addition, along with the detrimental effects on cellular integrity, ROS can inhibit 
complex enzymes in the electron transport chain of the mitochondria resulting in the blockade 
of mitochondrial respiration (Maiese et al. 2007). The mechanism of hDPCs injury by high 
glucose is still poorly understood and future studies are needed to identify the main mechanisms 
involved. 
The current results also showed that high glucose had direct effect on hDPCs and reduced 
their viability. The high concentration of D-glucose, a natural form of glucose, reduced the cells 
viability on day 5, while L-glucose, which is not utilized in the cells, did not affect the viability 
of hDPCs on day 5. These data suggest that the reduced viability of cells in high glucose was 
not due to the osmolarity effect of the medium but to the metabolic effect of glucose in the 
hDPCs.  
It was important to define the phenotype of the cell population in order to understand the 
cellular response in experiments. Vimentin expression confirmed the presence of fibroblast 
cells and the absence of haemopoietic and dentinogenesis markers excluded the presence of 
endothelial cells and odontoblasts (Wei et al. 2007, Alt et al. 2011, Chang et al. 2014).  
The main dental pulp ECM macromolecules are collagenous proteins (especially collagen 
types I and III) (Goldberg & Smith 2004). High glucose impairs healing and promotes fibrosis 
by increasing fibroblast collagen synthesis and decreasing MMPs activity (Asbun & Villarreal 
2006). The current study showed that culturing pulp cells in a high glucose media resulted in 
significantly more collagen type III (COL3A1) gene expression which increased significantly 
with concentration and time. This was not seen with collagen type I (COL1A1) gene expression. 
Some studies have demonstrated that culturing human gingival fibroblasts in even higher 
glucose concentrations (50 and 70mM/l) results in a reduction of collagen synthesis 
(Willershausen‐Zönnchen et al. 1991), while others found that fibroblasts treated with high 
glucose concentrations, show an increase in ECM protein synthesis (Tang et al. 2007, Li et al. 
2010). The difference in results may be attributable to difference in glucose concentration but 
the findings of the present study suggest that elevated glucose may contribute to pulp fibrosis.  
Matrix metalloproteinases are important in a different physiological and pathological 
processes, such as morphogenesis, wound healing, angiogenesis and inflammation. High 
glucose is recognised as affecting MMPs activity within several cell types including fibroblasts 
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(Tokudome et al. 2004, Asbun et al. 2005, Tsai et al. 2013, Argyropoulos et al. 2016). MMPs 
are able to degrade all ECM proteins (Sternlicht & Werb 2001). They are involved in normal 
ECM remodelling and are therefore tightly controlled at the level of synthesis. The MMPs 
(MMP1, MMP8) are collagenases which are able to cleave several types of collagen in addition 
to other ECM molecules (Sternlicht & Werb 2001). MMP1 and MMP8 are expressed by mature 
odontoblasts, within pulp tissue and in cell cultures (Palosaari et al. 2000, Palosaari et al. 2003). 
Human pulp fibroblasts can express collagenase after stimulating with cytokines (Tamura et al. 
1996, Lin et al. 2001). This provides further evidence suggesting that MMPs may participate 
in the regulation of defensive responses against external irritation in the dentine–pulp complex 
and can be used as a biomarkers of soft tissue breakdown in pulpal tissue (Palosaari et al. 2003). 
Previous studies have reported that MMP1, and MMP8 are involved in pulp tissue destruction 
(Shin et al. 2002). The current results coincided with some studies did which not find elevated 
MMPs in cells cultured in high glucose concentration (McLennan et al. 2000, Ho et al. 2007). 
MMPs are expressed in healthy dental pulp cells under conditions of ‘stress, such as chronic 
inflammation (Gusman et al. 2002) and so our findings may be because the hDPCs were 
isolated from a normal dental pulp which showed very low expression of cytokines genes. It 
would be interesting to observe the expression of MMPs when cells were in a ‘stressed’ 
environment to determine if the model is effective for investigating inflammatory responses (Li 
et al. 2010).  
Alkaline phosphatase is an enzyme which plays an important role in tissue mineralisation 
(Wei et al. 2007) and ALP activity has been shown to increase in an inflamed dental pulp (Spoto 
et al. 2001). The current study showed that the expression level of ALP increased significantly 
on day 5 in a high glucose concentration compared with day1. This confirms other reports that 
indicate high glucose concentration increases the expression of ALP in human dental pulp cells 
(Okamura et al. 2009).  
Cytokines are important in the immune response which is tightly regulated and involved in 
tissue destruction in pulpal disease. Interleukins IL1β, IL6 and TNF-& are considered to be 
important cytokines that induce a variety of biological activities (Steeve et al. 2004). The results 
of current study showed very low expression of NF-κB, with no differences between normal 
and high glucose concentrations and hDPCs did not show any expression of IL1β, IL6 and 
TNF-α. This confirmed that the status of the pulp was ‘normal’ (Abbott & Yu 2007, American 
Association of Endodontists 2013) but also indicates that there is a base line immune 
surveillance which is able to respond when required. Observation of the gene expression of 
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these immune markers over a longer period and with increased glucose load would be 
beneficial.  
RAGE is known as a multiligand member of the immunoglobulin superfamily of cell surface 
molecules. RAGE interacts with a varies ligands, such as AGEs, S100/calgranulins, 
amphoterin, and amyloid-β peptide (Schmidt et al. 2000, Barile & Schmidt 2007). 
Hyperglycaemia and AGEs increase the expression of RAGE in aortic endothelial cells (Yao 
& Brownlee 2010) and periodontal ligament fibroblast cells (Li et al. 2014). The expression 
level of RAGE in the present study increased between day 1 and 5 which may indicate that the 
expression of RAGE is time dependent. The increased expression of RAGE with the time in 
patients with diabetes may be responsible for some diabetic complications such as fibrosis and 
inflammation. When RAGE binds to AGEs, this affects the metabolism of collagen tissue by 
the activation of NF‐κB pathways resulting in an increased expression of inflammatory 
cytokines such as IL1β, IL6 and TNF‐α (Rasheed et al. 2010, Yang et al. 2010, Chen et al. 
2017). RAGE also interacts with S100 calcium binding proteins which belong to the DAMP 
superfamily (Sirois et al. 2013). S100A12 interacts with RAGE and activates NF‐κB resulting 
in the secretion of the proinflammatory mediators (Pietzsch & Hoppmann 2009, Kang et al. 
2015). However, the current study showed increase expression of RAGE over time in high 
glucose concentration but the expression of NF‐κB was not affected by glucose concentrations. 
Further investigation on the relationships of hyperglycaemia on RAGE, NF‐κB and S100A12 
expression and pathways is warranted.  
Galectin-3 is a receptor for the AGEs and it plays a main role in the pathogenesis of long-
term diabetic complications (Pugliese et al. 2014, Tan et al. 2018). Gal-3 is highly expressed 
by immune system cells such as macrophages, eosinophils, neutrophils and mast cells 
(Sundblad et al. 2011, Saccon et al. 2017). It plays a role in tissue fibrosis, immunity, and the 
inflammatory response (Chen & Kuo 2016). Gal-3 plays a dual role with both pro- and anti-
inflammatory actions (Nishi et al. 2007, Liu et al. 2009). Gal-3 and RAGE show opposite 
actions as AGEs’ receptors. Gal-3 plays a protective, anti-inflammatory role by removing 
AGEs, whereas RAGE mediates the proinflammatory effects of AGEs (Iacobini et al. 2003). 
Furthermore, Gal-3 protects the tissue when AGEs level increase by inducing tissue 
inflammation and injury (Pugliese et al. 2001, Iacobini et al. 2005). In current study, the 
expression level of Gal-3 in hDPCs significantly decreased in high glucose on day 3, while 
RAGE increased in normal and high glucose in day 5 indicating that T2D may be result in a 
loss of regulation at a molecular level.  
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Vascular endothelial growth factor (VEGF), is one of the primary pro-angiogenic growth 
factors. It stimulates vasodilatation, increases vascular permeability, and induces capillary 
formation (Ferrara et al. 2003) and so has important roles in inflammation and tissue healing 
(Tran-Hung et al. 2008). In response to injury, VEGF is secreted by many cells included pulp 
fibroblasts (Tran-Hung et al. 2008). T2D affects the wound healing process by decreasing 
proangiogenic growth factors, prolonging inflammation and impairing cell migration 
(Brownlee 2001). Stimulation of human pulp fibroblast by hypoxia, bacteria and 
proinflammatory cytokines have been shown to increase the gene expression of VEGF which 
can contribute to ongoing pulpal inflammation and pulpal destruction through the expansion of 
the vascular network (Chu et al. 2004, Yang et al. 2004, Tran-Hung et al. 2008, Bronckaers et 
al. 2013). Moreover, it has recently been shown in rats that elevated glucose can also upregulate 
VEGF expression in pulp tissue (Uysal et al. 2019). In the current study, the expression level 
of VEGF in hDPCs was increased in high glucose over the time in day 1 and 3, not day 5, but 
this was not significant. Inflammatory mediators released after pulpal irritation stimulate the 
VEGF expression (Artese et al. 2002) and so the findings of the current study may be attributed 
to due to the absence of inflammation, LPS or hypoxia in this model (Janjić et al. 2019). Taken 
together, these findings may indicate that the presence of sustained hyperglycaemia limits the 
ability of pulp cells to contribute to the angiogenic process and that VEGF has a greater role in 
inflammatory regulation, but more time points are required to validate this. Future modification 
to this model may enable the effect of these variables to be evaluated. 
5.8 Challenges and Limitations 
Cell culture models maintain a controlled, stable environment that is essential for cellular 
physiology (Hartung & Daston 2009), but do not simulate the multifactorial physiological body 
systems and so it is difficult to extrapolate these findings to the general population. Further, 
mono-cell cultures are an artificial environment and lack the complexity that occurs at a 
molecular level in physiological environments and nature (Hartung & Daston 2009). 
Nevertheless, the ability in part to control biological variability between samples is an obvious 
benefit of laboratory models and these are still considered an essential first step and useful tool 
to investigate cellular physiology and pathological conditions of many diseases. 
The present study had limitations in simulating the level of hyperglycaemia present in T2D 
while acknowledging that this occurs over a range of concentrations. A concentration of 25mM 
D-glucose is equivalent to 450mg/dl of blood glucose, which is a concentration that is 
diagnosed in patients with T2D and may not be enough to stress the cells, especially with the 
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lack of other contributing physiological factors in the body. The use of the correct concentration 
of D-glucose in a culture medium is very important to keep the cells in normal and controlled 
conditions and to obtain accurate experimental results. Different cell types are affected by 
various D-glucose concentrations in a culture medium due to differences in their physiological 
state.   
5.9 Conclusion 
Within the limits of an in vitro cell culture model mimicking T2D, the present study which 
was standardised for hyperglycaemic control indicates that elevated glucose levels alter the 
behaviour and gene expression of dental pulp cells. High glucose concentration is associated 
with a significant reduction in hDPCs viability over time. The use of a diabetic model can be 
considered useful for studying the potential of dental pulp cells to contribute to healing. Further 
observations over time may provide greater insight into the immune response to glucose.   
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Chapter 6  
Thesis Discussion and Conclusion 
6.1 Thesis Discussion 
Type 2 diabetes is a chronic multisystemic disorder and it is characterised by 
hyperglycaemia. Diabetes mellitus affects all ages, and its prevalence has been increasing. 
Epidemiological studies show that 90% of diabetes is T2D (World Health Organisation 2019, 
American Diabetes Association 2020). Diabetes can affect the management of pulp and 
periapical disease and the outcome of treatment (Bender & Bender 2003, Catanzaro et al. 2006, 
Ferreira et al. 2014, Madani et al. 2014). The present thesis aimed to investigate the effect of 
T2D and hyperglycaemia on the clinically normal dental pulp using multiple in vitro laboratory 
techniques. This research has provided new knowledge and understanding around the 
relationships between general health and oral health and in particular has offered insight into 
changes at a tissue and molecular level within the dental pulp in the presence of systemic 
disease.  
The maintenance of healthy dentition is important for overall health. Diabetes is becoming 
increasingly prevalent in patients receiving dental treatment and dental professionals must be 
aware and understand the relationship between pulpal inflammation, endodontic infection, 
healing and T2D, and apply this knowledge when making clinical decisions. The findings from 
this research add to our understanding of pulp-dentine biology and can potentially help 
clinicians rationalise some of the treatment outcomes seen in patients with T2D.  
The present study provides clear evidence that T2D is associated with morphological 
changes in the dental pulp, and hyperglycaemia may act as a DAMP to dental pulp by increasing 
the dental pulp mineralisation and enhancing pulp stone formation (Nakajima et al. 2013, 
Nakajima et al. 2015). The most obvious changes in the structure of the dental pulp involves 
collagen, blood vessels and mineralisation. There was a notable reduction in cellularity and 
blood vessels in the pulp of T2D samples together with increased collagen deposition, 
thickening of blood vessel walls, and an increased presence of pulp calcifications. Together, 
these features indicate a change in the nature of dental pulp and suggests hyperglycaemia 
associated with T2D may accelerate the physiological aging process within the tissue. The 
molecular and cellular investigations confirm that T2D and high glucose concentrations 
increase collagen type I and III and increase the mineralisation activity in the dental pulp. These 
changes may be recognised clinically by fibrosis and increased mineralisation. 
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Immunohistochemistry and IF showed that T2D increases glycation in the clinically normal 
dental pulp. However, the diabetic model which mimicked diabetes was less convincing. This 
may indicate the contribution of multiple physiological and environmental factors. The increase 
in cytokines and inflammatory pathways were clearly identified in this study at a molecular 
level. Increased inflammatory activity in the dental pulp can negatively affect the dental pulp’s 
healing and repair (Cooper et al. 2014, Goldberg et al. 2015). The increased inflammatory 
activity is likely to be a factor that drives morphological change. T2D affects the dental pulp 
through glycation and the accumulation of AGEs, and the increased expression of their receptor 
RAGE (Inagaki et al. 2010, Tancharoen et al. 2014, Nakajima et al. 2015). The RAGE binds 
to AGEs and S100A12 which activates NF-!B and subsequently increases inflammatory 
mediators and aggressively alters the immune response in the dental pulp by decreasing Tregs 
and increasing macrophage and Th activity.  
The use of several laboratory techniques enhanced the validity of our results and each 
improved understanding of the effect of T2D on the dental pulp. In this study, an in vitro 
diabetic model was used to overcome the limitations and challenges in other parts of study, and 
it provided new evidence of how elevated glucose negatively effects cell proliferation and may 
result in VEGF having greater roles in inflammation than angiogenesis. Extrapolated to a 
clinical situation this thesis adds to the body of knowledge informing our current understanding 
of pulp biology.  
Improved knowledge of pulp biology and understanding mechanisms which may modulate 
immune responses in the dental pulp are important for informing therapeutic strategies 
including development of biomaterials which may assist healing in patients with T2D. This 
thesis has shown that like other body sites, the proinflammatory nature of T2D alters the 
structure and functions of the dental pulp (Zozulinska & Wierusz-Wysocka 2006, Al-Shukaili 
et al. 2013, Daniele et al. 2014). Peripheral vascular changes associated with diabetes are well 
recognised, leading to a reduced immunological capacity and an increased susceptibility of 
infection (Verhulst et al. 2019). Hyperglycaemia has been shown to increase TNF&, IL6, IL1% 
and IL17 (Dandona et al. 2007, Hang et al. 2014, Samuel et al. 2019). Patients with T2D have 
decreased immunosuppressive Tregs and increased proinflammatory cytokines (Mahmoud & 
Al-Ozairi 2013, Qiao et al. 2016). There is abundant evidence that diabetes is associated with 
pathological changes in the oral tissues, particularly in the periodontium (Preshaw & Bissett 
2013, Kudiyirickal & Pappachan 2015, Verhulst et al. 2019). Until now, the influence of 
diabetes on the human dental pulp was unknown but this study has demonstrated that as in the 
periodontium, pathological change is also evident in the dental pulp.  
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According to the American Association of Endodontics , a clinically normal dental pulp is 
an ‘asymptomatic pulp that has no clinical or radiographic signs or symptoms of disease and 
normally responsive to pulp testing’ (American Association of Endodontists 2013). When 
dental pulp is exposed to irritants, pulpal inflammation is detected. Dental pulp inflammation 
is clinically diagnosed according to the signs and symptoms of reversible and irreversible 
pulpitis. The correct clinical diagnosis of dental pulp can be difficult but helps clinicians to 
understand the health of the pulp and to provide the appropriate treatment options to patients. 
In the absence of systemic disease, the normal pulp contains very few inflammatory cells, yet 
this work has shown that patients with diabetes show an increased expression of inflammatory 
markers and an altered morphological, and immunological response. These findings suggest 
that the clinically normal dental pulp of T2D has greater base-line inflammation and this needs 
to be considered when interpreting clinical diagnoses and planning treatment. 
Glycation affects the body through three main mechanisms (Singh et al. 2001). Firstly, 
glycation affects collagen by crosslinking and increasing stiffness of tissues (Negre-Salvayre 
et al. 2009). The histological stains showed more collagenous fibrous tissue in the ECM and 
around blood vessel walls. Furthermore, the IHC showed the AGEs accumulate in ECM, blood 
vessel walls and on predentine in T2D more than in non-T2D samples. The dental pulp texture 
of T2D samples was stiffer which led to modifying the grinding process of this tissue for the 
qPCR experiment. Moreover, the decalcification time was longer for teeth from patients with 
T2D than non-T2D participants possibly due to AGEs accumulation in dentine, causing 
hardening of the dental structure (Miura et al. 2014).  
The mechanical properties of dental pulp include elasticity, hardness and viscoelasticity, and 
can be tested by classical mechanical tests (macroscopic tests in tension, compression, torsion 
and flexion) and indentation tests on connective tissue specimen’s cross-sectional area (Zhang 
et al. 2014). These tests can be used to determine the mechanochemical properties of T2D and 
non-T2D samples in future studies. The physical properties of T2D dental pulp are unclear, and 
future research should consider biomechanical testing, thermal isometric contraction, analysis 
collagen fibers arrangement and the measurement of cross-links of collagen structure by AGEs.  
The accumulation of AGEs not only affects the ECM collagen of dental pulp, but also affects 
the collagen sheath of blood vessels. The blood vessel wall in T2D samples was thicker due to 
more collagen and fewer elastic fibres. This may lead to reduced blood flow and coupled with 
reduced VEGF expression is likely to dental pulp healing. The damage to blood circulation and 
ischemia may cause pulp necrosis in patients with diabetes (Lima et al. 2013, Claudino et al. 
2015). A similar effect was detected in the gingival tissue of diabetics, which showed increased 
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accumulation of AGEs in gingival fibroblasts and vessels leading to increased severity of 
periodontitis and delay healing (Zizzi et al. 2013).  
Secondly, glycation affects the tissue when AGEs bind to their receptors’ RAGE and 
increases cytokines and tissue destruction. The IHC and qPCR studies showed increased 
expression of RAGE with increased cytokines in the dental pulp of T2D samples. Dental pulp 
tissue from participants with diabetes showed more TLR2+ and TLR4+ immune cells, with an 
increase in immune cells (macrophages, dendritic cells and Th lymphocytes). These 
observations may indicate that RAGE is a DAMP and an irritant to the dental pulp leading to 
an increased expression of TLR2 and TLR4 and activation of the innate immune response. The 
persistence of inflammatory cytokines can activate adaptive immune cells such as CD4+ cells 
which were demonstrated with IF. Further, IHC showed that Tregs were reduced in the dental 
pulp of participants with T2D suggesting this may enhance activation of the inflammatory 
response as it does in other sites (Rojo-Botello et al. 2012, Qiao et al. 2016). 
Thirdly, glycation affects the tissue when RAGE binds to AGEs and S100A12 and activates 
the NF-'B pathway. The upregulation of RAGE, S100A12 and NF-'B genes was seen in qPCR 
results, and this can be responsible for the inflammatory status in the dental pulp of T2D 
patients. The higher expression of S100A12 mRNA may also contribute to the formation of 
pulp stones and calcification (Nakajima et al. 2015). 
The histological analysis has offered new knowledge related to the morphological changes 
of the pulp in association with T2D and may explain in part the unpredictable clinical outcome 
of vital pulp therapy for patients with T2D. There were changes in the morphological structure 
of the coronal pulp particularly in cellularity, vascularity and nerves. These morphological 
changes are similar to those typically seen in pulps of older adults. Degeneration of pulpal 
neurons, especially in the subodontoblastic layer and centrally, and degeneration of 
neurovascular bundles centrally, was seen in T2D samples. This may diminish dental pulp 
sensitivity, resulting in asymptomatic pulpitis. Further, this can create difficulties in diagnosis 
or misdiagnosis which in turn impacts on clinical decision-making and prognosis. Pulpal 
sensibility tests have an important role in endodontic diagnosis (Kamburoğlu & Paksoy 2005). 
The degeneration of nerve fibres and increased presence of pulpal calcifications may result in 
a greater incidence of false negative findings. Further development of pulse oximetry 
technology to measure tissue oxygenation (Gopikrishna et al. 2007) or laser doppler to directly 
measure blood flow (Emshoff et al. 2004, Mainkar & Kim 2018) may have potential for use in 
patients with diabetes.    
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T2D resulted in changes to odontoblasts which were less defined and discontinuous in some 
regions. The palisaded odontoblast layer was reduced to a single layer of flattened cells with 
changes in the position and orientation of the odontoblast nuclei in T2D samples. The junction 
between the odontoblasts and the predentine was irregular and there was thickened irregular 
tertiary dentine-like tissue in the dental pulp of the T2D samples which was not seen in controls 
suggesting that hyperglycaemia may contribute to these appearances. The characteristics of 
calcification and the role of fibroblasts in healing were further validated in the diabetic cell 
culture model where high glucose resulted in a significant increase in mineralisation activity 
(ALP mRNA)  
The dental pulp in T2D samples was associated with the thickening of predentine which 
reflects the high rate of mineralisation in the dental pulp of T2D. The development of pulp 
stones and/or dental pulp fibrosis has also been linked to the hyperglycaemia in rats dental pulp 
(Inagaki et al. 2010, Nakajima et al. 2013). Dental pulp has the capacity to form hard tissues, 
such as reparative dentine and pulp stones, in response to local and systemic stimuli. Pulp stones 
are frequently formed as a pathologic calcification product in dental pulp tissues. However, the 
pathogenesis is poorly understood. Pathologic pulp calcifications, such as pulp stones and 
increased predentine thickness, have been replicated in a diabetic rat model where high glucose 
significantly stimulated osteopontin production and alkaline phosphatase activity, indicating 
that high glucose levels increased the hard tissue formation in the dental pulp cells (Chen et al. 
2006, Inagaki et al. 2010). The incidence of pulp stones and thickened predentine may be 
enhanced by AGEs’ accumulation in dental pulp cells and in the ECM (Inagaki et al. 2010, 
Nakajima et al. 2013). However, the mechanism of mineralisation and pulp stone formation in 
diabetic dental pulp is unclear. 
Fibroblasts are the main pulp cells and are reduced in the presence of T2D. They are involved 
in the synthesis of collagen types I and III, and other collagenous and non-collagenous ECM 
components (Goldberg & Hirata 2017). Collagen type I, a component of ECM, is basically 
secreted by fibroblasts at the site of tissue repair (Hansen et al. 2016). The increased expression 
of collagen type I mRNA gene affected by increasing ECM deposition and tissue stiffening 
which act as a strong profibrotic stimulus (Giménez et al. 2017). Our gene expression findings 
of collagen type I in the dental pulp of T2D samples validated the trichrome special stains. 
Further, the in vitro diabetic model showed that collagen type III increased significantly with 
increased glucose concentration and the time of exposure. Together, with altered inflammatory 
responses these findings suggest that hyperglycaemia also increases the accumulation of 
collagen types I and III which may impair pulp healing (Darby et al. 2014).  
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In common with all research there were limitations. The questionnaires which were 
conducted along with the collection of the samples were a useful tool to collect participant 
information and screen for factors related to T2D but the sample size was small and so the 
results of the questionnaire are not be generalisable to the population. However, the primary 
questionnaire results provide pilot data and an opportunity for further epidemiological or 
practice based research to assess the association between demographic data and T2D related to 
dental pulp disease.  
The collection of the data for T2D using multiple exclusion criteria (for example, being a 
smoker, using antibiotics, having periodontal disease, or other systemic disease associated with 
T2D), important for controlling variables but it was a challenge to collect the samples in a 
timely manner. Further it was difficult to collect samples from age-matched participants in this 
study, particularly in Dunedin which has only 2.8% of New Zealand’s population, and the 
number of diabetic people registered with the Southern District Health Board Registered 
Diabetes in 2017 was 14.355 and 25% were 65-74 years old (Ministry of Health 2019). The 
samples from the two groups were collected concurrently. It would have been potentially better 
to collect the diabetic samples first then collect the healthy aged matched samples. However, 
as discussed, this has its own challenges. Despite this, efforts were made to match as close as 
possible and several analyses were made to verify the accuracy of the statistical findings. This 
study was conducted within the limits funding would allow and so a larger study would enable 
deeper analysis at a population level. 
The use of in vitro cell culture in scientific research is considered a useful tool to investigate 
cellular physiology and pathological conditions of many diseases. The cell culture diabetic 
model which is used for hDPCs cultured in different glucose concentrations worked well with 
the viability rate, gene expression markers and healing and repair genes, but it does not 
accurately mimic confounding stress factors or comorbidities. Infection and pulp irritation in 
the cell culture model can be simulated by using LPS supplementation. In an in vitro study, the 
effect of normal glucose (5.5mM) and high glucose (15 and 25mM) on macrophages, 
with/without stimulation with LPS, was investigated (Hua et al. 2012). They found that high 
glucose alone did not induce cytokine secretion; however, LPS-induced secretion of IL1% was 
higher in macrophages cultured in high glucose compared with those cultured in normal glucose 
(Hua et al. 2012). In vitro studies have further shown that high glucose and LPS resulted in up-
regulation of IL6 in macrophages and in up-regulation of IL6 and IL8 in human gingival 
epithelium (Hung et al. 2014). High glucose media environments with LPS have been shown 
to up-regulate IL6 and IL8 in a co-culture of human gingival fibroblast and macrophages (Chiu 
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et al. 2017). The effect of LPS and high glucose concentration on hDPCs could be investigated 
in the future to find the effect on inflammation and mineralization. Ongoing modification of 
the model is justified. 
The field of endodontics recognises the healing potential of the pulp and the restorative 
lifecycle of teeth as people age and so there is a move towards pulp preservation as a transition 
to root canal treatment (Morotomi et al. 2019). The success of vital pulp therapy is dependent 
on different factors. The most important factors are the status of the pulp tissue and an adequate 
blood supply to the tooth (Ghoddusi et al. 2014). Diagnosis remains the challenge and we still 
await technology to predictably determine the health of the pulp. How diabetes affects vital 
pulp therapy in human dental pulp is not clear. However, this human study does assist our 
understanding of why despite adherence to strict clinical protocols some pulps heal, and others 
do not. Regardless of the level of pulp removal, calcification, reduced cellularity and vascularity 
and thickening of blood vessel walls, together with the fibrosis nature of the dental pulp means 
healing is likely to be compromised. Careful consideration of HbA1c levels and co-ordinated 
care with physicians around the time since diagnosis, while the patients age and level of 
glycaemic control are important and may assist in predicting the outcome of vital pulp therapy 
and healing.  
6.1.1 Future Directions 
Our study has provided important steps in understanding the influence of T2D on the normal 
dental pulp. This serves as a base line but does not consider how an inflamed pulp may respond. 
The most obvious future direction is to expand this research to consider how an inflamed pulp 
responds to the irritation of hyperglycaemia. New knowledge around the role of AGEs-RAGE 
and Galectin 3 in the pulp is promising and so further work in this area is justified. Future 
studies in this field may need to include use of anti-inflammatory, antioxidant and 
hypoglygemic agents to study the effect on AGEs/RAGE pathways may be a starting point to 
reduce diabetic complications (Yang et al. 2019).  
AGEs are a heterogenous end product, and several types of AGEs have been described such 
as pentosidine (fluorescent cross-linking) and Carboxymethyl-lysine (CML, non-crosslinking). 
The evaluation of AGEs in the current research was performed by IHC and IF, and in future, 
the AGEs’ subtypes in dental pulp warrant investigation. Use of additional molecular 
techniques in future, for example, ELISA and Western blotting, to quantify the AGEs’ subtypes 
in the dental pulp can be helpful to better understand the glycation process in the dental pulp.  
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The in vitro model used to mimic hyperglycaemia may require more time points and stress 
factors on cells for detecting expression of inflammatory cytokines mRNA. Stressing the cells 
by microbial irritants besides glucose, such as LPS would offer opportunity to observe the 
response. Moreover, patients with diabetes frequently have associated co-morbidities. The non-
physiological conditions of cells are maintained in cell culture media and do not reflect the 
body physiological processes such as body temperature and the blood electrolyte 
concentrations. Type 2 diabetes is typically accompanied by other metabolic abnormalities, 
including hyperlipidaemia and hyperinsulinemia (Wang et al. 2017). Modification of the model 
media, for example the addition of lipid may simulate the physiology of patients with diabetes.  
Continuing to improve knowledge and understand the regulation of the immune response in 
dental pulp are the next preliminary steps in developing and delivering improved therapeutic 
strategies for patients. 
6.2 Thesis Summary Findings  
This study has shown distinct differences in morphology and immune responses between 
‘normal’ dental pulp in non-T2D participants and those with T2D. The use of different 
laboratory techniques (Histology stains; H&E, special stains, IF and DIF, qPCR, and a cell 
culture diabetic model) suggests the response in the dental pulp is similar to other tissues in the 
body with increased fibrous connective tissue and reduced vascularity which may influence the 
pulp’s response to irritants. Further, the findings from this thesis highlight the complexity of 
the inflammatory process in the dental pulp of T2D patients.  
• Histological stains and IHC: showed that the diabetes affects the clinically normal dental 
pulp by: 
1- Increased pulp calcification, and collagen deposition. 
2- Irregular predentine-odontoblast junction. The odontoblast layer is less well defined, 
discontinuous in some regions, with clear changes in the position and orientation of the 
odontoblast nuclei. 
3- Thickening of the predentine layer and irregular tertiary dentine-like tissue. 
4- Degenerative nerve and neurovascular bundles.  
5- Thickening of the blood vessels walls, with a reduction in vascularity.  
6- Decreased cellular density.  
7-  Increased collagen and elastin fibres, while reticulin decreased. 
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8- Glycation increased in the dental pulp by increasing AGEs’ accumulation and its 
receptors RAGE. 
9- Increased activation of the immune response by an increased expression of TLR2+ and 
TLR4+, macrophages, dendritic cells, and CD4+ve cells and decreased expression of 
Tregs. 
10- Increased expression of cytokines (IL1%, IL6, IL17 and TNF-&)  
 
• IF and DIF: showed that diabetes affects the clinically normal dental pulp structure by: 
1- Increased AGEs’ accumulation which reflects the glycation process. 
2- The co-localisation of RAGE and vimentin implicates the role of glycation products in 
activating fibroblasts to produce more collagen.  
3- The co-localisation of RAGE and CD4+ve cells implicates the role of RAGE in the 
adaptive immune response.  
 
• qPCR results of whole tissue showed that diabetes affects the clinically normal dental pulp 
mRNA expression by: 
1- An increase in the mRNA expression level of RAGE, S100A12, NF-'%, and collagen 
type I genes. 
 
• In vitro diabetic cell model:  the in vitro study used a diabetic cell model which used hDPCs 
cultured in different glucose concentrations mimicking clinical diabetes. The model worked 
well for evaluating cell viability and gene expression for markers associated with healing 
but may require modification and additional observation times to investigate the expression 
of markers for inflammatory cytokines.  
1- The high glucose level is associated with the reduced viability rate of hDPCs with an 
increased exposure time. 
2- The high glucose concentration resulted in an increased expression of collagen type III 
(COL3A1) with an increased exposure time, and a non-significant increase in the 
expression of collagen type I (COL1A1).  
3- The high glucose concentration resulted in an increased mineralisation process by 
increasing the expression level of ALP with an increased exposure time.  
The results of this thesis allow acceptance of the hypothesis that T2D affects the clinically 
normal dental pulp by altering the histological, immunological, and cytokine response. 
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Furthermore, the results of this thesis support the hypothesis that glycation and hyperglycaemia 
can increase cytokine expression and dental pulp calcification. The results also support the 
hypothesis that culturing of cells in the presence of high glucose results in altered cell behaviour 
and gene expression. The overall results of the thesis confirm all hypotheses and T2D affects 
the clinically normal dental pulp at molecular and cellular levels. 
6.3 Conclusion  
Diabetes alters the structure and function of many organs and tissues, including dental pulp. 
Hyperglycaemia and the AGEs’ pathway can lead to aggressive dental pulp tissue destruction 
and injury and this thesis has provided baseline knowledge of how this may occur otherwise in 
normal (healthy) dental pulps of T2D. The hyperglycaemia of T2D may act as a chronic irritant 
and DAMP to dental pulp and lead to an increased immune response, with an increased 
production of cytokines, collagen and reduced cellularity and vascularity suggesting resembling 
an aging of the dental pulp.  
Hyperglycaemia can be considered as an important irritant to dental pulp and leads to 
inflammation via glycation pathways and the accumulation of AGEs. T2D may result in AGEs’ 
accumulation not only in collagen and ECM, but also in vascular walls, and this may contribute 
to collagen stiffness, calcification and pathological changes in the vasculature of diabetics 
similar to physiological aging. Hyperglycaemia in T2D changes the vascular responses and 
alters immune responses in diabetes patients, and pulp healing may be impaired in these 
patients.  
The AGEs’ specific receptors RAGE when binding to S100A12, this will lead to the 
activation of intracellular signalling that causes the activation of NF‐κB and this causes a 
release of inflammation mediators in clinically normal dental pulp. The increased expression 
of cytokines mediators (IL1%, IL6, IL17 and TNF-&) in the dental pulp in association with T2D 
can result in altered innate and adaptive immune responses and subsequent changes in the 
morphological structure of dental pulp (fibrosis, pulp stones, blood vessel sclerosis, odontoblast 
and fibroblast dysfunction). The Gal-3 gene was identified for the first time in the human dental 
pulp and its reduction in a high glucose environment suggests it may have a role in increasing 
glycation and fibrosis of the dental pulp.  
In conclusion, understanding of T2D is complex and there are multiple individual modifying 
factors, but this thesis has shown that the dental pulp is as vulnerable as other body tissues to 
glycaemic change. There are some similarities to other sites, and it is apparent that glycation 
pathways and RAGE play an important role in the inflammation process potential for tissue 
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destruction as documented by the distinct differences in the normal dental pulp of non-T2D and 
T2D. Within the limits of the present study, the results suggest that the normal pulp in T2D has 
features seen with increasing age, including tissue fibrosis, reduced vascularity and an altered 
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Study title: Type 2 Diabetes and inflammatory markers in 
the dental pulp  
Principal 
investigator: 
Dr Lara Friedlander 
Sir John Walsh Research Institute 
Faculty of Dentistry 





03 4797126  
 
Introduction 
Thank you for showing an interest in this project that will look at the tissue inside your 
tooth (pulp) and provide information about healing. Please read this information sheet 
carefully. Take time to consider the information and, if you wish, talk with relatives or 
friends, before deciding whether or not to participate.  
If you decide to participate we thank you. If you decide not to take part there will be no 
disadvantage to you and we thank you for considering our request.   
 
What is the aim of this research project? 
The purpose of this study is to look at tooth tissue in type 2 diabetics and non-diabetics. 
We will look at the signs of inflammation in the pulp of teeth from diabetics and 
compare these with those without the disease. This will help us better understand how 
diabetes affects the healing following tooth injury or dental decay and will help dentists 
providing dental care to diabetics. This study is being carried out at the Faculty of 






Who is funding this project? 
This study is being funded by the Oral Molecular and Immunopathology Research 
Group within the Sir John Walsh Institute, Faculty of Dentistry, University of Otago  
 
Who are we seeking to participate in the project? 
We need 40 type 2 diabetic and 40 non-diabetic participants, aged between 25-65 
years of age of any ethnic group who require tooth extraction of teeth that are not 
decayed. Diabetics who will participate in the study should be diagnosed by physician 
and have a HbA1c of ³ 50 mmol/ml or a fasting glucose ≥ 7 mmol/ml. Dunedin. 
Participants must not smoke, be pregnant, take insulin or have taken antibiotics within 
last three months. 
 
If you participate, what will you be asked to do? 
We will ask you to complete a short questionnaire relating to you and your health. This 
will not identify you and will take no more than 10-15 minutes. You will be also asked 
to donate your tooth/teeth once it has been removed as part of your dental treatment. 
No personal data will be collected and following collection your tooth will be given a 
laboratory number code. No extra dental appointments will be required for this study. 
Normal fees for extraction of teeth will apply. 
Is there any risk of discomfort or harm from participation? 
There is no additional harm or discomfort from participating in this study.  
What specimens, data or information will be collected, and how will 
they be used?  
Questionnaire data will provide clinical information which will assist in understanding 
the relationship between diabetes and dental health. Your tooth tissue will be 
examined under a microscope and laboratory tests will look for inflammatory cells and 
immunological markers involved with dental pulp tissue inflammation. At the end of the 
study we would like to store some of your tooth tissue in our secure laboratory for use 
in future studies looking at pulp inflammation. Any future studies will be carried out 






9. I understand that the results of the project may be published but that I am not identifiable. 
10. I know that there is no remuneration offered for this study, and that no commercial use will 
be made of the data.  
11. At the end of the study I consent to any remaining samples being disposed of using  
                         Standard disposal methods. 
                         Disposed with appropriate karakia 
 
Signature of participant:  Date: 
   
   
I agree that the tooth tissue samples will be securely stored for use in future studies, any such 
study being subject to further ethical approval.       Yes                   
                                                                           No  
Signature of participant:   
Date: 










Type 2 Diabetes and inflammatory markers in the dental 
pulp 
Principal Investigator:  
Dr Lara Friedlander 
Email: lara.friedlander@otago.ac.nz 
Phone: 03 479 7126 
 
CONSENT FORM FOR PARTICIPANTS	
Following signature and return to the research team this form will be stored in a secure place for ten years. 
Name of participant:………………………………………….. 
1. I have read the Information Sheet concerning this study and understand the aims of this 
research project. 
2. I have had sufficient time to talk with other people of my choice about participating in the 
study.   
3. I confirm that I meet the criteria for participation which are explained in the Information 
Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I 
understand that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to 
withdraw from the project at any time without disadvantage. 
6. I know that as a participant I will donate my whole tooth to this study and this tissue will 
be de-identified. 
7. I understand that there is no additional harm or discomfort in my participation other than 
that associated with tooth extraction. 
8. I know that when the project is completed all personal identifying information will be 
removed from the paper records and electronic files which represent the data from the 






9. I understand that the results of the project may be published but that I am not identifiable. 
10. I know that there is no remuneration offered for this study, and that no commercial use will 
be made of the data.  
11. At the end of the study I consent to any remaining samples being disposed of using  
                         Standard disposal methods. 
                         Disposed with appropriate karakia 
 
Signature of participant:  Date: 
   
   
I agree that the tooth tissue samples will be securely stored for use in future studies, any such 
study being subject to further ethical approval.       Yes                   
                                                                           No  
Signature of participant:   
Date: 





A.1.5 Participants Questionnaire  
 













a. Are you?                                         Male                                     Female 
 
b. Your present age:      _______________    Years                        
 
c. To which ethnic group(s) do you belong? 
 
New Zealand European                                               Māori          Samoan  
Cook Island Māori                           Tongan                     Niuean  




d. Weight (If Known):                                                                  
 
Height (If Known):                                             
 
   Type 2 Diabetes and inflammatory markers in the dental pulp  
 


















a. Have you ever been told by a doctor that you have Type 2 diabetes?  
 
Yes                                               No                                                                                                            
 
     If No go to Question 3 – Dental History 
               
b. How old were you when you were first told by a doctor that you had Type 2 
diabetes? 
                               ____________________ Years 
 
c. How long ago were you told you had Type 2 diabetes? 
  
Less than 1 year                    1-5 years                5-10 years       
More than 10 years                                  
  
d. Does anyone in your family have Type 2 diabetes? 
  
Yes                                                   No                                  Don't Know                   
 
e. Do you regularly see a health professional for your diabetes?               
 
Yes                                                 No                           
 
     If Yes please tick below (you may choose more than one) 
 
General Medical Practitioner                                              Diabetes Specialist  
Practice Nurse at your general practitioner       Diabetes Nurse       
Others:  _______________________________________________________________ 
__________________________________________________________________________ 
         
 
2- Medical History  
   
 











f. How is your diabetes managed? 
 
No treatment                               Diet                            Exercise    




g. Are you taking any other regular medications?                  Yes                             No 
                                                    
     If Yes please list these 




h. How well controlled is your diabetes? 
 
Well controlled (blood sugar levels are stable) (4-8 mmol/L)  
Poorly controlled (blood sugar levels change) 
 
i. Do you have any other medical conditions associated with your Type 2 diabetes eg 
circulation, nerve problems, kidney or eye problems?            
Yes                       No   
 
Please describe ___ __________________________________________________________  
__________________________________________________________________________  
__________________________________________________________________________ 
      
    





















a. When did you last visit the dentist? 
 
Within the past year                                                 1-2 years ago   More than 5 years ago 
 
b. What is the reason you most commonly visit the dentist? 
 
Dental examination (Check-up)                                When you have a problem                                      
 
c. Why are you having your tooth/ teeth extracted? 
 
Wisdom teeth (third molars)                         Periodontal (gum) disease  




























a. In the last 12 months have you personally been forced to buy cheaper food so that you 
could pay for other things you needed?                                      
                                                                                                         Yes No 
 
b. In the last 12 months, have you been out of paid work at any time for more than one 
month?                                                                                                   
                                                                                               Yes            No 
                                                                                                       
 
c.  In the 12 months ending today did you yourself receive payments from any of these three 
benefits: Jobseeker Support, Sole Parent Support or Supported Living Payment?                                                                                           
                                                                                                   Yes                                    No 
  
d.  In the last 12 months have you personally put up with feeling cold to save heating costs?                                                                                                    
                                                     Yes                                     No 
  
e. In the last 12 months have you personally made use of special food grants or food banks 
because you did not have enough money for food?              
                                                                                                           Yes                         No 
f.  In the last 12 months have you personally continued wearing shoes with holes because 
you could not afford replacement?                                    
                                                                                               Yes                                   No 
 
g. In the last 12 months have you personally gone without fresh fruit and vegetables, often, 
so that you could pay for other things you needed?              
                                                                                           Yes                                  No 
 
h.  In the last 12 months have you personally received help in the form of clothes or money 
from a community organization (like the Salvation Army)?                                                                                            
                                                                                                     Yes                                    No 










A.2 Tissue Collection for Cell Culture 




Manager, Academic Committees, Mr Gary Witte
H18/077
Dr L Friedlander
 Sir John Walsh Research Institute
Department of Oral Diagnostic and Surgical Sciences
Faculty of Dentistry
Dear Dr Friedlander,
I am writing to let you know that, at its recent meeting, the Ethics Committee considered your
proposal entitled “Type 2 diabetes - How do human dental pulp cells respond to glucose
and lipopolysaccharides?”.
As a result of that consideration, the current status of your proposal is:- Approved
For your future reference, the Ethics Committee’s reference code for this project is:- H18/077.
The comments and views expressed by the Ethics Committee concerning your proposal are
as follows:-
While approving the application, the Committee would be grateful if you would respond to the
following:
Participants
Please clarify the number of participants to be recruited into the study. The protocol indicates
5 but the response to question 4.2 and the Information Sheet indicates 10 people will be
recruited.
Please provide the Committee with copies of the updated documents, if changes have been
necessary.
Approval is for up to three years from the date of this letter. If this project has not been
completed within three years from the date of this letter, re-approval must be requested. If
the nature, consent, location, procedures or personnel of your approved application change,
please advise me in writing.
Upon approval, it is expected that all members of the research team are made aware of what
the standard conditions of ethical approval covers. This includes the date ethical approval




The Human Ethics Committee asks for a Final Report to be provided upon completion of the







 c.c. Professor R D Cannon  Director   Sir John Walsh Research Institute
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Tuesday, 08 May 2018. 
Dr Lara Friedlander, 





Type 2 diabetes - How do human dental pulp cells respond to glucose and 
lipopolysaccharides? 
7KH1JƗL7DKX5HVHDUFK&RQVXOWDWLRQ&RPPLWWHHWKHFRPPLWWHHPHWRQ7XHVGD\0D\
2018 to discuss your research proposition. 






process is part of a number of requirements for researchers to undertake and does not cover 
other issues relating to ethics, including methodology they are separate requirements with 
other committees, for example the Human Ethics Committee, etc. 
:LWKLQWKHFRQWH[WRIWKH3ROLF\IRU5HVHDUFK&RQVXOWDWLRQZLWK0ƗRULthe Committee base 
consultation on that defined by Justice McGechan: 
Ǝ&RQVXOWDWLRQGRHVQRWPHDQQHJRWLDWLRQRUDJUHHPHQW,WPHDQVVHWWLQJRXWDSURSRVDOQRW
fully decided upon; adequately informing a party about relevant information upon which the 
proposal is based; listening to what the others have to say with an open mind (in that there is 
room to be persuaded against the proposal); undertaking that task in a genuine and not 
cosmetic manner. Reaching a decision that may or may not alter the original prRSRVDOƎ 
7KH&RPPLWWHHFRQVLGHUVWKHUHVHDUFKWREHRILPSRUWDQFHWR0ƗRULKHDOWK 
 
As this study involves human participants, the Committee strongly encourage that ethnicity 
data be collected as part of the research project. That is the questions on self-identified 
ethnicity and descent, these questions are contained in the latest census. 
 
The Committee notes and commends the dissemination strategy to be undertaken.  
 
 







This letter of suggestion, recommendation and advice is current for an 18 month period from 































University of Otago Human Ethics Committee (Health) 
 
Participant Information Sheet 
Study title: Effects of glucose and lipopolysaccharides on 
human dental pulp fibroblast cell proliferation 
Principal 
investigator: 
Dr Lara Friedlander 
Sir John Walsh Research Institute 
Faculty of Dentistry 





03 4797126  
 
Introduction 
Thank you for showing an interest in this project that will look at the tissue inside your 
tooth (pulp) and provide information about healing. Please read this information sheet 
carefully. Take time to consider the information and, if you wish, talk with relatives or 
friends, before deciding whether or not to participate.  
If you decide to participate we thank you. If you decide not to take part there will be no 
disadvantage to you and we thank you for considering our request.   
 
What is the aim of this research project? 
The purpose of this study is to isolate dental pulp cells from tooth tissue. We will culture 
the cells in glucose media and bacterial product to evaluate the influence of diabetes 
on pulp cells. This will help us better understand how diabetes affects the healing 
following tooth injury or dental decay and will help dentists providing dental care to 
diabetics. This study is being carried out at the Faculty of Dentistry, University of 









Version 2 – Information Sheet & Consent Form  1.7.16  
 
Who is funding this project? 
This study is being funded by the Oral Molecular and Immunopathology Research 
Group within the Sir John Walsh Institute, Faculty of Dentistry, University of Otago  
Who are we seeking to participate in the project? 
We need 5 unerupted wisdom teeth from healthy participants aged between 15-30 
years of age of any ethnic group who require tooth extraction of teeth that are free 
from decay. Participants must not smoke, be pregnant, take any antibiotics within last 
three months. 
If you participate, what will you be asked to do? 
You will be asked to donate your tooth/teeth once it has been removed as part of your 
dental treatment. No personal data will be collected and following collection your tooth 
will be given a laboratory number code. No extra dental appointments will be required 
for this study. Normal fees for extraction of teeth will apply. 
Is there any risk of discomfort or harm from participation? 
There is no additional harm or discomfort from participating in this study.  
What specimens, data or information will be collected, and how will 
they be used?  
Your tooth tissue will be used to isolated dental pulp cells. The cells will use with 
culture media which contains glucose. Then evaluate the healing and inflammatory 
markers by laboratory tests involved with dental pulp tissue inflammation. At the end 
of the study we would like to store isolated cells in our secure laboratory for use in 
future studies looking at pulp inflammation. Any future studies will be carried out with 
appropriate ethical approval. Please notify the researchers if you do not want this to 
occur. The cultural issues associated with storing your sample should be discussed 
with your family/whānau. Any tissue remaining at the end of this time will be disposed 
of as normal clinical waste. Whole teeth and tissue will be securely stored in the tissue 
bank within the MedLab Dental Oral Diagnostic Laboratory within the Faculty of 
Dentistry for up to 10 years. Any tissue remaining at the end of this time will be 
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What about anonymity and confidentiality? 
No material which could personally identify you will be used in this study. Only those 
directly involved in the research will have access to the data which will be stored 
securely for 10 years, as required by the University’s research policy, after which it will 
be destroyed.  
If you agree to participate, can you withdraw later? 
Your whole tooth will be required for this study and collected without personal 
identifying details. You are free to withdraw consent and request return of your tissue 
without disadvantage however once donated, your tooth will be cut and will undergo 
laboratory processes meaning tissue which is returned to you may not resemble the 
tooth you have donated.  
Any questions? 
If you have any questions now or in the future, please feel free to contact either: 
Dr Lara Friedlander 
Senior Lecturer / Endodontist 
Department Faculty of Dentistry 
Contact phone number: 
03 479 7126 
Professor Alison Rich 
Deputy Dean/ Oral Pathologist / Director 
Medlab Dental Oral Diagnostic Laboratory 
Faculty of Dentistry 
Contact phone number: 
03 479 5686 
Dr Haizal Hussaini 
Senior Lecturer / Oral Pathologist 
Faculty of Dentistry 
Contact phone number: 
03 479 7066 
Dr Trudy Milne 
Senior Research Fellow  
Faculty of Dentistry 
Contact phone number: 
03 479 5290 
This study has been approved by the University of Otago Human Ethics Committee (Health). If you have any 
concerns about the ethical conduct of the research you may contact the Committee through the Human 
Ethics Committee Administrator (phone +64 3 479 8256 or email gary.witte@otago.ac.nz). Any issues you 
raise will be treated in confidence and investigated and you will be informed of the outcome. 
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Effects of glucose and lipopolysaccharides on human 
dental pulp fibroblast cell proliferation         
Principal Investigator:  
Dr Lara Friedlander 
Email: lara.friedlander@otago.ac.nz 
Phone: 03 479 7126 
CONSENT FORM FOR PARTICIPANTS 
Following signature and return to the research team this form will be stored in a secure place for ten years. 
Name of participant:………………………………………….. 
1. I have read the Information Sheet concerning this study and understand the aims of this 
research project. 
2. I have had sufficient time to talk with other people of my choice about participating in the 
study.   
3. I confirm that I meet the criteria for participation which are explained in the Information 
Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I understand 
that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to 
withdraw from the project before its completion (specify a date if necessary). 
6. I know that as a participant I will donate my whole tooth to this study and this tissue will 
be de-identified. 
7. I understand that there is no additional harm or discomfort in my participation other than 
that associated with tooth extraction. 
8. I know that when the project is completed all personal identifying information will be 
removed from the paper records and electronic files which represent the data from the 
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1. I understand that the results of the project may be published and be available in the 
University of Otago Library, but that I am not identifiable. 
2. I know that there is no remuneration offered for this study, and that no commercial use 
will be made of the data.    
3. At the end of the study I consent to any remaining samples being disposed of using  
                         Standard disposal methods. 
                         Disposed with appropriate karakia 
 
Signature of participant:  Date: 
   
   
I agree that the tooth tissue samples will be securely stored for use in future studies, any such 
study being subject to further ethical approval.       Yes                   
                                                                           No  
 
Signature of participant: 
  
Date: 





Appendix B: Protocols 
B.1 Histological Staining Protocols 
Reagents and Materials 
• Acid Ethanol: 1ml concentrated HCl + 400ml 70% ethanol 
• Haematoxylin (Surgipath Europe LTD) 
• Eosin (Surgipath Europe LTD) 
• Histological mounting medium (Entellan®, Electron Microscopy Science, Hatfield) 
• Xylene 
• Absolute (100%), 90, 70, 50% ethanol 
• Running tab water  
• Scott’s water 
• Distilled water (dH2O) 
• 2% methyl blue 
• 1% phosphomolybdic acid 
• 1% oxalic acid 
• 1% Acetic acid 
• 2% iron alum (ammonium ferric sulphate) 
• 10% aqueous formalin  
• 0.2% aqueous gold chloride  
• 5% aqueous sodium thiosulphate  
• Silver nitrate, concentrated ammonia 
• Ammoniacal silver solutions (Note: potentially explosive; all glassware was washed 
and dried prior to use) 
• Acidified potassium permanganate 
• Neutral red   
• Filtered silver solution  
• Periodic acid, hydrochloric acid 
Equipment 
• Automatic H&E staining machine for H&E stain 
• Slides 
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B.1.1 Haematoxylin and Eosin Staining Protocol  
Haematoxylin and eosin staining were performed using an automatic staining machine 
(Shandon Varistain 24-3, Diversified equipment company Inc.). The operating time was 30 
minutes. The slides were loaded in a carriage and moved in a clockwise direction through the 
23 staining stations under a fume extraction unit. Finally, coverslipped the slides with the 
mounting medium (Entellan®, Electron Microscopy Sciences, Hatfield). 
The Sequence of the Automatic H&E Staining Machine   
1. Xylene (Deparaffinization)  one minute 
2. Xylene (Deparaffinization)  30 seconds 
3. Xylene (Deparaffinization)  30 seconds 
4. Xylene (Deparaffinization)  30 seconds 
5. Absolute ethanol  30 seconds 
6. Absolute ethanol  30 seconds 
7. Absolute ethanol  30 seconds 
8. Absolute ethanol  30 seconds 
9. Absolute ethanol  30 seconds 
10. Absolute ethanol  30 seconds 
11. Absolute ethanol  30 seconds 
12. Running water  30 seconds 
13. Gill’s number 2 haematoxylin  2 minutes 
14. Running water  30 seconds 
15. Scott’s tap water  30 seconds 
16. Running water  30 seconds 
17. Eosin  one minute 30 seconds 
18. Running water  30 seconds 
19. Absolute ethanol (Dehydration)  30 seconds 
20. Absolute ethanol (Dehydration)  30 seconds 
21. Xylene (Clearing)  30 seconds 
22. Xylene (Clearing)  30 seconds 
23. Xylene (Clearing)  30 seconds 





• Nuclei ------------------------------------- Blue 
• Cytoplasm -------------------------------- Pink 
• Connective tissue ------------------------ Pink 





























B.1.2 Masson’s Trichrome Staining Protocol 
Masson’s trichrome stain is widely used to differentiate between smooth muscle and 
collagen fibres in tissue sections. It consists of three dyes which are used to selectively stain 
including muscle (red), collagen fibres (blue) erythrocytes (red) and nuclei (black). Masson’s 
trichrome is a staining technique used to demonstrate muscle, fine collagen fibres, basement 
membranes, fibrin and erythrocytes. It stains Type I collagen that is normally present in vessel 
walls and highlights the presence and distribution of reactive fibrosis to tissue injury. 
Staining Sequence  
1. Deparaffinized in xylene (2X) 5 minutes 
2. Hydrated to dH2O through descending ethyl alcohol 2 minutes 
3. Stained in Celestine blue 10-15 minutes 
4. Wash in tap water 2 minutes 
5. Stained nuclei with Gills haematoxylin 10 minutes 
6. Washed in water 2 minutes 
7. Blue in Scott’s tap water 0 dips 
8. Washed in running tap water 
9. Staining in 0.5% acid fuchsin 5 minutes 
10. Rinsed in dH2O 
11. Treated with 1% phosphomolybdic acid solution 5 minutes 
12. Drained  
13. Stained with 2% methyl blue 2-5 minutes 
14. Rinsed in dH2O 
15. Treat with 1% Acetic acid  
16. Dehydrated Absolute, 90,70,50% ethyl alcohol 2 minutes 
17. Cleared Xylene 2 minutes 
18. The slides were mounted and coverslipped with the mounting medium  
 
Results 
• Nuclei -------------------------------------------------------------Blue/black  
• Cytoplasm, muscles, red blood cells ------------------------- Red  
• Collagen -----------------------------------------------------------Blue 
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B.1.3 Van Gieson Stain  
The Van Gieson stain is used to identify the presence or absence of elastic fibres in tissue. 
In VG-stained slides, elastic fibres and cell nuclei are black, collagen is red/orange, and other 
tissue elements are yellow. Elastic fibres are located in the walls of blood vessels. It may be 
used to demonstrate loss and thinning of elastic fibres in blood vessels.  
Staining Sequence  
1. Deparaffinized in xylene (2X) 5 minutes 
2. Hydrated to dH2O through descending ethyl alcohol 2 minutes 
3. Stained in Celestine blue 10 minutes 
4. Stained nuclei with Gills haematoxylin 10 minutes 
5. Washed in running water 5 minutes 
6. Blue in Scott’s tap water 10 dips 
7. Washed in running tap water 5 minutes 
8. Counterstain in VG stain 4 minutes (Note: VG stain is carcinogenic)  
9. BLOT dry 
10. Dehydrated (quickly) in absolute, 90,70,50% ethyl alcohol 2 minutes 
11. Cleared Xylene 2 minutes 
12. The slides were mounted and coverslipped with the mounting medium  
Results 
• Muscle ----------------------------------------------------------------- Yellow 
• Nuclei -----------------------------------------------------------------  Blue/brown 
• Cytoplasm, muscles, red blood cells ------------------------------- Red 
• Collagen ---------------------------------------------------------------- Red 









B.1.4 Reticulin Fibres Staining Protocol 
Reticulin stain is used to detect reticulin fibres, which are made of type III collagen. The 
fibres appear black against a gray to light pink background. Reticular fibres are composed of 
collagen and form a delicate framework around nerve fibres, fat cells, lymph nodes, and smooth 
muscle fibres. The reticulin staining was done with Gordon and sweet method 
Staining Sequence 
1. Deparaffinised sections with xylene then take through alcohols to water 
2. Oxidised sections in acidified potassium permanganate 5 minutes 
3. Rinsed in dH2O 3 minutes 
4. Decolourised with 1% oxalic acid 3-5 minutes 
5. Rinsed in tap water, followed by dH2O 
6. Mordant in 2% iron alum (ammonium ferric sulphate) 15 minutes 
7. Rinsed in three changes dH2O (Note: very important use 3 separate containers) 
8. Filtered silver solution one minutes 
9. Rinsed with dH2O 
10. Reduced with 10% aqueous formalin 2 minutes (not neutral buffered formalin) (Note: 
colours back immediately)  
11. Washed in dH2O, followed by tap water 2 minutes 
12. Toned in 0.2% aqueous gold chloride 3 minutes 
13. Rinsed in dH2O 3-5 minutes 
14. Fixed with 5% aqueous sodium thiosulphate 5 minutes 
15. Washed in running tap water 5 minutes 
16. Counterstained with 1% aq neutral red 1 minute 
17. Dipped in tap water and drained fast on paper towel  
18. Dehydrated through 50,70,90% and absolute ethyl alcohols and cleared in Xylene   
19. The slides were mounted and coverslipped with the mounting medium  
Results 
• Reticulin Fibres  ------------------------------------------ black 
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B.2 Decalcification Reagent Preparation  
B.2.1 10% EDTA Solution  
Reagents and Materials 
• EDTA (Cat. No. 1084181000, Merck)  
• Distilled water (dH2O) 
• Sodium hydroxide pellets (Cat. No. 1064980500, Merck) 
• pH meter  
Method 
1. Add 50g EDTA to 25ml distilled water 
2. Adjust the pH of the freshly mixed solution to 7.4 by adding sodium hydroxide pellets  
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B.3 Antigen Retrieval Reagent Preparation  
B.3.1 Sodium Citrate Buffer Dilute  
For antigen retrieval, prepare a solution of 10mM sodium citrate buffer, pH 6.0. 
Reagents and Materials 
• 10mM sodium citrate buffer (Cat. No. Sc-294091; Santa Cruz Biotechnology, Inc) 
• Distilled water (dH2O) 
• For pH adjust can use 0.10mol Hcl to increase acidity or 0.10mol NaOH to increase 
basically 
Equipment 
• pH meter probe 
Method 
1. Add 5ml from concentrated citrate and add 495ml dH2O according to manufacture 
recommendation  




B.4 Tooth Collection and Decalcification Protocol 
Reagents and Materials 
All instruments sterilised prior to sample collection, and included:  
• High-speed burs No. 33 (to be used once) and high-speed hand piece 
• Tweezer, dental forceps 
• Phosphate-buffered saline (PBS) pH 7.4 
• 10% neutral buffered formalin  
• 10% EDTA (Cat. No. 1084181000, Merck) prepared previously  
• Sterile surgical scalpel blade 
Method 
1. Place tooth immediately in the 10% neutral buffered formalin at RT 
2. Using dental forceps and tweezer to hold the tooth and cut 2mm under the 
cementoenamel junction to expose the coronal pulp tissue using a high-speed handpiece, 
water coolant and sterile bur  
3. Fix the crown by keeping the crown in the 10% neutral buffered formalin for 24 hours 
at RT 
4. Rinse the crown with PBS 
5. Immersion of the crown in 50-60ml of 10% EDTA and agitated at 4°C for 6-8 weeks 
6. 10% EDTA solution was replenished with a fresh solution every 3-4 days  
7. Check the decalcification after 6 weeks by manual press by fingers on the crown 
8. After confirming the decalcification, trim it with a sterile surgical scalpel blade 
9. Place the crown in a solution of 10% EDTA for an additional 7-10 days 
10. The crown samples were rinsed with two changes of PBS and agitated in PBS for 24 
hours to remove excess EDTA and prior to paraffin embedded  
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B.5 Paraffin Embedding and Tooth Sectioning  
After decalcification, the crown is dehydrated to enable embedding with paraffin.  
B.5.1 Dehydration (Graded Alcohol–Xylene Gradient)  
A gradual change in hydrophobicity minimises cell damage.  
• dH2O (2X) 2 minutes each  
• 50% ethyl alcohol 5 minutes  
• 70% ethyl alcohol 5 minutes  
• 95% ethyl alcohol 5 minutes  
• 100% ethyl alcohol 5 minutes  
• Xylene (3X) 5 minutes each 
B.5.2 Paraffin Embedding and Sectioning  
Reagents and Materials 
All instruments sterilised prior to sample collection, and included:  
• Water bath  
• Container with ice  
• Glass microscope slides  
• Microtome and blade  
• Oven  
Method 
1. Paraffin is heated to 60°C and then allowed to harden overnight 
2. Chill paraffin-embedded tissue blocks on ice before sectioning. Cold wax allows to 
obtain thinner sections, provide support for hard structure within the tissue specimen 
(enamel, dentine and cementum) and the amount of moisture that penetrates the block 
from the melting ice make the tissue easier to cut 
3. Fill the water bath and adjust the temperature to 40–45°C 
4. Place the blade in the holder, ensure it is secure and set the clearance angle. According 
to microtome manufacturer’s instructions for guidance on setting the clearance angle  
5. Insert the paraffin block and orientate and the blade will cut straight across the block  
6. Carefully approach the block with the blade and cut a few thin sections to ensure the 
positioning is correct. Adjust if require 
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7. Trim the block to expose the tissue surface to a level where a representative section can 
be cut 
8. Cut sections at a thickness of 4μm 
9. Pick up the ribbons of sections using tweezers and float them on the surface of the water 
in the water bath and let them to flat out 
10. Separate the sections and pick them, by using the tweezers, out of the water bath to be 
placed on slides and stored upright in a slide rack  
11. Place the slide rack into an oven and allow sections to dry overnight at 37℃.  
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B.6 Immunohistochemistry Staining of Paraffin-Embedded Tissue 
B.6.1 Immunohistochemistry at Day1 
Reagents and Materials 
• Xylene 
• 50%, 70%, 95% and 100% ethanol 
• Haematoxylin 
• Water  
• 1% PBS 
• 10mM sodium citrate buffer (Cat. No. Sc-294091, Santa Cruz Biotechnology, Inc) 
• 5% NaOCl  
• Antibody diluent (Cat. No. ab64211, Abcam) 
• Primary antibody (prepare calculation of dilution for each one before starting the 
experiment)   
Equipment 
• Water bath/ filled to half or less with distilled water  
• Container with ice  
• Glass microscope slides 
• Slides holder 
• Timer 
• Coplin jar  
• Humidified chamber  
• Pipette (different sizes), plastic pipette, gloves, microtubes 
• Control tissue slides 
• Sample tissue slides 
• ImmEdge® Hydrophobic Barrier PAP Pen (Cat. No. H-4000, Vector Laboratories, 
Maravai Lifesciences) 
Method 
Step 1: Slides Preparation 
1. Prepare the samples and control tissue slides, label them clearly with name of tissue, 
Ab, dilution factor and the date 
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Step 2: Deparaffinisation and Rehydration  
1. Deparaffinisation: Xylene (2X) 3 minutes 
2. Hydrate through a serious graded alcohol: 100, 95, 70, 50% ethanol (1X) 3 minutes  
3. Wash slides (in slide holder) under water tap  
4. Soak the slides in Coplin jar fill with PBS 5 minutes. (Note: very important to keep 
slides hydrate and not allow to dry till start next step [can hold in PBS longer time if 
required]) 
Step 3: Antigen Retrieval (Heat Induced Antigen Retrieval) HIAR by Water Bath Heat 
Treatment  
1. Before starting the experiment, turn on water bath and adjust the temperature according 
to each Ab    
2. Prepare 300ml of 10mM sodium citrate buffer (pH 6) 
3. Transfer slides from Coplin jar with PBS to other one filled with Tri sodium citrate 
buffer: 300ml of 10mM citrate buffer (pH 6) 
4. Cover the Coplin jar with it cover then keep in water bath (adjusted heat and time 
according to Ab) and cover the water bath with it cover 
5. Remove the slides from water bath and keep in their citrate buffer to cool for at least 10 
minutes in RT.  
6. Transfer the slides to Coplin gar with PBS and keep cooling for 20 minutes 
Step 4: Adding Primary Antibodies 
1. Prepare Humidified chamber and Arrange the slides with it 
2. Circle the sample with ImmEdge® to create hydrophobic barrier  
3. Prepare and dilute the Ab (Note: In this step should wear gloves) 
4. Add 100µl of diluted Ab to each slide 
5. Cover the humidity chamber and incubate in fridge 4℃ for recommended manufacture 
time 
B.6.2 Immunohistochemistry at Day2 
Reagents and Materials 
• EnVision™+ Dual Link System-HRP for both anti-mouse and anti-rabbit (Cat. No. 
K4063, Dako) 
• 3,3’-diamino-benzidine (DAB) (Cat. No. D3939, Sigma Aldrich) 
• Mounting medium DPX (Entellan®, Electron Microscopy Science, Hatfield) 
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• 0.01% Tween 20 (Cat. No. P5927, Sigma-Aldrich)  
• Skim milk powered 
• 0.3% hydrogen peroxide (H2O2) 
• Methanol  
• Xylene 
• 50%, 70%, 95% and 100% ethanol 
• Haematoxylin 
• Water tab 
• Scott’s water 
• 1% PBS 
• 5% sodium hypochlorite (NaOCl)   
Equipment 
• The same equipment’s used in day1 
Method 
Step 1: Washing  
1. Take the humidity chamber out of fridge and keep on working site and wash slides with 
PBS for 2 or 3 times by using plastic pipette, after finish wash dip the slide to remove 
extra water or buffer 
Step 2: Background Reduction 
Note: This step not required by all antibodies (Abs) 
1. Submerge tissue sections in 0.3% hydrogen peroxide (H2O2) in methanol/ 15 minutes 
(prepare 100ml of 0.3% H2O2 in methanol (just prior to use) by adding 1ml of 30% 
H2O2 to 100ml methanol 
2. Milk wash 10 minutes (1 milk wash = 1g skim milk powder + 100ml PBS, 2 minutes in 
magnetic stirrer)  
3. This step only AGE antibody required to wash extra with 0.01% Tween 20 for extra 10 
minutes 
4. Wash with 0.01M PBS pH 7.4 for 2 minutes 
Step 3: Secondary Antibodies/ Signal Amplification  
1. Apply one drop of Envision (horseradish peroxidase conjugated compact polymer 
system) to each slide (DakoVision™+ Dual Link System-HRP) at least 30 minutes at 
RT 
2. Rinse slide with PBS twice and dip the slide to remove extra buffer 
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Step 4: Visualization by 3,3'-Diaminobenzidine Tetrahydrochloride Chromogen (DAB) 
1. Prepare DAB immediately before use by mixing in falcon tube: (Add one drop of DAB 
to 1ml of Buffer and mix together) (Note: DAB toxic, carcinogenic and highly acid can 
cause skin burn, so need to wear gloves) 
2. Add 100µl for each sample on slide and watch for a brown colour developed to reveal 
the colour of antibody staining 
3. Allow the colour development for >5minutest (5-10 minutest) according to primary Ab 
4. Tip excess into waste flask for disposal  
5. Rinse each slide with PBS (twice to sure DAB removed and stop the reaction) in 
moisture chamber 
6. Remove the slides from chamber and keep in slide holder and wash in water tap 
7. Apply bleaching solution (5% NaOCl) to moisture chamber after finish to inactivate 
DAB and wash the chamber 
Step 5: Haematoxylin Counterstaining  
1. Haematoxylin (10X) in/out 1-2 minutes  
2. Rinse in water tap (10X) in /out 
3. Haematoxylin (5X) in/out and wash 
4. Scott’s water (1X) one minute  
5. Dehydrate through alcohol gradient starting at (50%,70%, 95, 100%) 3 minute each 
6. Clear the tissue slide in xylene (2X) 5 minute 
Step 6: Mounting and Prepare Slides to See Under Microscope  
Transfer slides to hood area and start cover the slide with cover slip by:   
1. Apply drop of mounting solution above the section on the slide 
2. Put coverslip on the slide and press well and slowly with tweezers back to sure the 
sealing and remove air bubbles. (Note: use tweezers to take slide from slide holder to 
working area in hood)  
3. Observe the colour of antibody staining in tissue section under microscope  
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B.7 Immunofluorescent Staining of Paraffin-Embedded Tissue  
B.7.1 Immunofluorescence (IF and DIF) at Day1 
Reagents and Materials 
• Xylene 
• 50%, 70%, 95% and 100% ethanol 
• Water  
• 1% PBS 
• 10mM sodium citrate buffer (Cat. No. Sc-294091, Santa Cruz Biotechnology, Inc) 
• Antibody diluent (Cat. No. ab64211, Abcam) 
• Primary antibody (prepare calculation of dilution for each one before starting the 
experiment)   
Equipment 
• Water bath/ filled to half or less with distilled water  
• Container with ice  
• Glass microscope slides 
• Slides holder 
• Timer 
• Coplin jar  
• Humidified chamber  
• Pipette (different sizes), plastic pipette, gloves, microtubes 
• Control tissue slides 
• Sample tissue slides 
• ImmEdge® Hydrophobic Barrier PAP Pen (Cat. No. H-4000, Vector Laboratories, 
Maravai Lifesciences) 
Method 
Step 1: Slides Preparation 
1. Prepare the samples and control tissue slides, label them clearly with name of tissue, 
Ab, dilution factor and the date 
Step 2: Deparaffinisation and Rehydration  
1. Deparaffinisation: Xylene (2X) 3 minutes 
2. Hydrate through a serious graded alcohol: 100, 95, 70, 50% ethanol (1X) 3 minutes  
3. Wash slides (in slide holder) under water tap  
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4. Soak the slides in Coplin jar fill with PBS 5 minutes. (Note: very important to keep 
slides hydrate and not allow to dry till start next step (can hold in PBS longer time if 
required) 
Step 3: Antigen Retrieval by Heat Induced Antigen Retrieval: Water Bath Heat 
Treatment  
1. Before starting the experiment, turn on water bath and adjust the temperature according 
to each Ab    
2. Prepare 300ml of 10mM sodium citrate buffer (pH 6) 
3. Transfer slides from Coplin jar with PBS to other one filled with Tri sodium citrate 
buffer: 300ml of 10mM citrate buffer (pH 6) 
4. Cover the Coplin jar with it cover then keep in water path (adjusted heat and time 
according to Ab)  
5. Remove the slides from water bath and keep cooling for 10 minutes in RT 
6. Transfer the slides to Coplin gar with PBS and keep cooling for 20 minutes 
Step 4: Adding Primary Antibodies 
1. Prepare Humidified chamber and Arrange the slides with it  
2. Circle the sample with ImmEdge® to create hydrophobic barrier  
3. Prepare and dilute the Ab (Note: In this step should wear gloves) 
4. In case of DIF mix the two diluted primary Abs (mouse and rabbit) 
5. Add 100µl of diluted Ab/Abs to each slide 
6. Cover the humidity chamber and incubate in fridge 4℃ for recommended manufacture 
time 
B.7.2 Immunofluorescence (IF and DIF) at Day2 
Reagents and Materials 
• 4',6-diamidino-2-phenylindole (DAPI) (Cat. No. D21490, InvitrogenTM, Life 
Technologies) for DNA stain 
• Methanol  
• Xylene 
• 50%, 70%, 95% and 100% ethanol 
• Water tab 
• Scott’s water 
• 1% PBS 
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• VECTASHIELD® Antifade Mounting Medium (Cat. No. H-1000, Vector 
Laboratories) 
Equipment 
The same equipment’s used in day1 
Method 
Step 1: Washing  
2. Take the humidity chamber out of fridge and keep on working site and wash slides with 
PBS for 5 times by using plastic pipette, after finish wash dip the slide to remove extra 
water or buffer 
Step 2: Secondary Antibodies/ Signal Amplification  
3. Add 100µl of secondary Ab (In case of DIF: Add 50µl from the two secondary Abs 
which are raised in different species with different fluorochromes 
4. Incubate the slides for one hour at RT in dark 
5. Rinse slide with PBS three times for 5 minutes in dark and dip the slide to remove extra 
buffer 
Step 3: Counter stain by DAPI 
8. Incubate the slides with DAPI for one minute 
9. Rinse each slide with PBS (twice to sure DAPI removed)  
Step 4: Mounting and Prepare Slides to See Under Microscope  
4. Transfer slides to hood area in dark chamber  
5. Apply drop of mounting solution above the section on the slide 
6. Put coverslip on the slide and press well and slowly with tweezers back to sure the 
sealing and remove air bubbles. (Note: use tweezers to take slide from slide holder to 
working area in hood)  
7. Seal coverslip with nail polish to prevent drying and movement under microscope  
8. Store the slides in dark at 4℃ for few weeks or -20℃ for longer time  
Results 
• AGE -------------------------------------------------------- Green 
• RAGE ------------------------------------------------------ Red 
• CD4 --------------------------------------------------------- Red 
• Vimentin -------------------------------------------------- Green  
• Double site stains ---------------------------------------- Yellow 
• Counterstained Nuclei with DAPI --------------------- Blue  
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B.8 Tooth Collection for PCR 
Reagents and Materials 
All instruments sterilised prior to sample collection, and included:  
• High-speed burs No. 33 (to be used once) and high-speed hand piece 
• Tweezer, spoon excavator, dental forceps 
• 1.5ml nuclease-free microcentrifuge tube 
• Phosphate-buffered saline (PBS) pH 7.4 
• RNAlater® (Cat. No. R0901, Sigma Aldrich, Merck)  
Method 
1. Place tooth immediately in the PBS at RT 
2. Using dental forceps and tweezer to hold the tooth and cut 2mm under the 
cementoenamel junction to expose the coronal pulp tissue using a high-speed 
handpiece, water coolant and sterile bur  
3. Excavate the dental pulp and transfer to nuclease-free microcentrifuge tube containing 
RNAlater 
4. Store the samples at -20℃ until require  
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B.9 Grind the Dental Pulp of Non-Type 2 Diabetic Participants Manually 
Reagents and Materials 
• RNase Away agent (Cat. No. 10328011, InvitrogenTM, Life Technologies) 
• TRIzol® reagent (Cat. No. 12183018A, InvitrogenTM, Life Technologies) 
Equipment 
• Falcon tube 
• 1.5ml microcentrifuge tube 
• Tweezer  
• Pipette  
• Ice box 
• Samples 
• Sterile suture scissors 
• Plastic pestle 
Method 
1. Take the samples from the freezer and keep them in box fill with ice 
2. Put RNase Away agent in falcon tube  
3. Keep the tweezer in RNase away agent before each use  
4. Prepare the Triazole and pipette  
5. Label new microtube with samples number and date   
6. Transferee the samples from their tube to the labelled new microtubes filled with 
500µl triazole  
7. Cut the dental pulp to small pieces by scissor 
8. Incubate at RT for 5 minutes  
9. Grind the dental pulp sample by using a plastic pestle  
10. Store the tubes in freezer -20℃ for 24 hour and start RNA extraction. 
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B.10 Grind the Dental Pulp of Type 2 Diabetic Participants by Homogeniser 
Machine 
Reagents and Materials 
• RNase Away agent (Cat. No. 10328011, InvitrogenTM, Life Technologies) 
• TRIzol® reagent (Cat. No. 12183018A, InvitrogenTM, Life Technologies) 
Equipment 
• Precellys Evolution tissue homogenizer machine (Cat. No. P000062-PEVO0-A, Bertin 
Technologies) 
• Precellys Lysing Kit (Cat. No. P000922-LYSK0-A, Bertin Technologies) 
• Tissue grinding CKMix50-R 2ml tube 
• Falcon tube, tweezer and pipettes  
• Ice box 
• Samples 
Method 
1. Take the samples from the freezer and keep them in box fill with ice 
2. Put RNase Away agent in falcon tube  
3. Keep the tweezer in RNase away agent before each use  
4. Label the Precellys Lysing tubes with samples number   
5. Transferee the samples from their tube to the Precellys Lysing tubes 
6. Set the programme of the Precellys homogenizer machine (6000xrpm, 3X (30 
second), 30 second breaks, 4℃) 
7. After finish, go to work in hood area 
8. Prepare the Triazole and pipette 
9. Label new tube with samples number and date   
10. Pipette 250µl of triazole and put in the Precellys tube and close it and mix well and 
pipette it and put in new tube  
11. Again, with new pipette, pipette 250µl of triazole and put again in the Precellys tube 
and close it and shakes it well  
12. Then transferee the triazole to the same new tube  
13. Store the tubes in freezer -20℃ for 24 hour and start RNA extraction 
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B.11 Gene Expression  
B.11.1 RNA Extraction 
Reagents and Materials 
• TRIzol® Plus RNA Purification Kit (Cat. No. 12183018A, Invitrogen™, 
ThermoFisher scientific) 
• PureLink™ DNase set (Cat. No. 12185010, Invitrogen™, ThermoFisher) to remove 
DNA from RNA: contain buffer and DNase I 
• RNase Away Reagent (Cat. No. 10328011, Invitrogen™, ThermoFisher) 
• Nuclease free water (Cat. No. AM9937, Applied Biosystems)  
• Chloroform  
• 70% ethanol  
Equipment 
• Centrifuge 
• Microcentrifuge  
• Vortex  
• Pipette (different sizes) 
• RNase- free pipette tips 
• Micro tubes, tubes 
• 1.5ml RNase free microcentrifuge tube 
• Falcon Tube (50, 15ml) 
• Disposable container 
• Timer, sterile tweezer, sterile long thin scissor, sterile Pellet Pestle (blue stick) 
• Samples  
• Spin cartridge (with white silicon barrier), collection tube, Recovery tubes (all come 
with TRIzol Plus RNA purification kit) 
• Pellet Pestle: blue stick used to grind tissue sample 
• Spectrophotometer machine and confirm the setting before use 
Method 
Step 1: Purification  
1. Switch on the Centrifuge 12,000xg before start work by at least 15 minutes  
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2. Put 5ml of RNase Away agent in falcon tube and use to put any instruments before 
touch samples to prevent cross contamination with other RNA such as Pellet Pestle, 
scissor, tweezer 
3. Transfer pulp sample by tweezer to labelled microtube filled with 500µl triazole   
4. Incubate the tissue with triazole at RT for 5 minutes 
5. Add 100µl chloroform to sample in triazole 
6. Close the tubes very well and shake it well by hand for 15 seconds 
7. Incubate sample at RT for 2-3 minutes 
8. Centrifuge the samples 12,000xg for 15 minutes at 4℃  
9. Check 3 layers in tubes after centrifuge. The upper colourless layer is RNA (aqueous 
phase) equal around 600µl 
10. Transfer the colourless layer (RNA) to new RNase-free tube  
11. Add equal volume 600µl of 70% ethanol to RNase free tube filled with RNA 
12. Mix well by vortex for few seconds or minutes 
Step 2: Binding 
1. Transfer 700µl of mixture which prepared in last step to spin cartridge with a 
collection tube  
2. Centrifuge 12000xg for one minute at RT. Discard the flow through and reinsert the 
spin cartridge into same collection tube  
3. Repeat last two steps  
Step 3: DNA Free Total RNA, DNase I (On-Column PureLink™ DNase)  
Note: Do this step before proceeds to wash step by using PureLink™ DNase set (Cat. No. 
12185010, Invitrogen™, ThermoFisher) 
1. Add 350µl of wash buffer I to spin cartridge  
2.  Centrifuge 12,000xg for one minute at RT and Discard the flow-through and the 
collection tube  
3. In clean RNase free microcentrifuge tube add the reagents in Table B.1  
4. Mix gently by inverting tube and Centrifuge briefly to collect the content of tube 
5. Transfer the solution to the centre of spin cartridge and incubate for one minute at RT 
6. Add 350µl of wash Buffer I to the spin cartridge, centrifuge at 12,000xg for one 
minute at RT and Discard flow-through and put new collection tube  
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Table B.1: DNase I treatment reagents  
Component Volume / one sample 
DNase Buffer 70µl 
DNase I (one unit/ µl) 10µl 
Final volume 80µl 
 
Step 4: Washing Step 
1. Add 500µl wash Buffer II with ethanol to spin cartridge 
2. Centrifuge 12,000xg for one minute at RT and discard flow through and reinsert spin 
cartridge into same collection tube 
3. Repeat last two steps 
4. Centrifuge the spin cartridge and collection tube at 12,000xg for one minute at RT to 
dry the membrane with attached RNA 
5. Discard the collection Tube and insert the spin Cartridge into a recovery tube (cut the 
cover and keep it besides, and label the tube with date, sample ID)  
6. Add 50µl RNase free water to the centre of spin cartridge and incubate at RT for one 
minute  
7. Centrifuge the spin cartridge with the recovery tube for two minutes or more at 
12,000xg at RT and discard the spin cartridge 
8. Recovery tube contain total pure RNA 
9. Determine the quality and quantity of purified RNA using Spectrophotometer  
10. Store RNA at -20℃ for month, if more than one-month store at -80℃ 
B.11.2 Concentration of Pre-Purified RNA Samples 
Reagents and Materials 
GeneJET RNA Clean and Concentration Micro Kit (Cat. No. K0841, Life Technologies, 
Thermo Scientific): 
• Binding Buffer 
• Wash Buffer 1 (concentrated) 
• Wash Buffer 2 (concentrated) 
• Nuclease-free water 
Equipment 
• Pipette and pipette tips 
• Nuclease-free microcentrifuge tubes  
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• Ice box  
• GeneJET RNA Purification Micro Column & Collection Tube (include in kit) 
• 1.5ml Collection Tube (include in kit) 
Method (Company Protocol) 
1. Adjust the volume of the reaction mixture to 200μl with nuclease-free water (included 
in the kit) 
2. Add 100μl of binding buffer. Mix thoroughly by pipetting 
3. Add 300μl of ethanol (96-100%) and mix by pipetting 
4. Transfer the mixture to the GeneJET RNA Purification Micro Column preassembled 
with a collection tube. Centrifuge the column for 30-60 seconds at 14,000×g. Discard 
the flow-through. Place the GeneJET RNA Purification Micro Column back into the 
collection tube 
5. Add 700μl of wash buffer 1 (supplemented with ethanol: if the kit new, then add 13ml 
of 96-100% ethanol to 7.5ml concentrated wash buffer 1) to the GeneJET RNA 
Purification Micro Column and centrifuge for 30-60 seconds at 14,000×g and discard 
the flow-through and place the purification column back into the collection tube 
6. Add 700μl of wash buffer 2 (supplemented with ethanol: if the kit new, then add 30ml 
of 96-100% ethanol to 7.5ml concentrated wash buffer 2) to the GeneJET RNA 
Purification Micro Column and centrifuge for 30-60 seconds at 14,000×g. Discard the 
flow-through and place the purification column back into the collection tube  
7. Repeat step No.6  
8. Centrifuge the empty GeneJET RNA Purification Micro Column for an additional one 
minute at 14,000×g to completely remove residual wash buffer. (Note: This step is 
essential to avoid residual ethanol in the purified RNA solution. The presence of 
ethanol in the RNA sample may inhibit downstream enzymatic reactions.)  
9. Transfer the GeneJET RNA Purification Micro Column into a clean Collection Tube 
(included in kit) 
10. Add 10μl of nuclease-free water (included in kit) to the GeneJET RNA Purification 
Micro Column. Centrifuge for one minute at 14,000×g to elute RNA 
11. Discard the purification column. Use the purified RNA immediately in downstream 
applications or store at -20°C or -70°C until use. (Note: For prolonged storage (more 
than 1 month), storage at -70°C is recommended)  
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B.11.3 Reverse Transcription (RT) 
Reagents and Materials 
• High Capacity Reverse Transcription Kit (Cat. No. 4368814, Life Technologies) 
(Table B.2)  
Equipment 
• Pipette and pipette tips 
• Nuclease-free PCR microcentrifuge tubes (Cat. No. 16950, SorensonTM BioScience, 
Inc) 
• Thermal cycler (Mastercycler® gradient, Eppendorf, Eppendorf South Pacific Pty. 
Ltd.) 
• Ice box  
Method 
Step1: Prepare the 2X Master Mix 
1. Allow the kit components to thaw on ice 
2. Calculate the volume of components needed to prepare the required number of 
reactions   
3. Prepare a RT master mix on ice according to Table B.2 
4. place the 2X RT master mix on ice and mix gently 
Step 2: Prepare the Reverse Transcription Reaction  
1. Pipette 10µl of 2X RT master mix into Nuclease-free PCR microcentrifuge tubes  
2. Pipette 10µl of RNA samples (100-500ng/µl) of each sample to each aliquot of 2X RT 
Master Mix for a final 20µl reaction volume in a nuclease-free PCR tube 
3. Pipette up and down two times to mix and cap the tubes 
4. Mix the reaction by gently inverting the tubes and centrifuge for few seconds to spin 
down the contents and to eliminate any air bubbles 
5. Load the tubes in a thermal cycler and incubated according to Table B.3 




Table B.2: Master mix preparation without RNase Inhibitor.  
Component Volume per one reaction 
10X RT Buffer 2.00µl 
25XdNTP Mix (100mM) 0.80µl 
10X RT Random Primes 2.00µl 
MultiScribe Reverse Transcriptase 1.00µl 
Nuclease- free H2O 4.20µl 
Total per reaction  10.00µl 
 
Table B.3: Thermal cycler settings for cDNA synthesis   
 
B.11.4 Quantitative Polymerase Chain Reaction (qPCR) 
Reagents and Materials 
• Nuclease-free water (Cat. No. AM9937, Applied Biosystems)  
• cDNA samples prepared previously  
• TaqMan® Gene Expression Assay 20X (various) (Applied Biosystem)  
• TaqMan® Fast Universal Master Mix (2X), no AmpErase™ UNG (Cat. No. 4352042, 
Applied Biosystems)  
Equipment 
• QuantStudio 6 Flex system (Applied Biosystem by Life Technologies).  
• 1.5ml RNase-free microtubes 
• Ice  
• Pipette and pipette tips 
• MicroAmp® Fast Reaction tube (8tube/strips) (Cat. No. 4358293, Applied 
Biosystem™) 
• MicroAmp® Optical (8cap/strips) (Cat. No. 4323032, Applied Biosystem™ by Life 
Technology)  
• MicroAmp™ Cap Insulating Tool (Cat. No. 4330015, Applied Biosystem™, 
ThemoFisher Scientific) 
• Small centrifuge, centrifuge for strips 
Setting Step1 Step2 Step3 Step4 
Temperature 25℃ 37℃ 85℃ 4℃ 
Time 10 minutes 120 minutes 5 minutes ∞ 
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Method 
1. Prepare all required material and reagents and sterile the hood working area before the 
work 
2. Dilute the cDNA samples prepared in previous step with Nuclease free water in new 
labelled microtubes (1ng/µl) 
3. Briefly centrifuge cDNA sample and keep them in ice pox until use 
4. In another labelled RNase-free microtubes, prepare qPCR reaction master mix enough 
for all reactions 
5. Prepare qPCR reaction master mix by mixing of TaqMan Gene expression Assay 
(1X), TaqMan Expression Master Mix (1X) and Nuclease-free water in 0.2ml RNase-
free microcentrifuge tubes (Tables B.4 and B.5).  
6. Mix the cocktail by gently pipetting up and down, cap the tube and keep in ice box 
until use  
7. Prepare the MicroAmp® Fast Reaction tube and place according to layout of 
experiment in tube plate base 
8. Centrifuge the master mix tube, and diluted CDNA tubes briefly to spin down the 
contents and eliminate air bubbles from the solutions  
9. Pipette 7μl (for Reference gene and GOI, Duplex technique) or 8μl (only one gene) of 
qPCR reaction master mix to each tube 
10. Add 3μl of diluted cDNA samples  
11. Cap the tubes with MicroAmp® Optical and secure the tube closure with MicroAmp™ 
Cap Insulating Tool and total 10μl reaction master mix ready for PCR 
12. Load the tubes in the Quantstudio 6 Flex machine for amplification using the 
manufacturer’s instructions shown in Table B.6  
13. Following amplification and real-time data acquisition, the threshold and Cq value 
were calculated using the software QuantStudioTM 6 Flex software (Life 
Technologies) 
Table B.4: Prepare qPCR reaction master mix for duplex assay (GOI and Reference gene)   
Component 10µl reactions per one sample Final concentration 
TaqMan® Fast Universal PCR Master Mix (2X) 5.00 1X 
TaqMan® Gene Expression Assay HKG (20X) 0.50 1X 
TaqMan® Gene Expression Assay GOI (20X) 0.50 1X 
H2O 1.00 - 
cDNA 3.00 1ng/µl 
Total volume 10.00µl - 
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Table B.5: Prepare qPCR reaction master mix for reference gene validation 
Component 10µl reactions per one 
sample 
Final concentration 
TaqMan® Fast Universal PCR Master Mix (2X) 5.00 1X 
TaqMan® Gene Expression Assay HKG (20X)  1.00 1X 
H2O 1.00 - 
cDNA 3.00 1ng/µl 
Total volume 10.00µl - 
 
Table B.6: Quantstudio 6 Thermal cycler fast system for VIC and FAM detection for 10µl reaction 
Step Stage Cycles Temperature Time 
Polymerase activation (hold) 1  95℃ 20 seconds 
Denature 2 40 95℃ 3 seconds 
Annealing and extension 3 40 60℃ 30 seconds 
 
Table B.7: Reference gene validate layout 
Well 1 2 3 4 5 6 7 8 9 10 11 12 
A H8 H8 OA OA D2 D2       
B H9 H9 H2O H2O D3 D3       
C H10 H10   D4 D4       
D H11 H11   D5 D5       
E H12 H12   D6 D6       
F H13 H13   D7 D7       
G H14 H14   D10 D10       
H H15 H15   D11 D11       
Note: H; samples from non-T2D, D; samples from T2D, and OA; osteoblast cell line cDNA library 
 
B.11.5 TaqMan Gene Expression 96-Well Plate Layout  
Table B.8: GOI duplex layout 
Well 1 2 3 4 5 6 7 8 9 10 11 12 
A H1 H1 H11 H11 D2 D2 D10 D10     
B H3 H3 H12 H12 D3 D3 D11 D11     
C H5 H5 H13 H13 D4 D4 OA OA     
D H6 H6 H14 H14 D5 D5 H2O H2O     
E H7 H7 H15 H15 D6 D6       
F H8 H8 H16 H16 D7 D7       
G H9 H9 OA OA D8 D8       
H H10 H10 H2O H2O D9 D9       




B.11.6 TaqMan Gene Expression Assay Results (Cq Values)  
Table B.9: Cq value for reference genes ACTB, HRT 1 and B2M 
Sample ID 
ACTB HPRT 1 B2M 
1st well 2nd well 1st well 2nd well 1st well 2nd well 
Non-T2D  
H8 25.08 25.14 30.35 30.38 22.17 22.36 
H9 26.08 26.33 33.28 32.83 23.29 19.10 
H10 23.76 24.00 31.80 32.29 20.14 20.87 
H11 27.50 24.46 28.47 28.64 18.51 18.38 
H12 22.03 22.40 28.45 28.80 18.53 18.39 
H13 22.86 23.05 29.79 29.77 20.21 20.20 
H14 25.61 25.44 30.67 30.97 19.66 19.68 
H15 21.27 22.52 28.00 28.14 17.67 17.35 
T2D  
D2 25.01 25.08 32.43 32.35 21.05 20.94 
D3 22.70 23.09 30.12 30.51 19.48 20.89 
D4 23.67 24.17 32.03 32.31 20.51 20.98 
D5 23.89 24.69 32.11 31.70 20.63 21.75 
D6 30.49 31.02 35.49 35.87 26.71 27.16 
D7 25.73 25.89 31.23 31.13 20.65 20.32 
D10 28.99 29.22 34.19 34.81 27.29 27.80 
D11 26.85 26.57 32.22 32.07 16.98 15.72 
Control  





















Table B.10: Cq value for RAGE and B2M duplex qPCR assay 
Sample ID 
RAGE B2M 
Well 1 Well 2 Well 1 Well 2 
Non-T2D  
H1 30.27 31.01 18.46 18.71 
H3 31.11 31.98 20.76 20.13 
H5 30.21 30.93 21.57 21.84 
H6 29.64 29.59 17.30 16.91 
H7 33.54 33.32 23.09 22.28 
H8 32.95 32.73 19.63 19.82 
H9 33.78 33.69 21.88 21.43 
H10 31.05 31.09 21.75 20.90 
H11 30.42 30.61 18.69 18.48 
H12 30.42 30.61 18.43 18.69 
H13 31.09 31.35 20.60 20.66 
H14 30.94 31.27 19.97 20.10 
H15 29.66 29.31 17.99 18.05 
H16 29.51 29.07 18.10 17.68 
T2D  
D2 28.21 28.02 21.03 21.06 
D3 27.43 27.14 18.42 19.82 
D4 25.25 24.17 20.70 20.93 
D5 27.03 27.89 20.66 21.31 
D6 28.54 28.91 27.50 27.42 
D7 26.83 26.00 20.46 20.28 
D8 25.06 26.43 29.09 29.94 
D9 27.62 27.08 19.20 19.40 
D10 26.43 26.32 24.31 24.38 
D11 24.25 24.72 21.04 21.15 
Control  
OA 29.85 28.98 18.98 19.04 

















Table B.11: Cq value for S100A12 and B2M duplex qPCR assay 
Sample ID 
S100A12 B2M 
Well 1 Well 2 Well 1 Well 2 
Non-T2D  
H1 35.18 34.94 18.43 18.98 
H3 33.61 33.09 21.23 21.67 
H5 32.74 32.00 22.15 22.69 
H6 29.63 29.59 20.24 20.01 
H7 29.49 29.88 22.62 22.18 
H8 33.04 33.81 21.09 21.51 
H9 34.97 34.42 22.29 22.00 
H10 32.83 32.98 21.85 21.29 
H11 33.80 33.59 21.40 21.37 
H12 32.39 32.22 21.92 21.48 
H13 30.54 30.74 20.99 20.70 
H14 32.87 32.89 20.03 20.28 
H15 30.09 30.00 19.51 19.39 
H16 31.68 32.74 20.07 20.22 
T2D  
D2 31.40 30.72 26.61 26.83 
D3 30.15 30.34 21.00 21.09 
D4 29.95 29.99 22.62 22.84 
D5 30.53 30.65 22.03 22.00 
D6 29.65 29.00 26.29 27.73 
D7 24.98 25.04 21.94 21.20 
D8 27.65 27.81 29.41 30.09 
D9 30.54 30.66 21.43 21.57 
D10 22.63 22.99 24.49 24.27 
D11 28.65 28.07 20.06 20.13 
Control  
OA 36.87 37.00 19.19 19.56 




Table B.12: Cq value of NF->0 and B2M (Duplex technique) 
Sample ID 
NF-%" B2M 
Well 1 Well 2 Well 1 Well 2 
Non-T2D  
H1 30.51 30.83 18.98 18.73 
H3 32.06 31.93 20.07 20.14 
H5 30.11 31.42 21.91 21.09 
H6 31.13 31.39 18.92 18.23 
H7 33.19 32.09 22.30 22.17 
H8 30.05 29.52 21.00 21.41 
H9 28.83 28.11 22.09 22.38 
H10 30.61 29.93 22.04 20.89 
H11 30.01 30.12 20.01 20.43 
H12 29.52 30.38 20.86 20.48 
H13 30.41 31.40 20.04 20.67 
H14 32.11 31.69 20.19 20.21 
H15 28.31 28.03 18.43 18.31 
H16 28.06 28.63 17.22 17.69 
T2D  
D2 25.98 25.23 26.09 25.99 
D3 22.45 23.09 22.32 22.13 
D4 29.21 30.00 21.73 21.44 
D5 20.65 20.07 20.61 20.09 
D6 28.18 28.22 27.29 27.00 
D7 23.76 23.49 20.05 20.16 
D8 18.23 18.77 22.50 21.60 
D9 24.55 26.23 19.01 19.22 
D10 19.65 20.65 23.20 23.00 
D11 29.54 29.09 20.24 20.82 
Control  
OA 28.99 29.97 29.54 29.98 




Table B.13: Cq value of Gal-3 and B2M (Duplex technique) 
Sample ID 
Gal-3 B2M 
Well 1 Well 2 Well 1 Well 2 
Non-T2D  
H1 23.93 23.49 19.18 19.04 
H3 25.74 25.43 20.77 19.56 
H5 22.09 22.89 21.81 21.69 
H6 24.04 24.61 16.78 17.10 
H7 28.98 29.05 22.40 22.05 
H8 25.28 24.66 21.27 20.82 
H9 25.54 25.72 23.20 21.60 
H10 25.87 25.24 22.62 20.63 
H11 26.72 27.03 19.51 19.66 
H12 25.57 24.86 21.69 21.41 
H13 24.86 24.86 20.68 20.21 
H14 26.77 26.21 20.28 21.33 
H15 23.97 23.15 18.58 19.69 
H16 22.58 22.87 17.82 18.71 
T2D  
D2 29.42 29.02 26.88 25.34 
D3 30.13 30.26 23.20 22.75 
D4 28.85 28.88 21.00 20.06 
D5 29.69 30.02 20.63 20.90 
D6 28.84 28.89 26.49 27.59 
D7 29.94 29.71 20.65 20.99 
D8 30.06 30.10 28.48 28.88 
D9 28.52 27.98 18.87 18.74 
D10 25.69 25.41 22.28 22.79 
D11 33.13 33.48 20.36 20.54 
Control  
OA 30.51 30.07 29.06 29.95 




Table B.14: Cq value of COL1A1 and B2M (Duplex technique) 
Sample ID 
COL1A1 B2M 
Well 1 Well 2 Well 1 Well 2 
Non-T2D  
H1 20.80 20.74 19.14 19.17 
H3 22.91 22.26 21.88 22.66 
H5 23.77 24.05 23.10 22.58 
H6 19.20 18.00 20.20 20.76 
H7 24.52 24.96 23.10 22.91 
H8 20.91 20.11 21.38 21.71 
H9 23.32 23.70 23.24 23.50 
H10 21.84 21.82 21.00 21.08 
H11 23.11 23.16 21.74 21.86 
H12 19.11 18.94 20.64 21.10 
H13 20.89 20.91 20.98 20.95 
H14 20.57 20.50 20.92 20.66 
H15 19.65 17.99 18.68 19.56 
H16 24.26 25.84 20.87 19.41 
T2D  
D2 22.26 22.75 26.00 26.67 
D3 20.52 19.77 21.81 22.83 
D4 19.57 18.83 23.51 23.61 
D5 17.93 17.85 22.88 21.80 
D6 20.18 20.03 28.83 30.15 
D7 15.70 15.45 22.65 23.72 
D8 17.82 16.98 31.04 30.92 
D9 20.08 20.27 21.16 20.67 
D10 21.25 21.71 24.44 24.91 
D11 19.12 18.31 20.34 20.62 
Control  
OA 18.03 17.28 19.57 20.98 




B.12 Tissue Culture Reagents Preparation 
B.12.1 Phosphate Buffered Saline (PBS) Preparation 
Reagents and Material 
• Phosphate buffered saline (PBS) (Cat. No. SALB000 Gibco, Thermo Fisher Scientific) 
Preparation 
1. Fill glass bottle with required PBS volume. Loosen lids 
2. Label clearly and apply autoclave indictor tape 
3. Autoclave at 12℃ for 40 minutes 
4. Check indictor tape  
5. Secure lids and store at RT 
B.12.2 Trypsin-EDTA (0.025%) 
Reagents and Material 
• 0.25% Trypsin-EDTA (Cat. No. 25200056, life technology)  
Preparation  
1. Aliquot Trypsin-EDTA into 15ml sterile falcon tubes and store at -20℃ for no more 
than 3 months 
B.12.3 Foetal Bovine Serum (FBS) 
Reagents and Material 
• Foetal bovine serum (FBS) (Cat. No. 10091148, Gibco, Thermo Fisher Scientific)  
Preparation  
1. Aliquot FBS into 15ml sterile falcon tubes and store at -20℃ for no more than 6-
months 
B.12.4 Cell Freezing Media 
Reagents and Material 
• Foetal bovine serum (FBS) (Cat. No. 10091148, Gibco, Thermo Fisher Scientific) 
• Dimethyl sulphoxide (DMSO) (Cat. No. D8418, Sigma)   
Preparation  
1. Add 10% DMSO to 90% FBS in a 15ml Falcon tube 
2. Mix well and store at -20℃ for no longer than 6 months 
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B.12.5 Supplemented DMEM Media: 
Three categories supplemented DMEM media were prepared and used in experiments:  
1. Commercially available DMEM media: containing 
5.5mM D-glucose: (Cat. No. 10567014, Thermo Fisher Scientific) 
25mM D-glucose: (Cat. No. 10569010, Life Technology)  
2. DMEM containing no glucose (Cat. No. 11966025, Thermo Fisher Scientific) and D-
glucose (Cat. No. A2494001, Gibco, Thermo Fisher Scientific) was used to prepare the 
four different concentrations of glucose containing media (5.5, 10, 15 and 25mM) 
3. Osmotic control medium: L-glucose (Cat. No. G5500-1G, Sigma) was used as an 
osmatic control at (10, 15, 25mM). For an osmotic control, 5.5mM D-glucose media 
(prepared from zero glucose DMEM) was supplemented with 4.5mM, 9.5mM and 
19.5mM of L-glucose to yield media with a similar osmotic pressure to the 10, 15 and 
25mM D-glucose supplemented media  
Reagents and Material 
• DMEM with GlutaMAX with 5.5mM Glucose (Cat. No. 10567014, Thermo Fisher 
Scientific) or  
• DMEM with GlutaMAX with 25mM Glucose (Cat. No. 10569010, Life Technology) 
or  
• DMEM with no glucose (Cat. No. 11966025, Thermo Fisher Scientific)  
• Foetal bovine serum (FBS) (Cat. No. 10091148, Gibco, Thermo Fisher Scientific)  
• Antibiotic antimycotic 100x; Penicillin, Streptomycin, Amphotericin B (Cat. No. 
15240062 Gibco, Thermo Fisher Scientific) 
• Gentamycin (Cat. No. 15750078, Gibco, Thermo Fisher Scientific) 
Preparation (500ml) 
1. Remove 57.5ml from 500ml DMEM media bottle and replace with 50ml FBS, 5ml 
Antibiotic antimycotic (100x) and 2.5ml Gentamicin 
2. Mix well 
3. Store at 4℃ for no longer than 3 months 
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B.12.6 Prepare (4.5, 9.5 and 19.5mM) L-Glucose 
Reagents and Materials 
• L-glucose (Cat. No. G5500-1G, Sigma) 
• Sterile water 
Equipment 
• Two 50 sterile falcon tubes (Cat. No. 227261, greiner bio-one, CELLSTAR® TUBES) 
• 0.2µM sterile filter (Cat. No. 760502, AHLSTROM, ReliaPrepTM) 
• Sterile syringe (Cat. No. 302100, BD) 
• Pipette and pipette tips 
• Pipette electrical pump and pipette tips 
• New sterile bottle (>250ml) 
Method 
1. Bring reagents to RT.  
2. Reconstitute L-glucose by adding 20ml of water to the vial 1000mg and gently swirl 
until the powder mixing well.  
3.  Sterile filter into two 15ml falcon tubes by using sterile syringe 
4. Store at 4℃  
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B.13 Tooth Collection and Dental Pulp Recovery 
Reagents and Materials 
All instruments sterilised the day prior to sample collection, and included:  
• Gauze  
• High-speed burs No. 33 (to be used once) and high-speed hand piece 
• Tweezer, dental forceps, dental mosquito forceps, tissue forceps  
• Phosphate-buffered saline (PBS) pH 7.4 
• Wet ice 
• 50ml falcon tube containing 10ml supplement DMEM media containing 25mM glucose 
Method 
1. Place tooth immediately in the PBS at RT 
2.  Using dental forceps, remove the tooth and cut under the cementoenamel junction to 
expose the coronal pulp tissue using a high-speed handpiece, water coolant and sterile 
bur at 2mm 
3. Transfer the crown to the 50ml falcon tube containing chilled 10ml Supplemented 
DMEM media containing 25mM glucose 
4. Place on ice for no longer than 2 hours 
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B.14 Dental Pulp Explant 
All procedures were conducted under aseptic conditions in a PC2 tissue culture hood (Figur 
B.1).  
Reagents and Materials  
• Supplement DMEM media containing 25mM glucose (see above section) 
• Sterile phosphate-buffered saline (PBS) pH 7.4 (Cat. No. 10010001, Life 
Technologies)  
• Petri dish 
• 24-well plate (Cat. No.662160, Greiner Bio-One)  
• Tweezer, dental forceps, dental mosquito forceps, tissue forceps 
• Spoon excavators   
• Scalpel No. 11 and 15 and blade handles    
Method 
1. Place one drop of supplement DMEM media into a petri dish 
2. Prepare a 24-well tissue culture plate by scratching the surface of the centre 4 wells with 
tweezers   
3. Using aseptic techniques, excavate the dental pulp from the tooth crown and cut into 
four small pieces transfer each piece to the well of a 24-well plate. Make tissue pieces 
smaller using a mincing action 
4. Add supplement media to each well as shown in Table B.15 to a final volume of 1ml 
5. Label plate with the sample ID, media and date 
6. Incubate the plate at 37°C in 95% air and 5% CO2 
7. On day 7 change 80% of the media and check under the microscope for outgrowth. 
8. Change the media every three days until monolayer forms and the cells are 80% 
confluent 
Table B.15: Volume of supplement media added on the first three days 
Day Volume of supplement media 
Day 1 300µl 
Day 2 500µl 
Day 3 200µl 
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Figure B.1: Dental pulp explant. (A-C) Tooth crown transferred to the Culture hood. (D-F) Dental 
pulp excavated. (G) and (H-I) Dental pulp tissue cut to pieces and transferred to well. (J) Add culture 
media, labial the plate.    
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B.15 Lifting of Adherent Cells Using Trypsin  
Reagents and Materials 
• Supplemented DMEM 25mM D-glucose: (Cat. No. 10569010, Life Technology)  
• Sterile PBS pH 7.4 (Cat. No. 10010001, Life Technologies)  
• 0.25% trypsin/ EDTA (Cat. No. 25200056, life technology)  
• 24-well plate (Cat. No.662160, Greiner Bio-One) 
• T-25 flask (25cm2, 50ml; Cat. No. 690170, Greiner Bio-One, CELLSTAR)  
• T-75 flask (75cm2, 250ml; Cat. No. 690170, Greiner Bio-One, CELLSTAR) 
• Pipette, pipette tips 
Methods 
Table B.16 shows the volumes of reagents used for trypsinisation of cell culture plates and 
flasks 
1. With an inverted microscope check if the cell growth has reached 60-80% confluency 
2. Warm the trypsin, PBS and culture media to 37℃ in water bath 
3. Discard the cell culture medium from the wells plate or flask  
4. Wash the wells or flask by using an appropriate volume of pre-warmed PBS  
5. Add trypsin to wells or flask. Cover cells with trypsin and incubate for 3 mins at 37°C 
in 95% air and 5% CO2 incubator 
6. Check under microscope to ensure cells have lifted. If not tap gently 
7. Quench the trypsin by adding 2x volume of supplemented DMEM medium 
8. Gently distribute the cells in the media using pipette with an up and down motion and 
transfer to new cell culture flasks 
9. Return flask to incubator 
Table B.16: Volumes of reagents used for trypsinisation of cell culture plates and flasks 
 24-well plate T-25 T-75 
Trypsin 200µl/well 2ml 3ml 
Culture medium (to quench the Trypsin) 800µl/well 4ml 6ml 
Culture medium (addition)  1ml 3ml 




B.16 Cell Counting Using a Haemocytometer 
Reagents and Materials 
•  Filtered 0.4% tryphan blue (Cat. No. T8154, Sigma-Aldrich) 
• 70% ethanol (Cat. No. R2470110, Thermo Scientific) 
•  Filter, sterile 1.5ml microfuge tube, pipettes (Gibco, Life Technology) 
•  Equipment  
• Light microscope (MRC/B146, Olympus) 
• Neubauer Haemocytometer (Cat. No. BS-748, Hawksley) 
• Multichannel pipette 
• Reservoir for Multichannel Pipettes 
Method  
1. Clean haemocytometer with 70% Ethanol. Moisten the shoulder of the haemocytometer 
and affix the coverslip  
2. Transfer cells (15µl) and tryphan (15µl) 1:1 to a 1.5ml microfuge tube 
3. Mix cells gently by pipetting up and down 
4. Pipette 15µl of the resulting solution onto a haemocytometer using capillary action with 
the end of the pipette tip at the edge of the coverslip. Repeat to filling the opposite 
chamber 
5. Use 10x magnification to bring the grid lines of the haemocytometer into focus. Count 
the live cells (clear cells with blue halos). Dead cells appear dark blue 
o Count the cells in each of the four corner squares of both chambers. Each square 
is made of 16 small squares (Figure B.2)  
o Calculate the average for the four large grids  
o Multiply by 2 to adjust for 1:1 dilution with tryphan blue  
o Total cell count is equivalent to = x cells/ ml x 104  
o Concentration (cell/ml) = counting # of cells/4 (squares) X dilution faction X 
104 




Figure B.2: Cell count using Neubauer Haemocytometer grid  
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B.17 Cell Cryopreservation  
Reagents and Material 
• Pre-warmed supplemented DMEM medium, PBS and FBS 
• 0.25% trypsin/ EDTA  
• Freezing solution containing (90% FBS and 10% DMSO) (Cat. No. C6295, Sigma 
Aldrich) 
• Cryogenic storage vials (Cat. No. 82050-154, Cryo.S, PP, Greiner Bio-One)  
• 1000 rpm capable centrifuge  
• 5100 Cryochamber (1℃ Freezing containers; Cat. No. 5100-0001, NALGENE TM Cryo) 
• -80℃ freezer and long-term liquid nitrogen storage container  
Method 
1. Grow cells to 80% confluent in a T-75 flask 
2. Lift cells using trypsin transfer cells and media to 50ml tube and pellet cells by 
centrifugation at 1000rpm for 5 minutes at RT and carefully discard supernatant 
3. Resuspend the cells in freezing media (3ml) and transfer 1.5ml labelled cryogenic 
storage vials (1ml/tube) and place in a cryo-freezing chamber for slow cooling at 1℃/ 
min in a -80℃ freezer for 24 hours 
4. Transfer cryovials to liquid nitrogen for long-term storage  
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B.18 Thawing Cryopreserved Cells 
Reagents and Materials 
•  Pre-warmed supplemented DMEM cell culture medium, PBS and FBS 
• Culture flasks T-25 (25cm2, 50ml) (Cat. No. 690170, Greiner Bio-One, CELLSTAR)  
• Safety equipment; full-face shield and gloves  
Method 
1. Prepare the cell culture flask containing pre-warmed supplement media 
2. Removed vial from liquid nitrogen and transfer the vial in dry ice 
3. Using tweezers carefully place the vial into a 37°C water bath  
4. Rotate gently until the contents has partial defrosted then gently tip cells from cryovial 
into the culture flask 
5. Check for the presence of cells under the microscope 
6. Place cells in incubator at 37℃ with 5% CO2 
7. After 24 hours, check the cells under the microscope and change the medium to remove 
DMSO and unattached cells  
8. Change media every three days until 80% cell confluent and then passage to P4 in a T-
75 flask  
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B.19 Preparation of Supplemented DMEM With Various Concentration of 
Glucose and Osmotic Control Media 
Reagents and Materials 
• Supplemented DMEM No glucose (Cat. No. 11966025, Thermo Fisher Scientific)  
• D-glucose solution (200g/l) (Cat. No. A2494001, Gibco, Thermo Fisher Scientific)  
• L-glucose (Cat. No. G5500-1G, Sigma) 
Equipment 
• Pipette and pipette tips 
• Pipette electrical pump and pipette tips 
• New sterile bottle (>250ml) 
Method  
A: To prepare different glucose media:  
1. Replace required volume ml from 50ml DMEM media (no glucose) bottle and replace 
with D-glucose solution as Table B.17 below   
2. Mix well 
3. Store at 4℃  
Table B.17: Prepare 5, 10, 15 and 25mM/l D-glucose (50 and 200ml) 
 
B: To prepare different osmotic media: 
1.  Replace required volume ml from 50ml DMEM media (D1: 5.5mM prepared from no 
glucose) bottle and replace with L-glucose solution as Table B.18 below   
2. Mix well 
3. Store at 4℃  
Table B.18: Prepare 10, 15 and 25mM/l L-glucose (50ml) 
 
Total molarity required D-MEM (no glucose) D-glucose solution Total 
5.5mM (D1) 49.76ml 0.24ml 50ml 
10mM (D2) 49.55ml 0.45ml 50ml 
15mM (D3) 49.32ml 0.68ml 50ml 
25mM (D4) 48.87ml 1.13ml 50ml 
Total molarity required DMEM (5.5mM) L-glucose Total 
5.5mM prepared from zero glucose  50.00ml - 50ml 
10mM (5.5+4.5) (L2) 49.68ml 0.32ml 50ml 
15mM (5.5 + 9.5) (L3) 49.32ml 0.68ml  50ml 
25mM (5.5 + 19.5) (L4) 48.6ml 1.40ml 50ml 
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B.20 Viability Assay  
B.20.1 PrestoBlueTM Cell Staining Protocol 
Reagents and Materials 
• PrestoBlue TM reagent (Cat. No. A13261, Invitrogen™, ThermoFisher). Supplied as a 
10x solution 
Equipment  
• Synergy 2 multi-mode microplate reader (Biotek) 535-560/590-615nm (plate settings: 
96-well sample; fluorescence, top 50% sensitivity 75) 
• Multichannel pipette 
• 96-well plate Nunclon ™ Delta Surface (Cat. No.167008, Thermo Fisher Scientific)  
• 96-well plate (Cat. No.662160, Greiner Bio-One)  
Method 
1. Add PrestoBlue TM at a 1:10 ratio to the media volume. Include a control well with 
media only to correct for background fluorescence 
2. Add 10µl Presto blue reagent to 90µl cells suspension in the 96-well plate well  
3. Incubate at 37°C and 5% CO2 for 2 hours 
4. Pipette 100 µl of suspension media with PrestoBlue by multichannel pipette to new 96-
well plate. 
5. The cell viability will be determined by measuring both fluorescence and absorbance 
spectroscopy  
6. Using a fluorescence microplate reader with filters set at excitation 535nm and emission 
615nm, record fluorescence levels. Cell growth is given as a percentage of untreated 
control (at 100%) at each time point, after correction for background fluorescence   
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B.21 TaqMan® Fast Advanced Cells-to-CTTM Kit Protocol 
Content of TaqMan® Fast Advanced Cells-to-CTTM Kit (Cat. No. A35374, Applied Biosciences, 
ThermoFisher Scientific):  
• Stop solution  
• DNase I 
• 20X RT Fast Advanced Enzyme Mix 
• 2X Fast Advanced RT Buffer  
• Lysis Solution  
• TaqMan ® Fast Advanced Master Mix 
B.21.1 Step 1. Cell Lysis 
Reagents and Materials 
• Lysis solution, DNase I and stop solution  
• PBS  
• RNase-free tubes  
Equipment  
• Adherent cells in 96-well plate Nunclon ™ Delta Surface (Cat. No.167008, Thermo 
Fisher Scientific) (three plates were used, one for each time point)  
• Pipette and pipette tips 
Method  
1. Wash the adherent cells with 1X PBS, then aspirate PBS 
2. Add 50µl of Lysis solution to each well  
Note: DNase I was added to the Lysis solution to remove genomic DNA 
3. Mix the lysis reaction by pipetting up and down five times  
4. Incubate the cells with Lysis solution at RT for 5 mins 
5. Add 5µl stop solution. Mix well  
6. Incubate for 2 mins at RT 
7. Store the cell lysate at -20℃ until required 
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B.21.2 Step 2. Reverse Transcription (RT) 
Reagents and Materials 
• 2X Fast Advanced RT Buffer and 20X RT Fast Advanced Enzyme Mix  
Equipment 
• Pipette and pipette tips 
• Nuclease-free PCR microcentrifuge tubes (Cat. No. 16950, SorensonTM BioScience, 
Inc) 
Method 
1. Prepare a RT master mix on ice according to Table B.19 
2. Pipette each cell lysate sample (22.5µl) to a nuclease-free PCR tube 
3. Add sample lysate to each aliquot of RT Master Mix for a final 50µl reaction volume  
4. The tubes were placed in a thermal cycler and incubated according to Table B.20  
5. The cDNA was stored at -20℃ until required 
Table B.19: Master mix preparation 
 
Table B.20: Thermal cycler set-up used in the RT reaction  
Step stage Cycles Temperature Time 
Reverse transcription (hold) 1 1 37℃ 30 minutes 
RT inactivate (hold) 2 1 95℃ 5 minutes 
Hold 3 1 4℃ indefinite 
 
B.21.3 Step 3. Quantitative Polymerase Chain Reaction (qPCR) 
Reagents and Materials 
• Nuclease-free water 
• cDNA samples prepared previously  
• TaqMan® Fast Advanced Master Mix (Cat. No. 4444557, Applied Biosciences, 
ThermoFisher Scientific) 
Equipment 
• 2x Custom TaqMan gene expression Assay 96-well plate (Gene marker and GOI). See 
Table B.21  
Component 1 reaction 
2X Fast Advanced RT Buffer 25µl 
20X RT Fast Advanced Enzyme Mix 2.5µl 
Total 40µl 
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• QuantStudio 6 Flex system (Applied biosystem by Life Technologies) 
• 1.5ml microcentrifuge RNase-free tubes   
• MicroAmpTM Optical Adhesive Film (Cat. No. 4311971, Applied Biosciences, 
ThermoFisher Scientific) 
• MicroAmp® Adhesive Film Applicator (Cat. No. 4333183, Applied Biosciences, 
ThermoFisher Scientific) 
Method 
1. Briefly centrifuge cDNA sample 
2. Prepare a qPCR reaction master mix for each sample containing sufficient for 16 wells 
(ie. 160µl) including TaqMan® Fast Advanced Master Mix (5µl), cDNA (1µl) and 
water (4µl) 
3. Centrifuge the tube briefly 
4. Transfer 10μl of qPCR reaction master mix to each well of the 96-well TaqMan gene 
expression Assay plate according to the ample layout 
5. Seal the plate before placing in the Quantstudio 6 Flex machine for amplification using 
the manufacturer’s instructions shown in Table B.21  
6. Following amplification and real-time data acquisition, the threshold and Cq value 
were calculated using the software QuantStudio TM 6 Flex software (Life 
Technologies) 
Table B.21: Quantstudio 6 thermal cycler FAST run parameter  
Step Stage Cycles Temperature Time 
Polymerase activation (hold) 1  50℃ 2 minutes 
Hold 2  95℃ 20 seconds 
Melt 3 40 95℃ 3 seconds 




Table B.22: TaqMan TM gene assays included on custom array plates. 
Genes 
symbol 
Genes full name Genes alias Assay ID 
GOI Array 
18s rRNA -   - Hs99999901_s1 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase G3PD Hs02786624_g1 
B2M Beta-2 microglobulin IMD34 Hs00187842_m1 
LGALS3BP Galectin 3 binding protein gp90 Hs00174774_m1 
NFKB1 Nuclear factor kappa B subunit 1 NF-kappa-B Hs00765730_m1 
RAGE  Advanced glycation end-product-specific receptor RAGE Hs00179504_m1 
S100A12 S100 calcium binding protein A12 CAAF1 Hs00942835_g1 
COL1A1 Collagen type I alpha 1 EDSC Hs00164004_m1 
COL3A1 Collagen type III alpha 1 chain EDS4A Hs00943809_m1 
ALPL Alkaline phosphatase, liver/bone/ kidney AP-TNAP Hs01029144_m1 
VEGF Vascular endothelial growth factor A VEGF Hs00900055_m1 
IL6 Interleukin 6 BSF-2 Hs00174131_m1 
IL1" Interleukin 1 beta  IL1F2 Hs01555410_m1 
TNF-# Tumor necrosis factor TNFSF2 Hs00174128_m1 
MMP1 Matrix metallopeptidtidase 1 CLGN Hs00899658_m1 
MMP8 Matrix metallopeptidtidase 8 CLG1 Hs01029057_m1 
Marker Gene Array 
18s rRNA -   - Hs99999901_s1 
THY1 Thy-1 cell surface antigen CD90 Hs00174816_m1 
CD44 CD44 molecule (Indian blood group) CDW44 Hs01075864_m1 
NES Nestin Nbla00170 Hs04187831_g1 
MCAM Melanoma cell adhesion molecule CD146; MUC18 Hs00174838_m1 
VIM Vimentin  CTRCT30; HEL113 Hs00958111_m1 
CD34 CD34 molecule CD 34 Hs02576480_m1 
PTPRC Protein tyrosine phosphatase, receptor type C CD45 Hs04189704_m1 
PECAM1 Platelet and endothelial cell adhesion molecule CD31 Hs01065279_m1 
ENG Endoglin CD105 Hs00923996_m1 
NT5E 5′-nucleotidase or ecto-5′-nucleotidase CD73 Hs00159686_m1 
DLX2 Distal-less homeobox 2 TES-1; TES1 Hs00269993_m1 
DSPP Dentin sialophosphoprotein  DFNA39 Hs00171962_m1 
COL2A1 Collagen type II alpha 1 chain  ANFH Hs00264051_m1 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase G3PD Hs02786624_g1 




B.22 TaqMan™ Gene Expression Assay Results 
Table B.23: Day1 - Cq value at 5.5mM and 25mM D-glucose concentration  
Genes symbol 5.5mM/ Day1 25mM/ Day1 
GOI  C2 C3 C4 C5 C2 C3 C4 C5 
18s rRNA NA NA NA NA NA NA NA NA 
GAPDH 25.38 24.98 29.25 26.64 25.91 23.59 26.33 26.54 
B2M 25.51 26.72 29.19 27.96 26.66 25.39 26.11 27.46 
LGALS3BP 27.81 28.56 32.02 26.90 30.59 29.95 29.61 32.37 
NFKB1 31.78 31.66 34.53 32.67 32.09 30.90 32.33 32.77 
RAGE  34.00 35.68 34.71 34.10 31.92 33.50 31.99 31.69 
S100A12 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
COL1A1 29.58 29.34 26.91 28.54 25.26 25.97 24.61 25.25 
COL3A1 31.77 31.91 31.73 31.26 25.73 24.11 29.59 26.79 
ALPL 37.51 40.00 38.65 40.00 35.54 37.33 36.99 37.36 
VEGF 32.17 31.73 32.86 33.52 30.60 29.72 29.00 29.82 
IL6 39.19 39.11 39.92 38.06 37.03 39.93 39.30 35.60 
IL1" 40.00 40.00 40.00 40.00 36.94 40.00 40.00 40.00 
TNF-# 40.00 40.00 38.38 40.00 38.98 40.00 40.00 40.00 
MMP1 32.66 35.71 34.64 36.14 27.96 32.13 30.91 31.33 
MMP8 39.02 39.74 38.00 38.60 37.04 38.51 36.06 35.10 
Marker Gene          
18s rRNA NA NA NA NA NA NA NA NA 
GAPDH 24.46 26.76 29.79 26.06 25.62 25.67 26.69 27.32 
B2M 24.68 27.64 29.37 26.77 25.80 25.95 25.98 27.41 
THY1 25.35 28.00 29.23 27.60 26.49 26.38 27.37 28.61 
CD44 23.65 26.19 28.35 24.42 24.41 24.79 24.44 25.01 
NES 23.46 26.85 28.61 24.90 23.29 25.30 26.19 26.43 
MCAM 27.96 31.85 32.82 30.96 28.56 30.28 30.68 30.63 
VIM 22.62 23.99 27.39 25.42 23.59 23.05 25.53 25.68 
CD34 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
PTPRC 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
PECAM1 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
ENG 26.58 29.94 31.18 30.53 27.41 28.03 29.43 30.57 
NT5E 26.10 28.10 30.43 27.33 25.86 25.75 26.32 27.75 
DLX2 28.39 31.63 33.55 30.77 30.15 29.78 30.52 31.20 
DSPP 40.00 40.00 40.00 40.00 40.00 40.00 37.44 40.00 




Table B.24: Day3 - Cq value at 5.5mM and 25mM D-glucose concentration 
Genes symbol 5.5mM/ Day1 25mM/ Day1 
GOI C2 C3 C4 C5 C2 C3 C4 C5 
18s rRNA NA NA NA NA NA NA NA NA 
GAPDH 22.21 22.09 25.99 25.63 25.52 22.23 21.70 23.09 
B2M 22.04 23.76 24.96 25.50 25.79 24.29 21.27 21.95 
LGALS3BP 27.47 28.87 31.98 33.43 33.00 29.37 27.25 29.35 
NFKB1 29.27 29.38 31.39 32.67 32.04 28.68 29.29 27.75 
RAGE  29.08 29.01 29.61 29.28 27.00 28.96 27.70 27.40 
S100A12 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
COL1A1 22.47 23.70 22.72 22.96 21.28 21.01 21.98 20.95 
COL3A1 23.52 24.59 25.54 26.93 23.12 21.21 20.94 21.75 
ALPL 33.39 34.32 35.81 35.01 32.15 32.87 31.14 30.82 
VEGF 28.36 28.80 29.77 28.12 25.55 25.81 26.87 26.26 
IL6 36.23 37.63 38.49 37.50 33.95 36.06 37.62 36.43 
IL1" 37.72 40.00 40.00 39.80 40.00 40.00 40.00 40.00 
TNF-# 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
MMP1 31.91 32.90 30.08 34.95 27.17 30.89 29.95 30.85 
MMP8 38.71 36.58 38.06 38.80 38.08 35.18 37.41 36.75 
Marker Gene          
18s rRNA NA NA NA NA NA NA NA NA 
GAPDH 21.70 23.72 27.61 22.90 24.71 24.21 21.94 27.43 
B2M 21.28 24.33 25.61 22.13 25.45 25.02 21.53 27.10 
THY1 24.08 25.27 27.80 24.61 27.44 25.61 23.74 28.95 
CD44 19.89 23.35 23.80 20.93 24.41 23.60 21.30 26.81 
NES 22.65 24.34 26.77 23.96 28.87 24.90 23.80 31.66 
MCAM 26.36 29.32 29.22 26.61 32.34 29.81 27.46 35.25 
VIM 22.06 21.20 23.95 21.16 23.96 21.65 20.72 26.02 
CD34 36.09 40.00 40.00 37.69 40.00 40.00 35.82 40.00 
PTPRC 34.60 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
PECAM1 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
ENG 24.62 27.00 28.56 25.56 29.63 27.02 25.62 32.30 
NT5E 22.18 24.21 25.90 22.87 26.27 24.47 22.87 28.80 
DLX2 27.44 29.13 30.97 28.80 30.62 29.57 28.30 31.69 
DSPP 40.00 40.00 40.00 40.00 37.25 38.03 40.00 40.00 




Table B.25: Day 5 - Cq value at 5.5mM and 25mM D-glucose concentration 
Genes symbol 5.5mM/ Day5 25mM/ Day5 
GOI C2 C3 C4 C5 C2 C3 C4 C5 
18s rRNA NA NA NA NA NA NA NA NA 
GAPDH 22.31 20.82 28.47 29.59 20.86 21.08 25.51 24.38 
B2M 22.03 21.95 28.53 31.06 20.98 22.12 26.06 24.22 
LGALS3BP 27.67 27.43 34.24 33.29 26.73 26.69 31.42 29.95 
NFKB1 28.78 28.04 35.42 33.90 27.63 27.83 32.06 30.38 
RAGE  25.33 25.53 26.93 26.42 20.52 20.30 21.44 20.90 
S100A12 38.72 40.00 38.92 40.00 35.20 38.49 35.06 38.50 
COL1A1 17.35 17.71 21.13 21.81 15.10 16.92 18.15 17.81 
COL3A1 20.04 19.57 24.61 24.36 16.98 17.79 19.58 18.60 
ALPL 28.89 28.49 30.93 30.90 24.63 22.93 24.64 26.06 
VEGF 32.30 24.36 25.61 26.31 21.30 21.46 21.33 21.52 
IL6 32.52 34.89 39.49 37.01 32.38 34.94 37.13 34.24 
IL1" 36.77 40.00 40.00 38.90 39.26 40.00 37.86 38.86 
TNF-# 40.00 40.00 40.00 40.00 40.00 40.00 37.22 39.22 
MMP1 30.51 29.50 31.63 31.32 29.63 27.70 28.89 28.81 
MMP8 32.62 34.99 38.02 35.32 35.78 37.82 40.00 38.21 
Marker Gene          
18s rRNA NA NA NA NA NA NA NA NA 
GAPDH 21.81 22.85 28.94 24.94 20.66 23.68 26.20 28.80 
B2M 21.84 22.57 28.48 23.52 20.54 22.91 26.05 27.22 
THY1 24.16 23.99 29.32 25.73 23.01 25.84 26.59 28.98 
CD44 21.70 22.58 27.96 24.10 20.84 22.73 25.44 26.26 
NES 24.25 23.58 29.59 25.74 22.85 23.94 27.31 27.23 
MCAM 27.00 28.75 32.53 29.35 25.85 29.21 29.57 32.28 
VIM 22.05 20.38 27.43 23.17 20.40 20.52 24.95 26.83 
CD34 35.83 40.00 40.00 38.64 34.65 40.00 40.00 40.00 
PTPRC 40.00 40.00 40.00 40.00 36.59 37.42 40.00 40.00 
PECAM1 32.81 36.77 40.00 34.79 32.11 35.20 37.50 37.51 
ENG 25.39 26.16 31.28 27.33 24.27 26.23 28.48 30.28 
NT5E 22.82 23.03 30.16 24.04 21.77 23.40 27.41 28.84 
DLX2 29.33 29.12 35.85 31.08 28.32 29.03 31.68 33.16 
DSPP 40.00 37.79 40.00 40.00 40.00 40.00 40.00 40.00 
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• Research Presentation:   
o Research day at Otago University, Sir John Walsh Research Institute, Faculty of 
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o NZ IADR Colgate Competition 2018 
o 19th ESE Biennial Meeting (11-14 September 2019, Vienna) 
  
 271 
• Research day at Otago University, Sir John Walsh Research Institute, Faculty of Dentistry 





• 58th Annual Scientific Meeting of the IADR ANZ in Perth (22nd-25th September 2018). 
Name of presenter: Shaikhah AlSamahi 
Title/status: PhD candidate   
Title of abstract: Advanced glycation end-products and receptor in dental pulp of Type 2 
diabetics. 
List of authors/affiliations: Shaikhah AlSamahi, Dr Trudy Milne, Dr Haizal Hussaini, 
Professor Alison Rich, Dr Lara Friedlander  
Sir John Walsh Research Institute, Faculty of Dentistry:  
Abstract  
Type 2 diabetes (T2D) is a chronic systemic disease and characterized by hyperglycaemia. 
Hyperglycaemia leads to generalized damage by increasing protein glycation and lead to 
formation of advanced glycation end products (AGEs) in body tissues. AGEs exert noxious 
effects on tissues through a specific receptor (RAGE). Aims: To evaluate histological 
differences between ‘normal’ dental pulp in diabetics and non-diabetics, to examine the protein 
expression of AGE and RAGE in the ‘normal’ dental pulp. Method: Clinically healthy teeth 
were collected from T2D (n=10) and non-diabetic participants (n=10), cut at level of the 
cementoenamel junction, formalin fixed, decalcified in 10% EDTA, and paraffin embedded. 
Sections were stained with haematoxylin and eosin and Massons Trichrome for histological 
evaluation. Immunohistochemistry was used to detect the presence of AGE and RAGE and 
analysed using light microscopy. Results: Histological differences were observed between 
diabetic and non-diabetic dental pulps. T2D samples had decreased cellularity, increased 
connective tissue and calcification. AGE and RAGE were detected in both control and T2D 
samples with increased intensity in latter.  Conclusion: T2D affects the morphology of normal 
dental pulp and the increased expression of AGE and RAGE in T2D may reflect and contribute 




• 19th ESE Biennial Meeting (11-14 September 2019, Vienna): gave two talks  
The influence of Type 2 Diabetes on clinically normal dental pulp tissues 
 
S.A. AlSamahi*, T.J. Milne, A.M. Rich, H.M. Hussaini, L.T. Friedlander 
 
Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New 
Zealand 
 
Aims 1) To compare the histology and morphology of normal dental pulp tissue from Type 2 
diabetes (T2D) and non-diabetic participants 2) To examine the expression and distribution of 
AGE, RAGE, inflammatory markers and immune cells using immunohistochemistry.  
 
Summary Ethical approval was obtained from the University of Otago Human Ethics 
Committee (H16/069). Twenty permanent extracted teeth (10 T2D, 10 non-T2D) that had been 
diagnosed clinically with a normal dental pulp were decalcified in 10% EDTA and embedded in 
paraffin. Sections were stained with Haematoxylin and eosin, and special stains (Massons 
Trichrome, van Gieson, silver stain) for histological evaluation. Immunohistochemistry using 
anti-AGE, anti-RAGE, anti-IL1-%, anti-IL6, anti-TNF-&, anti-CD4 (T Cell marker), anti-FOXP3 (Fork 
head transcription factor), anti-CD68 (monocyte marker) and anti-CD83 (T Cells and dendritic 
cells) and visualized with the chromogen DAB. Positive control tissues included lung (RAGE), 
thymus (AGE, IL1-%), dentigerous cyst (CD68), spleen (IL6, TNF- &, CD-83) and tonsil (CD-4). 
Non-specific anti-IgG was the isotype negative control. Qualitative and quantitative analyses 
was performed to evaluate pulpal morphology and protein expression. Data analyses were 
performed with GraphPad Prism, using students t- test at P < 0.05. Our results showed that the 
pulp of T2D was less cellular and had fewer blood vessels. Blood vessel walls tended to be 
thickened and within the central pulp, the calcifications were frequently seen. There was 
increased collagen and less elastin compared with non-T2D. IHC showed T2D had significantly 
greater expression of AGE, RAGE, IL1-%, TNF-&,	CD68 (P ≤ 0.001), IL6, CD-4 (P = 0.02), CD83(P 
= 0.04), and decreased expression of FOXP3 (P=0.01). FOXP3 was found to expressed in the 
subodontoblast region and endothelial cells of blood vessels.  While CD4 expressed only 
centrally and other proteins expression peripherally and centrally. The AGE strongly expressed 
in collagen fibers.  
Key Learning points: 
• T2D influences the morphology of the normal dental pulp 
• T2D reduces the vascularity and alter the immune response which is likely to impair 
pulp healing 
• There is increase expression of AGE, RAGE and the inflammatory markers in the 
presence of the T2D  
 
Acknowledgements This study was supported by the Ministry of Health Oral Health (NZ) 
Research Fund. Oral Pathology Centre and Oral Surgery Department (Faculty of Dentistry, 




The influence of Type 2 Diabetes on clinically normal dental pulp tissues 
 
S.A. AlSamahi*, T.J. Milne, A.M. Rich, H.M. Hussaini, L.T. Friedlander 
 
Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New 
Zealand 
 
Aims 1) To compare the histology and morphology of normal dental pulp tissue from Type 2 
diabetes (T2D) and non-diabetic participants 2) To examine the expression and distribution of 
AGE, RAGE, inflammatory markers and immune cells using immunohistochemistry. 
  
Methodology Ethical approval was obtained from the University of Otago Human Ethics 
Committee (H16/069). Twenty permanent extracted teeth (10 T2D, 10 non-T2D) that had been 
diagnosed clinically with a normal dental pulp were decalcified in 10% EDTA and embedded in 
paraffin. Sections were stained with Haematoxylin and Eosin, and special stains (Massons 
Trichrome, van Gieson, silver stain) for histological evaluation. Immunohistochemistry using 
anti-AGE, anti-RAGE, anti-IL1-%, anti-IL6, anti-TNF-&, anti-CD4 (T-helper (Th) Cell), anti-FOXP3 
(Fork head transcription factor), anti-CD68 (monocyte) and anti-CD83 (T Cells and dendritic 
cells) was visualized with the chromogen DAB. Positive control tissues included lung (RAGE), 
thymus (AGE, IL1-%), dentigerous cyst (CD68), spleen (IL6, TNF- &, CD-83) and tonsil (CD-4). 
Non-specific anti-IgG was the isotype negative control. Qualitative and quantitative analyses 
was performed to evaluate pulpal morphology and protein expression. Data analyses were 
performed with GraphPad Prism, using students t- test at P < 0.05.  
Results The pulp of T2D had fewer blood vessels and was less cellular. Blood vessel walls were 
thickened, and pulp calcifications were common in the central pulp. There was increased 
collagen and less elastin compared with non-T2D. IHC showed T2D was associated with 
significantly greater expression of AGE, RAGE, IL1-%, TNF-&,	CD68 (P ≤ 0.001), IL6, CD-4 (P = 
0.02), CD83(P = 0.048), and decreased expression of FOXP3 (P=0.01). FOXP3 was expressed in 
the subodontoblast region and on endothelial cells while AGE was strongly expressed in 
collagen fibres throughout the pulp. Immunity markers were expressed throughout the pulp, 
but Th cells were most common within the central pulp.   
Conclusions T2D alters the morphology and immune response of the dental pulp suggesting 
this systemic disease may influence pulpal healing following injury or infection.  
 
Acknowledgements This study was supported by the Ministry of Health Oral Health (NZ) 
Research Fund. Oral Pathology Centre and Oral Surgery Department (Faculty of Dentistry, 








Type 2 Diabetes and inflammatory markers in the 
dental pulp
S ALSAMAHI*, T MILNE, H HUSSAINI, AM RICH, LT FRIEDLANDER
Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand
Background
Type 2 diabetes (T2D) is a chronic systemic disease which is associated with altered immune responses and
delayed healing. There is a relationship between oral health and general health and the influence of diabetes
on the immune response of periodontal tissues is well established but understanding how this disease may
affect the dental pulp is unclear. TLR2 and TLR4 proteins are detectable in odontoblasts of healthy and
cariogenic teeth.1 T-lymphocytes CD4 was found in healthy dental pulp and considered as essential
constituents of dental pulp.2
Aim
1) To examine the histological appearance of the ‘normal’ human dental pulp in mature permanent teeth in 
the presence of T2D compared with health. 
2) To investigate the expression of a range of inflammatory markers in the coronal pulp of mature permanent 
teeth in the presence of T2D using immunohistochemistry (IHC).
Method
Ethical approval was obtained (H16/069). Teeth were collected from non-diabetic participants (n=10) and T2D participants (n=10). The teeth
were cut at the level of the cementoenamel junction (CEJ) and fixed in 10% formalin, decalcified in 10% EDTA, and paraffin embedded.
Sections were stained with haematoxylin and eosin and, Massons Trichromeand by IHC using antibodies to CD4, TLR2 and TLR4. A
dentigerous cyst was used as a positive control for CD4 and TLR2 while a tonsil for TLR4. Nonspecific IgG was the isotype negative control.
Slides were evaluated using light microscopy and the distribution of markers within the dental pulp were analysed semiqualiatively.
Results
Conclusions
• T2D increases connective tissue within the
dental pulp, reduces blood vessels and cells, and
is associated with increased expression of
inflammatory markers.
• These differences from health may influence the
healing response in T2D following pulpal injury.
References
1-Farges J-C, Alliot-Licht B, Renard E et al. Dental Pulp Defence and Repair Mechanisms in Dental Caries. Mediators of inflammation 2015; 20151-16.
2- Manolea H, Mogoanta L, Margaritescu C, Deva V, Surlin P, Caraivan O.) Immunohistochemical aspects of the evaluation of the inflammatory answer of the 
dental pulp. Romanian Journal of Morphology and Embryology.2008; 50(2), 207-212
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The New Zealand Ministry of Health for funding this project
• There were histological differences in the pulp
associated with T2D compared with non-diabetics.
• There was some biological variability between the T2D
samples.
• There was increased dense fibrous connective tissue,
fewer blood vessels and the tissue was less cellular,
Pulp stones were frequently seen in pulps associated
with T2D.
• IHC staining showed increased expression of CD4,
TLR2 &TLR4.
• CD4 was mainly expressed in the central pulp
• TLR2 & TLR4 positive cells were observed in and
around odontoblast and less so in the central pulp. It
also observed on cells resembling macrophages and
monocytes cells.
Figure 1 – Dental pulp of healthy 





(1 & 2) H&E, and Massons stain.
(3, 4, & 5) Immunohistochemistry of healthy
and T2D dental pulp of CD4, TLR2 & TLR2.
(A): Healthy, (B): T2D, (C): Dentigerous cyst &












































BV=blood vessel, N= nerve, CRZ=cell rich
zone, FCZ= free cell zone, RD= reparative
dentin
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The influences of Type 2 diabetes
on clinically normal dental pulp tissues
AlSamahi S*, Milne TJ, Rich AM, Hussaini HM, Friedlander LT
Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand
Abstract R116
Aim
(1) To compare the morphology of normal
dental pulp from Type 2 diabetes (T2D)
and non-diabetic participants.
(2) To determine the expression pattern
of AGE, RAGE, inflammatory proteins
and immune cells in the dental pulp of
T2D.
Type 2 diabetes (T2D) is a chronic systemic disease and a growing global health problem that is
characterized by hyperglycaemia resulting in an altered immune response with delayed healing.
Hyperglycaemia impairs tissues via glycation and induces systemic low-grade inflammation and
inflammation-induced oxidative stress1,2. Advanced glycation end-products (AGEs) are the
irreversible toxic products of protein glycation. AGEs exert noxious effects on tissues through a
specific receptor (RAGE) resulting in upregulation of proinflammatory cytokines IL-1β, IL-6, and
TNF-α. The effect of diabetes on clinically normal dental pulp is unclear .
Background
Method
Twenty permanent extracted teeth (10 T2D, 10 non-T2D) diagnosed clinically as a normal dental pulp were decalcified in 10% EDTA, and
embedded in paraffin. Sections were stained with haematoxylin and eosin (H&E), and special stains (Massons Trichrome, van Gieson, silver stain)
for histological evaluation. Immunohistochemistry using anti-CD4 (T-helper lymphocytes), anti-CD68 (monocyte marker), anti-CD83 (dendritic
cells), anti-FOXP3 (T regularity lymphocytes), anti-IL1-", anti-IL6, anti-TNF-α, anti-AGE and anti-RAGE were visualized with the chromogen 3, 3’
diaminobenzidine. Non-specific anti-IgG was the isotype negative control. Qualitative and quantitative analyses were performed with microscopy




• Thickened irregular predentine with loose
odontoblast may affect the dentine bridge
formation
• Denser connective tissue, reduced vascularity
and thickened blood vessels in the presence
of diabetes may delay healing
• Calcification in the pulp space may increase
the difficulty of performing root canal
treatment
• Increased expression of AGE and RAGE
associated with increased proinflammatory
cytokines and altered immune cell response
result in inflammation of dental pulp.
• Decreased expression of regularity T-
lymphocytes may decrease the suppression
of T-helper lymphocytes.
Fig. 3; Photomicrograph showing  
immunohistochemistry of healthy and T2D dental pulp 
(40x; scale bar 50µm and 20x; scale bar 100 µm). 
Fig. 1; Photomicrograph showing histological 
stains of normal dental pulp of healthy and 
T2D dental pulp (40x; scale bar 50 µm). 
D-dentine, O-odontoblast, P- central pulp, N-
nerve bundles, CFZ-cell free zone, CRZ-cell 
rich zone, BV-blood vessels, F-fibroblast cell   
Fig. 2; Quantity analysis of blood vessels of healthy 














(Collagen and elastic fibres)
(Reticulin fibres) 
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Table 1; Immunoreactive score (IRS) results of healthy and
T2D dental pulp.
